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 Chap. 1 – New chiral ligands featuring two 
aziridine rings separated by pyridine spacer: 
Synthesis and applications. 
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1.1 - Introduction 
1.1.1 – N-Ligands in asymmetric synthesis 
The enantioselective syntheses of complex chiral molecules, such as those routinely 
demanded by the pharmaceutical industry, rank among the most important and problematic 
objectives in all of chemistry. Progress in this area has been greatly accelerated by the 
development of reliable metal-catalyzed asymmetric reactions that create stereocentres 
with programmable absolute configurations.1 
In principle, asymmetric catalytic processes are desirable because they give precise 
control over chirality and generate maximum complexity in the minimum number of reactions. 
These efficiencies may dramatically reduce the number of steps required in synthesis and 
therefore minimize the use of toxic solvents and reagents, labour and cost. Catalyzed 
reactions may also be conducted under milder conditions that are less energy intensive and 
that yield fewer undesirable side products than other routes. They may relieve some of the 
tedium and wastefulness associated with installation and removal of stereodirecting groups, 
and may provide other synthetic approaches that are much shorter and simpler than 
convoluted pathways involving lengthy modifications of naturally occurring chiral starting 
materials. 
The discovery of new asymmetric catalysts involves to a great degree the 
development of new ligands, which support the central metal ions and govern their 
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 enantioselectivity in asymmetric reactions. The development process is the combined result 
of rational design, intuition, trial and error and serendipity. Often, a chance observation 
uncovers a lead candidate, which is optimized iteratively in successive improvement cycles. 
Successful ligand design/synthesis/test cycles are greatly aided by the following guiding 
principles: 
Proposed syntheses should be modular, i.e., it should be possible to generate many 
different members of a ligand family using the same reaction(s) simply by varying the 
combination of starting materials. 
Ligands should be accessible in only a very few steps, and the diversification step(s) 
should be placed as close as possible to the end of the synthetic route. 
Simple, high-yielding reactions should be used whenever possible. 
In order to generate meaningful quantities of material and to avoid enantiomeric 
and/or diastereomeric separations, the reagents should be readily available and optically pure 
as both enantiomers. Moreover, the synthetic chemistry should be stereospecific and not 
affect any of these built-in stereocentres in an unpredictable way. 
It should be possible to install multiple stereocentres that are independently variable. 
This in turn should allow for trivial expansion of ligand families. 
Basic ligand frameworks should be easily modifiable to allow production of “next 
generation” ligands of higher complexity. 
 
The ready availability of optically pure amino acids/alcohols from the chiral pool, by 
resolution processes and in part by stereoselective syntheses, the ease transformation of the 
amine group to other nitrogen-containing functional groups with different electronic and 
chemical (acid, base) properties, e.g., amides and imines, and the rapid development of 
peptide-based synthesis has positioned chiral nitrogen-donor ligands to fullfill the preceding 
criteria. Although nitrogen-containing ligands were only rarely used in the 1970s and the 
1980s, some of the first historic asymmetric catalysts were heterogeneous nitrogen-
containing chiral systems. Very early, asymmetric reduction was reported on silk fibroin with 
palladium2 and with Raney nickel modified by amino acids. The field has been developed by the 
pioneering work of Brunner, Pfaltz, Evans and Sharpless, among others. 
Nitrogen-containing ligands are increasingly applied in asymmetric catalysis,3 since 
they present several advantages with respect to the more conventional phosphorus-containing 
ligands, even in transition metal-catalyzed reactions. Indeed, the amine functionality can 
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 coordinate any metal species, ranging from lithium and magnesium to zinc, copper, early 
transition metal complexes and also precious metals. 
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Scheme 1 
Diimine-based chiral ligands is easily synthesized via simple base condensation 
between aldehyde and a chiral amine. The C2-symmetry, which is commonly displayed by a 
variety of chiral ligands, limits the number of diastereomeric pathways in the asymmetric 
reaction can transverse, and also renders the ligands easier to assemble in some cases. A 
number of chiral diimines have since been developed, some example of which are shown in 
(Scheme 1). Their simple syntheses by condensation of a chiral diamine, the most common 
trans-1,2-diaminocyclohexane, with two equivalents of an achiral aldehyde (1), or by 
condensation of an achiral dialdehyde (e.g.,glyoxal) with two equivalents of a chiral amine (2, 
3), allow quick variation of steric bulk and the incorporation of different chiral elements. The 
simple C2-symmetric chiral diimines, show in Scheme 1, present poor or moderate 
enantioselectivities  in the relative asymmetric reactions. A few examples are excluded, e.g. 
the reduction of ketones by polymethylhydrosiloxane/Et2Zn in the presence of ligands of 
type 1.4 Enantioselectivities of up to 99% have been achieved using ligands of type 4 in the 
Cu-catalyzed aziridination of electron deficient olefins.5 
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 More popular derivatives of diimine ligands and the most widely and successfully used 
are the salens.6 These ligand systems, which employ an O,N,N,O metal coordination mode, 
were first made by Combes via the condensation of a diamine with two equivalents of 
salicylaldehyde.7 Salen complexes of Mn, Ru, Co, V, Cr and Ti (5) have been employed in 
enantioselective aziridinations, oxidations, hydroxylations, cyclopropanations, epoxide ring 
openings and hetero-Diels–Alder reactions. 
In the last years a lot of N,N’-bidentate ligands have been development, in particular 
the 2,2’-bipyridine scaffold with one or more chiral substituent chelates a wide variety of 
different metals in asymmetric catalysis.8 The chiral C2-symmetric bipyridines are primarily 
made by the Ni-catalyzed coupling of two halopyridines with appended chiral groups. Bolm and 
coworkers reported one of the first examples of non-racemic chiral 2,2’-bipyridyl ligands, 6 
(Scheme 2).9 Other examples, such as 7 and 8, that use substituents from the naturally 
available chiral pool, have been developed by Kwong and coworkers.10 
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Scheme 2 
C1-symmetric variations on the bipyridine ligand scaffold have also been developed (9-
11, Scheme 2). Standard synthetic protocols are based on cross-coupling reactions between 
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 2-pyridyl derivatives and chirally substituted 6-halopyridines.9 Another approach employs Co-
catalyzed co-cyclotrimerization reactions between 2-cyanopyridines and acetylene.11 A wide 
variety of such ligand scaffolds have been used for many asymmetric transformations. These 
primarily include: Cu-catalyzed cyclopropanations and allylic oxidations, Rh-catalyzed 
hydrosilylations, and alkylations using R2Zn. 
Other types of nitrogen ligands widely used  in asymmetric catalytic transformations 
are based on the oxazoline (4,5-dihydrooxazole) ring (Scheme 3) discovered by Evans in the 
1980s.12 Oxazoline ligands could easy prepared from readily available enantiopure amino 
alcohols derived from reduction of naturally occurring amino acids. In this class of bidentate 
ligands we could found symmetric bis(oxazoline) ligands (box’s)  (12) or C1-symmetric ligands, 
where togheter with the oxazoline ring is present another nitrogen heterocycle. 
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Scheme 3 
C2-symmetric bis(oxazolines) are one of the most popular classes of compounds, which 
have received a great deal of attention as ligands in coordination chemistry13 and in 
asymmetric catalysis.14 These ligands have two oxazoline rings separated by a spacer, and C2-
symmetric bis(oxazolines) having a single carbon atom with two identical substituents 
different from hydrogen as the spacer. This ligands have seen widespread and very 
successful application that is not possible to discuss in this thesis. 
Brunner and coworkers developed the first series of pyrrolyl- (15, 16) and 
pyridyloxazoline (13, 14) ligands for asymmetric catalysis.15 These ligands are easily and 
modularly made by ZnCl2-catalyzed condensation of 2-cyanopyrrole (or 2-cyanopyridine) with 
different amino alcohols,16 to give a library of ligands with different absolute configurations 
of the stereocentres and of the ligand’s steric bulk. Pyridyl-2-oxazolines (13) were first used 
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 as ligands in the asymmetric Cu-catalyzed monophenylation of meso-diols17 and then more 
successfully applied in asymmetric Rh-catalyzed hydrosilylations, which gave 
enantioselectivities as high as 83%.18 Pyrrolyl oxazoline 15 and 16 are used in the Rh-
catalyzed hydrogenation of ketopantolactone19 with lower e.e.. 
A significant niche in the domain of nitrogen ligands is hold by N,N’,N”-terdentate 
ligands, especially those having C2-symmetry (Scheme 4). The pyridine ring is present in most 
compounds of this type, where it has the role of a spacer between two identical N-containing 
moieties as in the widely used and highly performing pyridine-bis(oxazolines) 17 (Pybox’s)20 
and the more recently developed pyridine-bis(oxazines) (Pyboxazines) 1821 and pyridine-
bis(imidazolidines) 19.22 Both ligands 17 and 18 are readily prepared from 2,6-
pyridinedicarboxylic acids and enantiopure β- and γ-aminoalcohols, respectively, without need 
to construct new stereocenters. 
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Scheme 4 
Pyridinediimines 20, which are similarly prepared from 2,6-pyridinedicarbaldehyde, 
have been also used as ligands in metal-catalyzed asymmetric reactions.23 Moreover, N,N’,N”-
terdentate ligands 2124 bearing two chiral amine functions in the lateral chains of the 
pyridine ring were prepared from 2,6-di(chloromethyl)pyridine, then used in transamination 
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 reactions with moderate enantioselectivities. However, only a few compounds with 
stereocenters at the benzylic positions have been described. The (R,R)- and (S,S)-
enantiomers of the ligands 2225 and 2325 were obtained after separation from the meso-
compounds and resolution of the racemic mixture or copper complex, but no application of 
these ligands in asymmetric syntheses has been until now described. 
1.1.2 – N-Ligands in the Pd catalyzed asymmetric allylic substitution (AAA) 
Metal-catalyzed asymmetric allylic substitution, which involves the attack of diverse 
nucleophiles at an η3-allylic metal intermediate or SN2’-type allylic substitution, has been 
investigated with great intensity.26 Besides a high level of asymmetric induction, the 
advantages of this method are its tolerance of a wide range of functional groups and a great 
flexibility in the type of bonds that can be formed. For example, H-, C-, N-, O-, and S-
centered nucleophiles can be employed. Many ligands have been designed for the benchmark 
allylic alkylation with 1,3-diphenylallyl acetate. It should be noted that the asymmetric 
alkylation of unsymmetrical allylic substrates was seldom simultaneously regio- and 
enantioselective. However, useful results have recently been reported because of the 
availability of many new chiral ligands. 
Palladium is the most studied and used metal in the asymmetric allylic substitution. In 
the last twenty years a wide number of chiral ligands have been designed to chelate the metal 
for improving the enantioselectiviy of the reaction. Here I give some examples of nitrogen 
chiral ligands which are used in the Pd-catalyzed allylic substitution reaction and present 
aziridine or pyridine ring inside. 
The prototype reaction to test new chiral ligands is the reaction of 1,3 
diphenylpropenyl acetate 24a,b with the anion of dimethyl malonate, in the presence of a 
palladium source (complex or salt) to give the substitution product 25 (Scheme 5). 
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 The accepted mechanism for this reaction involves first the oxidative addition of a 
Pd(0) specie on the allylic substrate to yield an η3 allyl-Pd(II) complex (Scheme 6). The 
equilibrium between the neutral complex I and the cationic species II depends on many 
factors, e.g. the solvent and the nature of the ligand, but with bidentate ligands it is usually 
shifted to the side of the cationic complex. This is highly reactive towards soft nucleophiles, 
which attack at the less substituted allylic terminus leading to a η2-olefin-Pd(0) complex III, 
then to the final product and a Pd(0) complex that restarts another catalytic cycle. 
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Scheme 6 
In the literature are described many examples of ligands which contain the pyridine 
ring and efficiently catalyse this reaction in an asymmetric fashion. Chiral aziridines have 
been seldom used in the AAA. It is noteworthy that the C2-symmetric bis(aziridine) 2627 
(Scheme 7) afforded a complete enantioselectivity, while the pyridine derivative 2728 gave a 
64% e.e. and the phenantroline derivate 2929 gave a 96% e.e.. In C1-symmetric 2-(2’-
pyridyl)oxazolines 29a,b30 and 3030c,31 a remarkable effect of the substituent in both rings 
was observed; particularly, the substitution of Ph for the i-Pr group in the oxazoline was 
beneficial, as a better e.e. was provided by 30 with the same pyridine substituent (R = H). 
Most importantly, the presence of a (chiral) bulky substituent at the pyridine-C6, or the 
presence of a benzo[b]-fused ring as in 31, caused an increase of the enantioselectivity.30,31 
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 It should be observed that the ligands 30-31 form a rigid five-membered chelation ring in 
the cationic (η3-allylic)Pd complexes however, six-membered chelation rings like those 
derived from the ligands 32-34 have been also studied. In the case of 8-quinoline-oxazolines 
32, an unexpected effect of the substitution was observed, as with R = Me32 and the 
benzo[b]-derivative[4] the opposite enantiomer of 25 was produced. Similarly, the 2-
(quinolylmethyl)oxazoline 34 displayed the opposite enantioselectivity with respect to 33.32 
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Scheme 7 
The Savoia’s group has studied (N,N')* ligands containing both the pyridine and 
aziridine rings. We have described the preparation of 35 and its cationic η3-allylpalladium 
complex 36 (Scheme 8), which is more effective than the free base in the above mentioned 
Pd-catalysed allylic substitution reaction, providing (R)-25 with moderate yield and 41%  
e.e..33 The ligand 35 differs from 26-32 for the presence of a stereocentre in the carbon 
chain linking the two rings, besides the one present on the aziridine carbon. The two 
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 stereocentres in 35 have a combined role compelling the aziridine nitrogen to assume the R 
configuration when forming the Pd complex, as shown by the X-ray structure analysis of 36. 
This happens to avoid the severe interaction of the two iPr substituents, which instead would 
occur in the alternative complex with the S configuration. 
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After this first work, we prepared new ligands containing the aziridine and pyridine 
rings and then converted them to the [(N,N')*(η3-allyl)Pd][SbF6] complexes, which were used 
as catalysts in the allylic substitution reaction.34 The ligand prepared from (R)-phenylglycinol 
(37) was considerably more enantioselective in the catalytic application (e.e. 90%), as a 
consequence of the more demanding steric effect of the phenyl substituent in the aziridine 
ring, which is oriented towards the Pd-allylic ligand. On the other hand, structural variations 
in the starting heterocyclic aldehyde (38-40), also allowing the ligand to form either a five- 
or six-membered chelation ring with palladium, and the substitution pattern in the aza-
heteroaromatic ring had relevant effects on both reactivity and stereocontrol. Especially, 
inversion of enantioselectivity was observed using the ligand bearing a 6-benzyl-substituted 
pyridine (40). The moderate efficiency of the alkylation reactions catalysed by our 
ligands/complexes can be attributed to the weakness of the Pd-N(pyridine) bond(s), which 
affects the stability of [(N,N')*(η3-allyl)Pd]+ cations. Moreover, the absence of a π-acceptor 
N ligand in (N,N')* does not allow the effective stabilization/dissolution of the Pd(0) species 
which are formed by nucleophilic attack to the intermediate cationic complex as a matter of 
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 fact, formation of a black palladium precipitated was observed, after that the reaction 
stopped. 
As an evolution of these chiral pyridine-aziridine chiral ligands we envisioned a similar 
three step route to enantiopure C2-symmetrical N,N’,N”-terdentate ligands35 involving the 
addition of organometallic reagents to chiral diimine derived from 2,6-pyridinedicarbaldehyde 
and (S)-valinol and (S)-phenylglycinol followed by conversion of the β-aminoalcohols to 2,6-
di[1-(1-aziridinyl)alkyl]pyridines (DIAZAP’s) was achieved by a Mitsunobu reaction (Scheme 
9). By this strategy, the carbon skeleton of the starting chiral aminoalcohol and the absolute 
configuration of the inherent stereocenters are retained in the final molecule. The new 
ligands were then used in palladium catalyzed asymmetric allylic alkylation (AAA) of stabilized 
carbanions, where they provided higher enantioselectivity with respect to the analogous, 
previously described, bidentate pyridine-aziridine ligands.33,34 Our idea was also based on the 
report that a higher reaction rate was obtained using a P,N,N-terdentate ligand instead of a 
bidentate P,N-ligand in Pd-catalyzed AAA reactions;36 a result that may have been the 
consequence of the capability of the terdentate ligand to effectively stabilize either Pd(0) or 
the (allylic)Pd(II)+ complexes involved in the catalytic cycle. However, in the case of our 
terdentate ligands, taking into account the effects of substituents in the bidentate ligands 
on enantioselectivity, it was difficult to foresee the importance of the C6 pyridine 
substituent (aziridine-alkyl group), which could potentially oppose the asymmetric induction of 
the aziridine substituent. 
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1.2 - Results and discussion 
1.2.1 – Preparation of the DIAZAP Ligands 
The starting O-silylated diimines 41a and 41b (Scheme 10) were prepared in almost 
quantitative yields by the protocol previously described for the analogous monoimines,33,34,37 
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 and were used directly in the following step without purification. As stated before, Grignard 
reagents and allylic zinc reagents were not effective and lead generally to mixture of 
products coming from the further attack to the pyridine moiety. Organolithium compounds 
were found to be the reagents of choice to achieve a highly efficient, regio- and 
diastereoselective double addition to the azomethine groups in anhydrous tetrahydrofuran 
(THF) at -78 °C (Table 1Table 1). 3,3-Dimethylbutyllithium was prepared by the reaction of t-
butyllithium (2 equivalents) with THF (solvent) at room temperature, involving the addition of 
t-butyllithium to ethylene, which is formed together with the lithium enolate of acetaldehyde 
following the initial cleavage of THF by t-butyllithium.38 It is noteworthy that almost all the 
reactions gave the expected products 42a and 42b in high yields and with very high 
diastereoselectivities (Table 1). As a matter of fact, apart from the addition of t-
butyllithium to both imines (entries 3 and 8), which provided the corresponding aminoalcohols 
with low diastereomeric ratios, the reactions of organolithium reagents with the valinol-
derived imine 41a occurred in most cases with higher diastereoselectivities (d.r. of 42a 94:6) 
with respect to the phenylglycinol-derived imine 41b (d.r. of 42b 91:9). For the imine 41a, the 
best result was obtained with phenyllithium, which afforded the aminoalcohol 42ae' in 95% 
yield and d.r. 98:2. However, the addition of methyllithium to 41b (entry 6) was even more 
diastereoselective, as the pure compound (S,S)-41ba’ was obtained in 94% yield after column 
chromatography of the crude reaction product, no trace of the other diastereomers were 
detected by 1H NMR spectroscopy. 
It should be observed that all the organometallic additions produced only two of 
three possible diastereomers of the compounds 42: the prevalent one had C2-symmetry, as 
observed by 1HNMR spectroscopy. The S,S configuration of the two newly formed 
stereocenters at the benzylic positions was at first assumed considering the sense of 
asymmetric induction previously observed in the addition of organolithium reagents to the 
analogous 2-pyridine monoimine,37  and was then confirmed by the X-ray structure obtained 
for one palladium complex (see later). Column chromatography of the crude reaction products 
often allowed isolation of the main diastereomer only, however, enriched chromatographic 
fractions of the minor diastereomer were obtained, allowing its C1 symmetry to be 
determined. In particular, the separation of the diastereomers was difficult for 42aa’ and 
42ac’, and low yields of the pure main (S,S)-diastereomer were obtained. In these cases, it 
was preferable to merely filter the crude reaction mixtures through a small pad of silica and 
use the diastereomeric mixtures in the subsequent step, that is the cyclization to DIAZAP’s 
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 43aa’ and 43ac’, since the diastereomers of the latter compounds were more readily 
separated by chromatography.  
 
Scheme 10 
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Table 1 
Entry Imine (R1) R2Li Product D.r.[a] 
42, 
Yield %[b] 
43, 
Yield %[c] 
1 41a (i-Pr) MeLi 42aa’ 95:5 95 43aa' (85) 
2 “ n-BuLi 42ab’ 95:5 95 (79)[c] 43ab' (87) 
3 “ t-BuLi[d] 42ac’ 84:16 95 (54)[c] 43ac' (84)[e] 
4 “ t-BuCH2CH2Li[f] 42ad’ 94:6 84 (70)[c] 43ad' (86) 
5 “ PhLi 42ae’ 98:2 95 43ae' (90) 
6 41b (Ph) MeLi 42ba’ >99:1 94[g] 43ba' (85) 
7 “ n-BuLi 42bb’ 91:9 93 (76) 43bb' (90)[h] 
8 “ t-Bu[d] 42bc’ 86:14 94(59) 43bc' (86)[i] 
9 “ PhLi 42be’ 92:8 98 (84) 43be’ (89)[j] 
[a] Determined by 1H NMR spectroscopy of the crude reaction products. [b] Yield of the crude reaction product. 
Unless otherwise indicated, the diastereomers were not separated. [c] Yield of pure (S,S)-42 isolated after column 
chromatography. [d] The reaction was performed in diethyl ether. [e] The product was obtained after column 
chromatography as a 89:11 mixture of diastereomers. [f] The reagent was prepared in situ by adding t-BuLi to THF 
(solvent) at 0 °C. [g] The crude product was apparently pure by 1H NMR spectroscopy. [h] The product was obtained 
after column chromatography as a 91:9 mixture of diastereomers. [i] The product was obtained after column 
chromatography as a 86:14 mixture od diastereomer. [j] The product was obtained after column chromatography as a 
a 92:8 mixture of diastereomers. 
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 The reaction protocols that were successful for the construction of the mono-
aziridine ligands did not give good results. Instead we found that the Mitsunobu reaction 
using diethylazadicarboxylate (DEAD) and triphenylphosphine in THF at room temperature 
gave much better results. DIAZAP’s 43a and 43b were so obtained with high yields. In the 
case of phenylglycinol derivatives, the diastereomers of the aminoalcohols 42bb’, 42bc' and 
42be’ and the corresponding aziridines 43bb’, 43bc'and 43be’ could not be separated. 
1.2.2 – Pd-Catalyzed AAA in presence of DIAZAP ligand: substituent effects 
A number of reactions were carried out on the allylic carbonate 24b with the anion of 
dimethyl malonate, generated by treatment of dimethylmalonate with either sodium hydride 
or bis(trimethylsilyl)amide (BSA) and a catalytic amount of potassium acetate in different 
solvents (Scheme 11, Table 2). Allylpalladium chloride dimer and the terdentate ligands 43a 
and 43b were used as precursors of the effective enantioselective catalyst. The ligands 
derived from (S)-valinol were examined first. The carbonate 24b was treated with the pre-
formed sodium salt of dimethyl malonate (1.5 molar equivalents) and catalytic amounts of 
allylpalladium chloride dimer (5 mol%) and ligand 43aa' (10 mol%) in tetrahydrofuran at room 
temperature. The course of the reaction was monitored by GC and TLC analysis and an almost 
complete conversion of the starting compound was observed after 24 h. The product 25 was 
isolated in high yield and 76% e.e. in favour of the R enantiomer (Table 2, entry 1). It should 
be observed that use of performer palladium salt [(η3-allyl)(43aa')Pd][SbF6] was unnecessary. 
In fact a smooth reaction occurred and the formation of black palladium was observed only 
when the reaction was almost complete. In a second run (entry 2) at -20 °C, with all the other 
experimental conditions being unchanged, we observed that the same e.e. was obtained, but a 
longer reaction time was required to obtain a satisfactory yield of product. Hence, all the 
successive reactions were carried out at 25 °C. 
The role of the solvent was then examined and it was found that the reaction took 
place also in dichloromethane, despite the poor solubility of sodium dimethyl malonate and the 
consequent lower reaction rate, but a slightly lower e.e. was obtained (entry 3). The same 
trend was observed when the n-butyl substituted ligand 43ab’ was used in both solvents, but 
the e.e.’s (60-63%) were lower (entries 4, 5). Similar results were obtained with the t-butyl 
substituted ligand 43ac’ (used as a 84:16 mixture of unseparable diastereomers) and the 
ligand 43ad’ (R2 = t-BuCH2CH2) in different experimental conditions. Finally, the phenyl 
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 substituted ligand 43ae’ provided high levels of enantioselectivity with e.e. up to 88% in entry 
12. 
 
Scheme 11 
Ph Ph
OCO2Et
(allylPdCl)2 (5 mol%),
L* , Solvent, Base
Ph Ph
MeO2C CO2MeCH2(CO2Me)2 N
NN
R2R2
i-Pri-Pr24b 25
  
Table 2 
Entry Ligand (mol%) Base Solvent Time (h) Yield (%) E.e. (%) 
1 43aa’ (10) NaH THF 24 79 76 
2 43aa’ (10) [b] " THF 96 69 76 
3 43aa’ (10) " CH2Cl2 48 85 73 
4 43ab’ (10) " THF 24 81 63 
5 43ab’ (10) " CH2Cl2 48 86 60 
6 43ac’ (10, d.r. 89:11) BSA/AcOK CH2Cl2 48 84 69 
7 43ad’ (10) NaH THF 48 86 70 
8 43ad’ (10) BSA/AcOK CH2Cl2 16 90 62 
9 43ae’ (10) NaH THF 24 85 76 
10 43ae’ (10) NaH CH2Cl2 18 89 86 
11 43ae’ (10) BSA/AcOK CH2Cl2 15 90 82 
12 43ae’ (10) BSA/AcOLi CH2Cl2 24 89 88 
13 43af’ (10) BSA/AcOK CH2Cl2 24 87 13 
 
Again, we wanted to demonstrate the need of a substituent at the benzylic positions 
since this would induce the stereoselective formation of the N-aziridine stereocenter in the 
cationic palladium complex. It should be observed that N-alkyl aziridines are not pyramidally 
stable at room temperature, and the bulkiness of the substituent decrease the barrier of 
inversion.39 As demonstrated in the previous chapter, all the previously prepared η3-allylic 
palladium complexes carrying bidentate (N,N)*-ligands displayed a unique configuration of the 
aziridine nitrogen atoms, that is dictated by the configuration of the benzylic carbon 
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 stereocenters and minimises the steric interactions between the benzylic (R2) and aziridine 
(R1) substituents. To that purpose, we synthesized the ligand 43af' by reduction of the 
diimine 41a to give the intermediate diaminediol 42a,f’, followed by the usual cyclization 
step (Scheme 10). The correctness of our hypothesis was demonstrated by the observation 
that the typical allylic alkylation of sodium dimethyl malonate with the allylic carbonate 24b 
in THF at 25 °C in the presence of 10 mol% of ligand 43af’ occurred with very low 
enantioselectivity (13% e.e., entry 13). 
 
Scheme 12 
Ph Ph
OCO2Et
(allylPdCl)2 (0.5-5 mol%),
L* , Solvent, Base
Ph Ph
MeO2C CO2MeCH2(CO2Me)2 N
NN
R2R2
PhPh24b 25
 
 
Table 3 
Entry Ligand (mol%) Base Solvent Time (h) Yield (%) E.e. (%) 
1 43ba’ (10) NaH THF 72 82 82 
2 43ba’ (10) NaH CH2Cl2 3 90 98 
3 43ba’ (10) BSA/AcOK CH2Cl2 2 92 98 
4 43ba’ (3) BSA/AcOK CH2Cl2 8 87 98 
5 43ba’ (3) BSA/AcOLi CH2Cl2 5 90 98 
6 43ba’ (1) BSA/AcOK CH2Cl2 38 68 98 
7 43bb’ (10, d.r. 91:9) NaH THF 48 77 80 
8 43bb’ (10, d.r. 91:9) BSA/AcOK CH2Cl2 16 89 81 
9 43bc’ (10, d.r. 86:14) BSA/AcOK CH2Cl2 48 64 70 
9 43be’ (10, d.r. 92:8) BSA/AcOK CH2Cl2 16 88 83 
10 43bf’ (10) BSA/AcOK CH2Cl2 24 92 76 
 
The terdentate ligands 43b, derived from (S)-phenylglycinol and hence carrying 
phenyl substituents on the aziridine rings, were then examined in the same typical AAA 
reaction (Table 3). (R)-25 was formed in all cases with e.e.’s definitely superior to those  
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obtained with the corresponding (S)-valinol-derived ligands 43a. For example, using 
sodium hydride as the base in THF in the presence of allylpalladium chloride dimer (5 mol%) 
and the ligand 43ba' (10 mol%) the product (R)-25 was obtained with 82% yield and 82% e.e. 
after 72h (entry 1,  
Table 3). Then, we observed that in dichloromethane, despite the very low solubility of 
sodium dimethyl malonate, the reaction with the ligand 43ba' was almost complete after only 
3 h and the product was obtained with excellent yield and 98% e.e. (entry 2). The same level 
of enantioselectivity was obtained by performing the reaction with the same ligand and 
generating the nucleophile by the alternative protocol (BSA-AcOK in DCM, entry 3), even with 
reduce
.e., entry 13 Table 2), provided a moderate 
enantioselectivity (76% e.e., entry 10 Table 2). 
1.2.3 – 
tly lower 
e.e.s; u to 85% yield and 96% e.e. were obtained with the latter catalyst (entry 4). 
 
Scheme 13 
Ph
d amounts of ligand (1 mol%, entries 4 to 6).  
It was apparent that an increase in the bulkiness of the R2 substituents in the ligands 
43b caused a decrease of the reaction rate. The n-butyl- and phenyl-substituted ligands 
43bb', 43bc' and 43be' were used as an unseparable mixture of diastereomers, with the 
(S,S) and (S,R) configurations of the two benzylic stereocenters (d.r. 91:9, 86:14 and 92:8, 
respectively); nevertheless high e.e.’s were obtained (e.e.’s 80, 81, 70 and 83% in entries 7 to 
9). Finally, we were surprised to find that the ligand 43bf’ (R2 = H, Scheme 1), in contrast to 
the analogous (S)-valinol-derived 43af' (13% e
Pd-Catalyzed AAA in the presence of DIAZAP ligand: Pd source. 
The role of different palladium sources was briefly investigated carrying out the 
allylation of the malonate anion (BSA, AcOK) with the carbonate 24b in the presence of the 
ligand 43ba’ in dichloromethane at 25 °C (Scheme 13). In comparison with the reaction 
catalyzed by allylpalladium chloride dimer (entry 1, Table 4), which was almost complete after 
only 3 h, the reactions catalyzed by palladium acetate, palladium chloride and the 
dibenzylideneacetonate complex required 24 h to give comparable yields and sligh
p 
Ph
OCO2Et
Pd-Source (5 mol%), 43ba',
BSA (3 equiv.), AcOK (0.1 eq.)
Ph Ph
MeO2C CO2MeCH2(CO2Me)2 N
NN
Ph Ph43ba'24b 25
 
 Table 4 
Entry Pd catalyst (5 mol%) Time (h) Yield (%) of (S)-25 E.e. (%) 
1 (allylPdCl)2 3 87 98 
2 Pd(OAc)2 24 76 87 
3 PdCl2 24 81 94 
4 Pd(dba)2CHCl3 24 85 96 
1.2.4 - Pd-Catalyzed AAA in presence of DIAZAP ligand: different nucleophiles and 
substrates 
Then, to extend the scope of our catalytic system, we investigated the AAA reactions 
of other stabilized enolates as well as diversely substituted allylic carbonates. The enolates 
derived from substituted malonates have been relatively less employed as nucleophiles, and 
chiral (P,P), (P,N) and (N,P,N) ligands have been used.40 We were pleased to find that the 
alkylations of the benzyl- and phenyl-substituted malonate esters 44a and 44b, respectively, 
proceeded smoothly in the presence of the ligand 43ba’ to give the products 45a and 45b in 
high yields and with 97-99% e.e.’s. The S configuration of the stereocenter in 45a was 
assigned on the basis of the optical rotation (-)40c. Since the new compound 45b is also 
levorotatory 45a, the same configuration is assumed. 
Ph Ph
OCO2Et
24b
RCH(CO2Me)2 44 (2.5 equiv.)
BSA (3 equiv.), AcOK (0.1 equiv.),
(allylPdCl)2 (5 mol%),
43ba' (10 mol%),
CH2Cl2, 25 °C, 38 h
Ph Ph
45
MeO2C CO2Me
R
a: R = Bn, 88%, e.e. 97%
b: R = Ph ,89 %, e.e. 99%  
Scheme 14 
The cyclohexenyl carbonate 46 was poorly reactive in the usual experimental 
conditions and the e.e. of the derived product 4741 was low. For example, using ligand 43ba’, a 
40% yield and 6% e.e. were achieved, whereas a 68% yield and 37% e.e. were obtained with 
the ligand 43ae’, in both cases after 3 days. The reaction rate could be slightly increased in 
the presence of silver tetrafluoroborate, and good yields of the cyclohexenyl-substituted 
malonate 19 were obtained after 2 days using either ligand 43ad’ or 43ae’, but the e.e. did 
not exceed 38%. Surprisingly, the use of ligand 43ba' resulted in a low yield of 47 (40%) and 
very low e.e. (6%).  
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 BSA (3 equiv.), AcOK (0.1 equiv.),
(allylPdCl)2 (5 mol%), 43 (10 mol%),
AgBF4 (10 mol%), CH2Cl2, 25 °C,
24 h
46
OCO2Et
CO2MeMeO2C
cat. 43ad': 74%, e.e. 38%
cat. 43ae': 85%, e.e. 37%
cat. 43ba': 40%, e.e. 6%
CH2(CO2Me)2
47
 
Scheme 15 
Similarly, the reaction of dimethyl malonate anion with ethyl 3-penten-2-yl carbonate 
48 (Scheme 16) in the presence of the ligands 43ae' and 43ba' afforded the substitution 
product 49 in good yields in the presence of AgBF4, but with low e.e.s (up to 28%).  
 
Me Me
OCO2Et
48
CH2(CO2Me)2 (2.5 equiv.)
(allylPdCl)2 (5 mol%),
AgBF4 (10 mol%), 43 (3 mol%),
BSA (3 equiv.),
AcOK (0.1 equiv.), 25 °C, 24 h
Me Me
CO2MeMeO2C
49
43ae': 85%, e.e. 28%
43ba': 78%, e.e. 18%  
Scheme 16 
Performing the reaction an the unsymmetrically disubstituted allylic carbonate 50 
(Scheme 17), a mixture of products (ratio 95:5) was obtained, as usually found with other 
ligands:42 the prevalent product 51 was formed by attack at the methyl-substituted allylic 
terminus with low enantioselectivity (e.e. 14%), whereas the minor regioisomer 52 was 
obtained with 95% e.e.. 
Ph Me
OCO2Et
50
CH2(CO2Me)2 (2.5 equiv.)
(allylPdCl)2 (1.5 mol%), 43 (3 mol%),
BSA (3 equiv.), AcOK (0.1 equiv.),
25 °C, 24 h
Ph Me
CO2MeMeO2C
51 52
PhMe
MeO2C CO2Me
+
43ba': 88%, 51/ 52 = 95:5, e.e. 51 14%, e.e. 52 95%
43ae': 89%, 51/ 52 = 85:15, e.e. 51 10%, e.e. 52 95%
Scheme 17 
Finally, we turned our attention to the capability of our catalytic system to induce 
enantioselectivity in the formation of a quaternary stereogenic center at the nucleophilic 
carbon. This goal should be achieved by the discrimination of the two diastereotopic faces of 
a fully substituted planar enolate attacking the η3-allylic ligand. This is difficult to realise 
because the chiral N,N,N-ligand does not interfere in any way with the incoming nucleophile, 
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 and the newly formed stereocenter is more remote from the inducing stereocenter(s) than in 
previous experiments. Hence, we investigated the reaction of (E )-cinnamyl ethyl carbonate 
53 (Scheme 18) with the anion derived from 2-ethoxycarbonylcyclohexanone 54 under 
different reaction conditions. The reaction proceeded smoothly to give the linear alkylation 
product 55 with high yield but only 27% e.e.. An increase in the enantioselectivity was 
observed when we used a lithium enolate as nucleophile but a decrease of the yield was 
observed. This result can be compared with the reported Pd-catalyzed enantioselective 
synthesis of 55 using a P-chirogenic diaminophosphine oxide as the ligand, where 92% e.e. was 
obtained.43 We assigned the S configuration to the major enantiomer of 55 by comparison 
with the authentic enantiomer.43 
Scheme 18 
Ph OCO2Et
53
43 (10 mol%),
CH2Cl2, 25 °C, 38 h
O
CO2Et
O
Ph
CO2Et
54 (1.5 equiv.)
+
BSA (), AcOK,
(allylPdCl)2 (5 mol%)
55  
Table 5 
Entry Ligand Base Time (h) Yield (%) of 55 E.e. (%) 
1 43ab’ NaH 2 95 13 
2 43ae’ BSA/AcOK 24 84 5 
3 43ba’ BSA/AcOK 38 83 27 
4 43ba’ BSA/AcOLi 72 68 35 
 
1.3 – Tentative explanation of mechanism and enantioselectivity 
Aiming to get information on the possible structural factor effecting the 
enantioselctivity, we prepared different (allyl)- and (1,3-diphenylallyl)Pd+ salts bearing the 
(S)-valinol- and (S)-phenylglycinol-derived ligands, 43ae' and 43ba', with PF6, SbF6 or BF4 
counterions, were prepared by standard methodology. These salts were generally obtained as 
white or yellowish powders, and some of them appeared impure by 1H NMR analysis. Up till 
now, we have succeeded to obtain crystals suitable for X-ray crystallographic structure 
determinations only in the case of the salt [(43ae')(allyl)Pd][PF6]. 
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 The crystal structure is quite similar to those of the previously reported allylic 
palladium salts with pyridine-aziridine ligands,37 featuring the bidentate coordination of the 
ligand to palladium cation and the η3 hapticity of the endo/exo allyl ligand. The palladium-
aziridine bond is shorter than the palladium-pyridine bond (2.109(3) vs 2.158(3) Å), and the 
terminal allylic carbon anti to the aziridine form a bond with palladium (2.178(4) Å) longer 
than the allylic terminus anti to the pyridine ring (2.126(4) Å). This observation supports the 
hypothesis that the allylic terminus anti to the aziridine has a more electrophilic character. 
The 1H NMR spectra of the CD2Cl2 solutions of this salt and all the other [(allyl)- or (1,3-
diphenylallyl)(43a or 43b)]Pd+ salts with PF6-, SbF6- and BF4- counterions were complex and 
showed broad absorptions, indicating the presence of several species, although the endo- and 
exo-(η3-allyl) (N,N)Pd+ species were predominant. Most importantly, in the case of the 1,3-
diphenylallyl complexes, a higher ratio of rotamers (>3:1) was observed for the complex 
derived from the ligand 43ba', which afforded the highest enantioselectivity. Moreover, the 
spectra were complicated by the lack of C2-symmetry of the ligand complex, demonstrating 
that only one aziridine nitrogen was involved in Pd coordination. For example, for each 
rotamer, distinct absorptions were observed for the two benzylic protons. 
 
 
Figure 1 
In the absence of information on the reactive intermediate involved in the 
enantioselective step, we can only speculate on the the origin of the enantioselectivity. We 
take into account the available structural information of the bidentate complex 40 and the 
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 mechanistic hypothesis that has been suggested to explain the sense of asymmetric induction 
provided by such ligands.37 Moreover, several studies on the binding properties of potentially 
terdentate ligands towards (allyl)Pd(II) cations have been reported.44,45,46 For example, the 
X-ray crystal structure of a (terpyridine)(allyl)palladium complex has been determined and its 
dynamic behaviour in solution has been studied by 1H- and 13C-NMR spectroscopy.47 It was 
therein shown that terpyridine binds the (η1-allyl)Pd+ fragment in the terdentate fashion and 
η3-allyl)Pd+ as a bidentate ligand. In fact, the two species are present both in the crystal and 
in a CD2Cl2 solution in a dynamic equilibrium, which is strongly displaced towards the η3-allyl 
form at low temperature. On the other hand, the 2,6-bis(diphenylphosphanylmethyl)pyridine 
(PNP) ligand in the complex [(PNP)(allyl)Pd][BF4] adopts the terdentate coordination mode 
both in the crystal and in solution, where the complex is fluxional through η1-η3 equilibrium 
processes.45,46 This is in contrast to the behaviour of (N,P,N) ligands which act as (P,N)-
bidentate ligands in (η3-dimethylallyl)Pd+ complexes.48 Similarly, the presence of the pyridine 
ring in a chiral (P,N,N) ligand was unnecessary for high selectivity in the AAA reaction, 
suggesting that the ligand acts in a (P,N)-bidentate fashion.49 
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Scheme 19 
On the basis of the precedent studies, we believe that the prevalent rotamer of the 
reactive (η3-1,3-diphenylallyl)(N,N,N)Pd+ complex is 57 (Scheme 19), featuring the syn,syn-
configuration of the allylic ligand and reduced interactions of the allylic phenyl groups and 
the aziridine substituent. Moreover, in solution the chiral aziridinylalkyl substituent not 
involved in palladium chelation should take the same spatial arrangement as observed in the 
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 crystal structure, with the methine hydrogen oriented towards the allylic ligand in order to 
reduce the steric interactions. Obviously, owing to the C2-symmetry of the nitrogen ligand, 
identical η3-(N,N)-complexes are formed when one or the other aziridine nitrogen is involved 
in Pd coordination. The complex 57 is equilibrium with the less stable complex 59 trought the 
(η1-1,3-diphenylallyl)(N,N,N)Pd+ where all the nitrogen chelating the metal. 
If this assumption is correct, the sense of enantioselectivity is easily explained by 
the attack of the nucleophile on the more electrophilic allylic terminus anti to the aziridine 
nitrogen of the more stable intermediate 57 to give the (η2-alkene)Pd(0) complex η2-(N,N)-
58. The regioselectivity of the nucleophilic attack is also favoured by the preferential clock-
wise rotation of the hydrocarbon ligand occurring during the formation of the most stable 
(η2-alkene)Pd complex 58, as the steric interactions between the alkene and the nitrogen 
ligand are reduced concurrently. 
 
1.4 - Conclusion 
C2-symmetrical N,N',N"-terdentate ligands featuring two aziridine rings in the lateral 
arms of a pyridine ring are constructed by a short and efficient route starting from 
commercially available building blocks: 2,6-pyridinedicarbaldehyde, optically pure β-
aminoalcohols and organolithium reagents. These ligands (DIAZAP's) induce high levels of 
enantioselectivity (e.e. up to 98%) in the allylic alkylation of dimethyl malonate anion and 
analogous C2-substituted anions. Contrary to the corresponding bisdentate ligands derived 
from 2-pyridinecarbaldehyde, the DIAZAP ligands are capable of stabilizing both cationic and 
zerovalent palladium, thus avoiding the ready interruption of the catalytic cycle by deposition 
of Pd black. Unfortunately, application of these ligands in the allylic alkylation of different 
nucleophiles has met with low enantioselectivity or no success. However, it is expected that 
they can be used in other transition metal catalyzed reactions.  
 
1.5 – Experimental section 
1.5.1 – General protocol for the preparation of Imines 41 
To a solution of (S)-valinol (6 mmol, 0.618 g) or (S)-phenylglycinol (6 mmol, 0.823 g) in 
THF (50 mL) was added anhydrous MgS04 (5 g), the aldehyde (3 mmol, 0.405 g) and the 
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 mixture was stirred overnight. The solid phase was filtered off on a pad of Celite and the 
organic solvent was evaporated under reduced pressure. The residue was dissolved in CH2Cl2 
(20 mL) and triethylamine (7 mmol, 0.708 g) and chlorotrimethylsilane (7 mmol, 0.97 mL. 
0.760 g) were added at 0 °C. After 3 h the solvent was removed under vacuum. A solution of 
cyclohexane/diethyl ether 1:1 was added and the solid phase was filtered off on a pad of 
Celite. The organic solvent was evaporated under reduced pressure to leave the imine in 
almost quantitative yield; this was used in the following step without further purification. 
N
NN
Me3SiO OSiMe3  
N,N'-Bis((S)-1-trimethylsilyloxy-3-methyl-butan-2-yl)-2,6-bis(imino)pyridine 
(41a): Yellowish oil; [α]D25 = -19.7 (c 0.7, CHCl3); 1H NMR (CDCl3, 200 MHz): δ = 0.05 (s, 18 H), 
0.92 (d, J = 6.9 Hz, 6 H), 0.94 (d, J = 6.9 Hz, 6 H), 2.0 (sept, J = 6.9 Hz,  2 H), 3.1 (m, 2 H), 
3.69 (dd, J = 7.8 Hz,  J = 10.3 Hz, 2 H), 3.89 (dd ,  J = 4.3 Hz, J = 10.3 Hz , 2 H), 7.76 (t, J = 
7.6 Hz, 2 H), 8.07 (d, J = 7.6 Hz, 1 H), 8.36 (s, 2 H); 13C NMR (CDCl3, 50 MHz): δ = -0.4, 18.5, 
20.0, 29.9, 64.3, 78.4, 121.9, 136.7, 154.5, 161.6; IR (neat): ν = 2958, 2872, 1648, 1585, 1569, 
1457, 1251, 1107,1077, 877, 841, 746 cm-1; GC-MS m/z : 73 (100), 171 (70), 346 (36), 103 
(27), 316 (11), 449 (10, M). 
N
NN PhPh
Me3SiO OSiMe3  
N,N'-Bis((S)-2-trimethylsilyloxy-1-phenylethyl)-2,6-bis(imino)pyridine (41b): 
white solid; m.p. = 117 °C; [α]D25 = +25.1 (c 0.8, CHCl3); 1H NMR (CDCl3, 200 MHz): δ = 0.02 (s, 
18 H), 3.89 (d, J = 1.7 Hz, 2 H), 3.91 (s, 2 H), 4.52 (dd, J = 5.6 Hz, J = 7.8 Hz, 2 H), 7.2-7.4 
(m, 7 H), 7.5-7.6 (m, 3 H), 7.81 (t, J = 7.6 Hz, 1 H), 8.20 (d, J = 7.6 Hz, 2 H), 8.49 (s, 2 H); 13C 
NMR (CDCl3, 50 MHz): δ = - 0.4, 67.6, 76.7, 122.2, 127.4, 128.4, 136.7, 140.7, 155.4; IR 
(Nujol): ν = 3067, 3029, 1647, 1364, 1251, 1118, 1081, 1054, 884, 841, 757, 699 cm-1. 
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 1.5.2 – Preparation of β-Aminoalcols 42 by additin of organolithium reagents ti  imines 41: 
Organolithium reagent (9 mmol) was added to a magnetically stirred solution of the 
imine 41 (3 mmol) in THF (10 mL) cooled to –78 °C. After 30 minutes, the reaction mixture 
was slowly warmed at 0 °C, and quenched after 3 h by adding 1 N HCl (10 mL). After 2 h 
NaOH pellets were added until the solution reached pH 11, and the organic phase was 
extracted with diethyl ether (3 ×10 mL). The collected ethereal phases were dried over 
Na2SO4 and concentrated to leave the crude  products. The diastereomeric ratio was 
determined by 1H NMR analysis. Flash column chromatography (SiO2), eluting with 
cyclohexane/ethyl acetate mixtures, gave the product which was directly used in the 
subsequent step. 
N
HNNH i -Pri -Pr
OHHO  
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-
aminoethyl)pyridine (42aa'): White solid; m.p. = 86 °C; [α]D25 = -74.6 (c 0.18, CHCl3); 1H NMR 
(CDCl3, 200 MHz): δ = 0.81 (d, J = 6.8 Hz, 6H), 0.86 (d , J = 6.8 Hz, 6 H), 1.37 (d, J = 6.7 Hz, 6 
H), 1.65 (sept, J = 6.8 Hz, 2 H), 2.19 (dd, J = 4.2 Hz, J = 4.8 Hz, 2 H), 2.70 (bs, 4 H), 3.38 
(dd, J = 4.8 Hz, J = 10.8 Hz, 2 H), 3.61 (dd, J = 4.2 Hz, J = 10.8 Hz, 2 H), 3.89 (q, J = 6.7 Hz, 
2 H), 7.05 (d, J = 7.7 Hz, 2 H), 7.57 (t, J = 7.7 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ = 18.8, 
19.6, 23.5, 29.4, 56.2, 60.0, 62.0, 119.8, 136.7, 163.7; IR (KBr): ν = 3404, 3968, 1572, 1449, 
1361, 1172, 1074, 834 cm-1; anal. calcd. for C19H35N3O2: C 67.62, H 10.45, N 12.45; found: C 
67.37, H 10.48, N 12.41. 
N
HNNH
n-Bun-Bu
i -Pri -Pr
OHHO  
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-
aminopentyl)pyridine (42ab’): Yellowish oil; [α]D25 = -48.5 (c 1.1, CH2Cl2); 1H NMR (CDCl3, 200 
MHz): δ = 0.77 (d, J = 6.8 Hz, 6 H), 0.79 (d, J = 6.8 Hz, 6 H),  0.82 (t, J = 6.6 Hz, 6 H), 1.25 
(m, 8 H), 1.63 (sept, J = 6.8 Hz, 2 H), 1.72 (m, 4 H), 2.08 (dd, J = 3.8 Hz, J = 6.4 Hz, 2 H), 
3.73 (bs, 4 H), 3.39 (dd, J = 3.8 Hz, J = 10.8 Hz, 2H), 3.61 (dd, J = 6.4 Hz, J = 10.8 Hz, 2 H), 
3.62 (t, J = 6.9 Hz, 2 H), 6.97 (d, J = 7.6 Hz, 2 H), 7.52 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 
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 50 MHz): δ = 13.9, 18.8, 19.6, 22.6, 28.7, 29.4, 37.5, 59.5, 61.3, 62.0, 120.9, 136.0, 163.2; IR 
(neat): ν = 3160, 2957, 2926, 2858, 1590, 1464, 1260, 1089, 801 cm-1; ESI-MS m/z : 422.4 
[M+ 1], 423.3 [M+ 2]; anal. calcd. for C25H47N3O2: C 71.21, H 11.23, N 9.97; found: C 71.08, H 
11.25, N 9.93. 
 
 
N
HNNH
t -But -Bu
i -Pri -Pr
OHHO  
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-amino-2,2-
dimethylpropyl)pyridine (42ac’): Colourless oil; [α]D25 = -82.9 (c 1.4, CHCl3); 1 H NMR (CDCl3, 
200 MHz): δ = 0.75 (d, J = 6.6 Hz, 6 H), 0.8 (d , J = 6.6 Hz, 6 H),  0.93 (s, 18 H), 1.62  (sept, J 
= 6.6 Hz, 2 H), 2.00 (dd, J = 3.4 Hz, J = 3.9 Hz, 2 H), 2.40 (bs, 4 H), 3.39 (dd, J = 3.4 Hz, J = 
10.9 Hz, 2 H) 3.42 (s, 2 H), 3.62 (dd, J = 3.9 Hz, J = 10.9 Hz, 2 H), 7.00 (d, J = 7.6 Hz, 2 H), 
7.50 (t, J = 7.6 Hz, 1 H); 13C NMR(CDCl3, 50 MHz): δ = 18.7, 19.9, 27.3, 29.6, 35.4, 59.0, 62.4, 
69.9, 121.8, 131.0, 161.3; IR (Nujol): ν = 3444, 1644, 1496, 1205, 1090, 933 cm-1; ESI-MS m/z 
: 422.6 [M+ 1], 423.2 [M+ 2]; anal. calcd. for C25H47N3O2: C 71.21, H 11.23, N 9.97; found: C 
71.00, H 11.28, N 9.94. 
N
HNNH i -Pri -Pr
OHHO
t -But -Bu
 
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-amino-4,4-
dimethylpentyl)pyridine (42ad’): Colourless oil; [α]D25 = -47.7 (c 1.4, CHCl3); 1H NMR (CDCl3, 
300 MHz): δ = 0.80 (d, J = 6.9 Hz, 6 H), 0.82 (s, 18 H), 0.83 (d , J = 6.9 Hz, 6 H), 1.00 (dt, J = 
4.4 Hz, J = 13.1 Hz, 2H), 1.35 (dt, J = 4.4 Hz, J = 13.1 Hz, 2 H), 1.65 (m, 6 H), 2.12 (dd, J = 3.9 
Hz, J = 6.8 Hz, 2 H), 3.42 (dd, J = 3.9 Hz, J = 10.8 Hz, 2 H), 3.60 (dd, J = 6.8 Hz, J = 10.8 Hz, 
2 H), 3.63 (t, J = 3.9 Hz, 2 H), 7.00 (d, J = 7.8 Hz, 2 H), 7.55 (t, J = 7.8 Hz, 1 H); 13C 
NMR(CDCl3, 50 MHz): δ = 18.9, 19.8, 29.3, 29.5, 30.1, 32.9, 40.7, 59.5, 62.0, 62.1, 120.7, 136.2, 
163.2; IR (neat): ν = 3420, 2925, 1646, 1591, 1376, 1278, 997 cm-1; anal. calcd. for 
C28H52N3O2: C 72.68, H 11.33, N 9.08; found: C 72.38, H 11.40, N 9.07. 
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 N
HNNH
PhPh
i -Pri -Pr
OHHO  
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-
amino(phenyl)methyl)pyridine (42ae’): Yellowish oil; [α]D25 = + 95.7 (c 1.6, CHCl3); 1H NMR 
(CDCl3, 300 MHz): δ = 0.91 (d, J = 6.9 Hz, 6 H), 0.95 (d , J = 6.9 Hz, 6 H),  1.92 (sept, J = 6.9 
Hz, 2 H), 2.46 (ddd, J = 3.9 Hz, J = 6.0 Hz, J = 10.2 Hz, 2 H), 2.92 (bs, 2 H), 3.42 (dd, J = 6.6 
Hz, J = 10.8 Hz, 2 H), 3.57 (dd, J = 4.2 Hz, J = 10.8 Hz, 2 H), 5.0 (s, 2 H), 6.92 (d, J = 7.8 Hz, 
2 H), 7.27-7.42 (m, 11 H); 13C NMR (CDCl3, 75 MHz): δ = 18.2, 19.5, 30.2, 60.5, 62.1, 35.0, 
120.8, 127.4, 127.9, 128.5, 136.9, 142.9, 161.2; IR (neat): ν = 3417, 3333, 3061, 3027, 2957, 
2872, 1589, 1572, 1448, 1045, 839, 736, 700 cm 1; ESI-MS m/z : 462.0 [M+ 1]; anal. calcd. for 
C29H39N3O2: C 75.45, H 8.52, N 9.10; found: C 75.24, H 8.65, N 9.04. 
N
HNNH PhPh
OHHO  
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-aminoethyl)pyridine 
(42ba’): White solid; m.p. = 95 °C; [α]D25 = +30.7 (c 1.5, CHCl3); 1H NMR (CDCl3, 300 MHz): δ = 
1.40 (d, J = 6.6 Hz, 6 H), 3.59 (dd, J = 7.8 Hz, J = 10.8 Hz, 2 H),  3.65-3.88 (m, 6 H), 7.03 (d , 
J = 7.8 Hz, 2 H), 7.2-7.4 (m, 10 H), 7.81 (t, J = 7.8 Hz, 1 H); 13C NMR (CDCl3, 75 MHz): δ = 
21.4, 55.7, 61.8, 66.1, 119.3, 127.5, 127.3, 128.3, 136.8, 141.1, 162.7; IR (KBr): ν= 3383, 3065, 
3032, 2973, 2930, 2846, 1577, 1458, 1327, 1233, 1096, 751, 733, 699 cm-1; ESI-MS m/z : 
406.2 [M+ 1], 428.3 [M + Na]; anal. calcd. for C25H31N3O2: C 74.04, H 7.70, N 10.36; found: C 
73.98, H 7.75, N 10. 33.  
N
HNNH
n-Bun-Bu
PhPh
OHHO  
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-aminopentyl)pyridine 
(42bb’): Colourless oil; [α]D25 = +110.3 (c 0.6, CHCl3); 1H NMR (CDCl3, 300 MHz): δ = 0.88 (t, J = 
6.7 Hz, 6 H), 1.0-1.4 (m, 8 H), 1.6-1.8 (m, 4 H), 3.1 (bs, 4 H), 3.4-3.6 (m, 4 H), 3.6-3.8 (m, 4 H), 
6.88 (d, J = 7.7 Hz, 2 H), 7.1-7.4 (m, 11 H); 13C NMR (CDCl3, 75 MHz): δ = 14.0, 22.7, 28.3, 
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 36.4, 61.4, 62.2, 65.3, 120.2, 127.0, 127.2, 128.2, 136.0, 141.6, 162.5; IR (neat):  ν = 3324, 
2923, 2853, 1576, 1457, 1366, 1129, 1052, 701 cm-1; anal. calcd. for C31H43N3O2: C 76.03, H 
8.85, N 8.58; found: C 75.75, H 8.87, N 8.55. 
 
N
HNNH
t -But -Bu
PhPh
OHHO  
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-amino-2,2-
dimethylpropyl)pyridine (42bc’): Colourless oil; [α]D25 = +105.0 (c 1.5, CHCl3), 1H NMR (CDCl3, 
300 MHz): δ = 0.84 (s, 18 H), 3.31 (s, 2 H), 3.43 (dd, J = 4.8 Hz, J = 5.1 Hz, 2 H), 3.51 (dd, J = 
5.1 Hz, J = 10.6 Hz, 2 H), 3.73 (dd, J = 4.8 Hz, J = 10.6 Hz, 2 H), 6.73 (d, J =7.5 Hz, 2 H), 
7.00-7.10 (m, 5 H), 7.15-7.55 (m, 5 H), 7.46 (t, J = 7.4 Hz, 2 H); 13C NMR (CDCl3, 75 MHz): δ = 
27.1, 35.5, 63.3, 64.9, 70.0, 122.4, 128.2, 134,3, 142.0, 160.9; IR (neat):  ν = 3408, 3055, 2952, 
2863, 1588, 1576, 1469, 1453, 1395, 1361, 1031, 824, 757, 701 cm-1; ESI-MS m/z : 490.4 [M+ 
1], 512.3 [M+ Na]; anal. calcd. for C31H43N3O2: C 76.03, H 8.85, N 8.58; found: C 75.80, H 8.91, 
N 8.52. 
N
HNNH
PhPh
PhPh
OHHO  
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-
amino(phenyl)methyl)pyridine (42be’): Colourless oil; [α]D25 = +123.2 (c 1.1, CHCl3); 1H NMR 
(CDCl3, 300 MHz): δ = 3.00 (bs, 4 H), 3.72 (m, 6 H), 4.78 (s, 2 H), 6.72 (d, J = 7.6 Hz, 2 H), 
7.30-7.40 (m, 23 H); 13C NMR (CDCl3, 75 MHz): δ = 61.2, 64.0, 67.0, 120.4, 127.1, 127.5, 127.7, 
128.3, 128.6, 128.7, 130.0, 131.5, 133.2, 136.9, 145.0, 141.7, 167.0; IR (neat):  ν = 3411, 3060, 
3026, 2925, 2850, 1590, 1573, 1493, 1451, 1054, 1027, 700 cm-1; ESI-MS m/z: 530.4 [M+ 1], 
531.5 [M+ 2], 552.5 [M+ Na]; anal. calcd. for C35H35N3O2: C 79.37 , H 6.66, N 7.93; found: C 
79.00, H 6.71, N 7.90. 
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 1.5.3 - Preparation of β-Aminoalcohols 42af’ and 42bf’ by Reduction of Imines 41a and 41b 
To a solution of imine 41a or 41b (1 mmol) in methanol (5 mL), NaBH4 (2 mmol, 0.076 
g) was added in one portion. After 1 h the reaction was quenched with 1 N HCl (5 mL) and 
further stirred for 2 h. Then NaOH pellets were added until the solution reached pH 11, and 
the organic phase was extracted with diethyl ether (3 × 10 mL). The collected ethereal 
phases were dried over Na2SO4 and concentrated to leave the crude product in quantitative 
yield. Pure compounds were obtained by column chromatography (SiO2) eluting with 
cyclohexane/ethyl acetate mixtures. 
N
HNNH i -Pri -Pr
OHHO  
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis(aminomethyl)pyridine 
(42af’): Colourless oil; [α]D25 = +41.6 (c 0.9, CHCl3); 1H NMR (CDCl3, 300 MHz): δ = 0.89 (d, J = 
6.9 Hz, 6 H), 0.95 (d, J = 6.9 Hz, 6 H), 1.89 (sept, J = 6.9 Hz, 2 H ), 2.43 (dd, J = 3.3 Hz, J = 
7.5 Hz, 2 H), 3.42 (dd , J = 7.5, J = 11.1 Hz, 2 H), 3.42 (dd , J = 3.3, J = 11.1 Hz, 2 H), 3.87 (d, 
J = 14.7 Hz, 2 H), 3.97 (d, J = 14.7 Hz, 2 H), 7.11 (d, J = 7.5 Hz, 2 H), 7.58 (t, J = 7.5 Hz, 1 H); 
13C NMR (CDCl3, 75 MHz): δ = 18.6, 19.5, 29.5, 52.3, 61.4, 65.0, 120.6, 137.3, 159.5; IR (neat):  
ν = 3322, 2957, 2866, 1594, 1576, 1455, 1386, 1367, 1155, 1047, 787 cm-1; anal. calcd. for 
C17H31N3O2: C 65.98, H 10.10, N 13.58; found: C 66.01, H 10.11, N 13.54. 
N
HNNH PhPh
OHHO  
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis(aminomethyl)pyridine (42bf’): 
Viscous oil; [α]D25 = +106.2 (c 2.0, CHCl3); 1H NMR (CDCl3, 200 MHz): δ = 3.67 (m, 4 H), 3.72 
(d, J = 14.1 Hz, 2 H), 3.80 (d, J = 14.1 Hz, 2 H), 3.86 (dd, J = 5.3 Hz, J = 9.6 Hz, 2 H), 4.1 (bs, 
1 H), 7.0 (d , J = 7.6 Hz, 2 H), 7.2-7.4 (m, 10 H), 7.52 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 50 
MHz): δ = 51.9, 64.6, 67.0, 120.6, 127.4, 127.5, 128.4, 136.8, 140.4, 158.7; IR (Nujol):  ν = 3310, 
3061, 3028, 2924, 2862, 1594, 1577, 1492, 1452, 1357, 1057, 1027, 759, 702 cm-1; ESI-MS 
m/z : 378.3 [M + 1], 379.4 [M  + 2], 400.4 [M + Na]; anal. calcd. for C23H27N3O2: C 73.18; H 
7.21, N 11.13; found: C 72.83, H 7.24, N 11.10. 
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 1.5.4 - Preparation of Aziridines 43 
To a solution of β-aminoalcohol 42 (2.8 mmol) in THF (20 mL) was added PPh3 (6.2 
mmol, 1.6 g). To this solution DEAD (6.2 mmol, 1.082 g) was added dropwise. After 4 h, a 
solution of 2 N  KOH (10 mL) was added to the mixture, which was stirred for 3 h. Diethyl 
ether was added (30 mL) and the organic phase was separated. The aqueous phase was 
extracted with Et2O (3 x 20 mL), and the collected organic phase was washed with 2 N KOH 
(3 x 10 mL), then with brine. The organic phase was dried over Na2SO4 and concentrated 
under reduced pressure. The residue was flash-chromatographed on a SiO2 column eluting 
with cyclohexane/ethyl acetate mixtures. In order to obtain analytically pure samples, 
further purification by chromatography or crystallization was carried out. 
 
N
NN
i -Pri -Pr  
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)ethyl)pyridine (43aa’): Colourless oil; 
[α]D25 =    -119.6 (c 0.5, CHCl3); 1 H NMR (CDCl3, 200 MHz): δ = 0.53 (d, J = 6.6 Hz, 6 H), 0.75 
(d, J = 6.6 Hz, 6 H),  1.10 (sept, J = 6.6 Hz, 2 H), 1.22 (m, 2 H), 1.33 (d, J = 6.3 Hz, 2 H), 1.38 
(d, J = 6.6 Hz, 6 H), 1.63 (d, J = 3.3 Hz, 2 H), 2.53 (q, J = 6.6 Hz, 2 H), 7.37  (d , J = 7.6 Hz, 2 
H), 7.63 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ = 19.5, 20.4, 21.2, 31.4, 32.6, 45.8, 
71.6, 119.6, 136.7, 162.7; IR (neat): ν = 3041, 2962, 1591, 1576, 1460, 1327, 1176, 822 cm-1; GC-
MS m/z: 56 (100), 55 (87), 84 (63), 132 (35), 218 (18), 162 (9); anal. calcd. for C19H31N3: C 
75.70, H 10.36, N 13.94; found: C 75.78, H 10.41, N 13.88.  
 
N
NN
n-Bun-Bu
i -Pri -Pr  
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)pentyl)pyridine (43ab’): Colourless oil; 
[α]D25=  -140.7 (c 0.5, CHCl3);  1H NMR (CDCl3, 200 MHz): δ = 0.47 (d, J = 6.5 Hz, 6 H), 0.74 (d, 
J = 6.5 Hz, 6 H), 0.78 (t, J = 7.0 Hz, 6 H), 0.86 (m, 2 H), 1.04 (m, 2 H), 1.21 (m, 8 H), 1.40 (d, 
J = 6.3 Hz, 2 H), 1.67 (d, J = 3.6 Hz, 2 H), 1.88 (q, J = 7.6 Hz, 2 H), 2.44 (t, J = 7.2 Hz, 2 H), 
7.31  (d , J = 7.6 Hz, 2 H), 7.63 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ = 14.1, 19.9, 
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 20.6, 22.0, 28.6, 31.9, 34.2, 35.9, 45.0, 77.3, 120.8, 136.7, 162.1; IR (neat):  ν = 3040, 2957, 
2871, 1591, 1576, 1457, 1364, 1029 cm 1; GC-MS m/z : 84 (100), 302 (75), 259 (53), 174 (35), 
55 (30), 385 (1, M); anal. calcd. for C25H43N3: C 77.86, H 11.24, N 10.90; found: C 77.58, H 
11.26, N 10.85. 
 
 
 
N
NN
t-But -Bu
i -Pri -Pr  
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)-2,2-dimethylpropyl)pyridine (43ac’): 
White solid; m.p. = 84 °C; [α]D25= -18.8 (c 1.0, CHCl3); 1H NMR (CDCl3, 300 MHz): δ = 0.53 (d, J 
= 6.6 Hz, 6 H), 0.72 (d, J = 6.6 Hz, 6 H),  0.98 (m, 2 H), 0.99 (s, 18 H), 1.18 (sept, J = 6.6 Hz, 
2 H) 1.49 (d , J = 6.3 Hz, 2 H), 1.76 (d, J = 3.9 Hz, 2 H), 2.73 (s, 2 H), 7.33  (d , J = 7.5 Hz, 2 
H), 7.57 (t, J = 7.5 Hz, 1 H); 13C NMR (CDCl3, 75 MHz): δ = 19.6, 20.8, 27.8, 30.8, 36.3, 36.7, 
42.8, 85.5, 122.4, 134.4, 160.2; IR (KBr):  ν = 3064, 2873, 1588, 1571, 1497, 1449, 1286, 1031, 
872 cm-1; anal. calcd. for C25H43N3: C 77.86, H 11.24, N 10.90; found: C 77.91, H 11.28, N 
10.86. 
N
NN
t-But -Bu
i -Pr i -Pr  
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)-4,4-dimethylpentyl)pyridine (43ad’): 
Colourless oil; [α]D25 = -149.5 (c 1.1, CHCl3); 1H NMR (CDCl3, 300 MHz): δ = 0.50 (d, J = 6.6 Hz, 
6 H), 0.79 (d, J = 6.6 Hz, 6 H), 0.83 (s, 18 H), 1.10 (sept, J = 6.6 Hz, 2 H), 1.17-1.37 (m, 6 H), 
1.43 (d, J = 6.5 Hz, 2 H), 1.70 (d, J = 3.5 Hz, 2 H), 1.91 (dt, J = 7.1 Hz, J =9.8 Hz, 4 H), 2.40 
(t, J = 7.1 Hz, 2 H), 7.36  (d , J = 8.0 Hz, 2 H), 7.68 (t, J = 8.0 Hz, 1 H); 13C NMR (CDCl3, 50 
MHz): δ = 19.7, 20.4, 29.2, 30.1, 31.1, 31.7, 34.0, 40.0, 44.7, 77.5, 120.6, 136.6, 161.9; IR 
(neat): ν = 3060, 2879, 1591, 1568, 1490, 1450, 1281, 1038, 878 cm-1; GC-MS m/z : 57 (100), 
84 (92), 56 (71), 287 (28), 258 (22), 132 (16), 202 (12); anal. calcd. for C29H51N3: C 78.85, H 
11.64, N 9.51; found: C 78.75, H 11.68, N 9.47. 
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 N
NN
PhPh
i -Pri -Pr  
2,6-Bis((S)-((S)-2-isopropylaziridin-1-yl)(phenyl)methyl)pyridine (43ae’): Yellowish 
oil; [α]D25 = -158.3 (c 0.6, CHCl3); 1H NMR (CDCl3, 200 MHz): δ = 0.47 (d, J = 6.6 Hz, 6 H), 0.82 
(d, J = 6.6 Hz, 6 H), 1.23 (m, 2 H), 1.44 (d , J = 7.2 Hz, 2 H), 1.54 (dd, J = 3.6 Hz, J = 7.2 Hz, 
2 H), 3.78 (s, 2 H), 7.25-7.39 (m, 8 H), 7.54-7.62 (m, 5 H); 13C NMR (CDCl3, 50 MHz): δ = 19.5, 
20.2, 31.4, 46.4, 79.8, 120.9, 126.9, 127.4, 128.1, 137.9, 142.4, 151.0; IR (neat):  ν = 3071, 2933, 
2862, 1589, 1573, 1455, 1306, 1258, 1029, 699 cm-1; ESI-MS m/z: 426.1 [M + 1], 427.2 [M + 
2]; anal. calcd. for C29H35N3: C 81.84, H 8.29, N 9.87; found: C 81.78, H 8.32, N 9.84. 
N
NN
i -Pri -Pr  
2,6-Bis(((S)-2-isopropylaziridin-1-yl)methyl)pyridine (43af’): Colourless oil; [α]D25 = 
-97.5 (c 1.1, CHCl3); 1H NMR (CDCl3, 300 MHz): δ = 0.89 (d, J = 6.6 Hz, 6 H), 0.91 (d, J = 6.6 
Hz, 6 H), 1.30 (m,  2 H), 1.37 (dd, J = 3.3 Hz, J = 6.3 Hz, 2 H), 1.41 (d, J = 6.3 Hz, 2 H), 1.69 
(d, J = 3.3 Hz, 2 H), 3.48 (d, J = 14.0 Hz, 2H ), 3.59 (d, J = 14.0 Hz, 2 H), 7.44 (d, J = 7.7 Hz, 
2 H), 7.69 (t, J = 7.7 Hz, 1 H); 13C NMR (CDCl3, 75 MHz): δ = 19.6, 20.6, 31.6, 33.2, 46.7, 66.6, 
120.6, 136.9, 158.6; IR (neat):  ν = 3044, 2958, 2872, 1592, 1578, 1458, 1363, 1340, 1287, 
1035, 896, 829, 783 cm-1; anal. calcd. for C17H27N3: C 74.68, H 9.95, N 15.37; found: C 74.22, 
H 9.99, N 15.33. 
N
NN
PhPh  
2,6-Bis((S)-1-((S)-2-phenylaziridin-1-yl)ethyl)pyridine (43ba’): White solid; m.p. = 
79 °C; [α]D25 = +176.6 (c 0.4, CHCl3); 1H NMR (CDCl3, 300 MHz): δ = 1.52 (d, J = 6.6 Hz, 6 H), 
1.89 (d, J = 6.6 Hz, 2 H), 2.06 (d, J = 3.3 Hz, 2 H), 2.50 (dd , J = 3.3 Hz, J = 6.6 Hz, 2 H), 
2.84 (q, J = 6.6 Hz, 2 H), 7.17-7.29 (m, 10H), 7.36 (d, J = 8.1 Hz, 2 H), 7.46 (t , J = 8.1 Hz, 1 
H); 13C NMR (CDCl3, 75 MHz): δ = 21.6, 37.3, 40.8, 71.7, 118.8, 126.1, 126.6, 128.1, 137.3, 140.0, 
162.5; IR (KBr): ν= 3032, 2972, 1576, 1580, 1459, 1326, 1207, 1095, 815, 698 cm-1; ESI-MS 
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 m/z : 370.4 [M+ 1], 371.4 [M  + 2], 392.4 [M+ Na]; anal. calcd. for C25H27N25: C 81.26, H 7.37, N 
11.37; found: C 81.01, H 7.39, N 11.34. 
N
NN
PhPh
n-Bu n-Bu
 
2,6-Bis((S)-1-((S)-2-phenylaziridin-1-yl)pentyl)pyridine (43bb’): Yellowish oil; d.r. 
91:9; [α]D25 = +124.5 (c 0.9, CHCl3); 1H NMR (CDCl3, 200 MHz): δ (major diastereomer) = 0.86 
(t, J = 6.6 Hz, 6 H), 1.2-1.4 (m, 8 H), 1.92 (d,  J = 6.2 Hz, 2 H), 1.94 (m, 2 H), 2.09 (d, J = 3.2 
Hz, 2 H), 2.45 (dd, J = 3.2 Hz, J = 6.2 Hz, 2 H), 2.77 (dd, J = 6.2 Hz, J = 7.0 Hz, 2 H), 7.07-
7.27 (m, 10 H), 7.29 (d, J = 7.9 Hz, 2 H), 7.47 (t, J = 7.9 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ 
= 14.0, 23.0, 26.9, 28.1, 36.1, 38.4, 39.4, 119.9, 126.3, 126.6, 128.1, 137.0, 146.2, 161.7; IR 
(neat):  ν = 3031, 2978, 1574, 1588, 1454, 1329, 1198, 1092, 818, 701 cm-1; anal. calcd. for 
C31H39N3: C 82.07, H 8.66, N 9.26; found: C 82.23, H 8.80, N 9.22. 
N
NN
PhPh
t -Bu t -Bu
 
2,6-Bis((S)-2,2-dimethyl-1-((S)-2-phenylaziridin-1-yl)propyl)pyridine (43bc’): 
Colourless oil; [α]D25 = +132.6 (c 1.0, CHCl3); 1H NMR (CDCl3, 200 MHz): δ = 1.06 (s, 18 H), 1.97 
(d, J = 6.4 Hz, 2 H), 2.07 (dd, J = 3.2 Hz, J = 6.4 Hz, 2 H), 2.14 (d, J = 3.2 Hz, 2 H), 2.67 (s, 2 
H), 7.07-7.40 (m, 13 H); 13C NMR (CDCl3, 50 MHz): δ = 27.5, 36.5, 37.6, 42.9, 85.4, 121.6, 
126.1, 126.3, 128.0, 141.0, 151.0, 159.4; IR (neat): ν = 3033, 2974, 1572, 1584, 1456, 1323, 
1187, 1097, 813, 705 cm-1; anal. calcd. for C31H39N3: C 82.07, H 8.66, N 9.26; found: C 82.12, H 
8.70, N 9.25. 
N
NN
PhPh
Ph Ph
 
2,6-Bis((S)-phenyl((S)-2-phenylaziridin-1-yl)methyl)pyridine (43be’): Colourless 
oil; d.r. 92:8; [α]D25 = +104.5 (c 1.1, CHCl3); 1H NMR (CDCl3, 200 MHz) δ (major diastereomer) = 
2.00 (d, J = 6.4 Hz, 2 H), 2.13 (d, J = 3.5 Hz, 2 H), 2.79 (dd, J = 3.5 Hz, J = 6.4 Hz, 2 H), 4.06 
(s, 2 H), 7.17-7.74 (m, 23 H); 13C NMR (CDCl3, 50 MHz): δ = 38.0, 41.2, 79.5, 120.0, 126.3, 
126.6, 126.8, 127.1, 127.7, 128.1, 128.2, 137.3, 140.0, 142.2, 161.3; IR (neat): ν= 3036, 2974, 
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 1575, 1586, 1453, 1324, 1203, 1096, 829, 679 cm-1; ESI-MS m/z: 494.5 [M + 1], 495.5 [M  + 2]; 
anal. calcd. for C35H31N3: C 85.16, H 6.33, N 8.51; found: C 84.92, H 6.35, N 8.48. 
N
NN
PhPh  
2,6-Bis(((S)-2-phenylaziridin-1-yl)methyl)pyridine (43bf’): Colourless oil; [α]D25 = 
+124.3 (c 1.5 CHCl3); 1H NMR (CDCl3, 200 MHz): δ = 1.92 (d, J = 6.6 Hz, 2 H), 2.03 (d , J = 3.2 
Hz, 2 H),  7.03 (dd, J = 3.2 Hz, J = 6.6 Hz 2 H), 3.65 (d, J = 15.0 Hz 2 H), 3.91 (d, J = 15.0 Hz, 
2 H) 7.20-7.74 (m, 13 H); 13C NMR (CDCl3, 50 MHz): δ = 38.1, 41.6, 66.3, 120.1, 126.1, 126.9, 
128.3, 128.4, 128.6, 131.9, 132.0, 132.2, 137.3, 140.1, 158.3; IR (neat):  ν = 3031, 2978, 1570, 
1586, 1461, 1321, 1204, 1095, 819, 694 cm-1; anal. calcd. for C23H23N3: C 80.90, H 6.79, N 
12.31; found: C 81.15, H 6.83, N 12.30. 
1.5.5 - Preparation of allylic palladium complexes. Typical procedure: [43ae'(η3-allyl)Pd][PF6]. 
Allyl palladium chloride dimer (73 mg, 0.1 mmol) was added to a solution of ligand 
43ae' (80 mg, 0.2 mmol) in CH2Cl2 (4 mL) in one portion. After one hour a solution of NH4PF6 
(39 mg, 0.24 mmol) in THF (1mL) was added. The solution was stirred overnight, then filtered 
through a HPLC filter (0.45 μm) and the solvent was removed under reduced pressure to give 
a white solid: 0.130 g, 91%. White crystals, suitable for X-ray diffraction analysis were 
obtained from a double-layer of CH2Cl2 and pentane: white crystals; m.p. 124-126 °C (dec.); 
[α]D20 = +21.1 (c 1.2, CHCl3); IR (KBr) ν = 3052, 3030, 2882, 1605, 1567, 1496, 1452, 1265, 
1014, 840, 732, 701, 553 cm-1. 
The 1H NMR spectra of all the allyl and 1,3-diphenylallyl cationic Pd complexes 
synthesized showed the presence of different species, but the exo and endo rotamers were 
prevalent with variable ratios. Specifically, the spectrum of the complex 43ae'(1,3-
diphenylallyl)PdPF6 (600 MHz, CDCl3) showed a 55:45 ratio of two rotamers, with the 
following absorptions of the allylic protons: major rotamer,  δ = 5.98 (t, J =11.4  Hz, 1 H), 4.75 
(d, J =  11.4 Hz, 1H), 4.67 (d, J =  11.4 Hz, 1H) ppm; minor rotamer, δ= 6.13 (t, J = 11.4 Hz, 1 
H), 5.0 (d, J = 11.4 Hz, 1 H), 4.40 (d, J = 11.4 Hz, 1 H) ppm. On the other hand, the 1H NMR 
spectrum (300 MHz, CDCl3) of 43ba'(1,3-diphenylallyl)PdPF6 showed the presence of a 
prevalent species (ca 75%) with the syn,syn geometry of the allylic ligand, whose protons gave 
absorptions at δ = 6.16 (t, J = 11.4 Hz, 1 H), 4.43 (d, J = 11.4 Hz, 1 H) and 3.80 (d, J = 11.4 Hz, 
1 H). 
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 [(43ae')(allyl)Pd][PF6]. X-Ray details: Bruker APEX II CCD diffractometer (Mo-Kα 
radiation λ = 0.71073 Å). Results: C32H40F6N3PPd, Mr = 718.04, monoclinic P21, a = 11.0990(13), 
b = 13.3802(16), c = 11.9282(14)Å, β = 112.045(2), V = 1641.9(3)Å3, Z = 2, ρx 1.452 Mgm3, μ 
0.674 mm1, F(000) = 736, T = 296(2) K, θmax = 28.51, 13905 reflections collected, 6099 
I>2σ(I). Final R1 = 0.0347, wR2 = 0.0860, GOF = 0.997, absolute structure parameter = 
0.04(2).CCD 297723. Crystallographic data (excluding structure factors) for the structure 
reported in this thesis have been deposited with the Cambridge Crystallographic Data Centre 
as supplementary publication no. CCDC 297723. Copies of the data can be obtained free of 
charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. code + 
44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
1.5.6 - Palladium-Catalyzed Allylic Alkylation 
To a solution of DIAZAP 43ba' (0.03 mmol, 10 mg) in CH2Cl2 (2 mL) was added 
(allylPdCl)2 (0.014 mmol, 5 mg) and the solution was degassed and stirred for 1h. 1,3-diphenyl-
2-propenyl ethyl carbonate (24b) (0.27 mmol, 76 mg) was then added followed by dimethyl 
malonate (0.67 mmol, 90 mg), BSA (0.81 mmol, 0.165 g) and KOAc (0.02 mmol, 2 mg) after 10 
min. The reaction was monitored by TLC analysis and, when complete, quenched with 1 N HCl 
solution (1 mL) and the organic phase was extracted with diethyl ether (3 ×10 mL). The 
organic layer was dried over Na2SO4 and the solvents were evaporated to dryness. The crude 
product was purified by chromatography on a silica gel column (hexane/AcOEt, 75:5) 
affording methyl (R)-(E)-3,5-diphenyl-2-methoxycarbonyl-4-pentenoate (25): 73 mg, 84%. An 
e.e. of 99% was determined by chiral HPLC (Chiralpak AD; 2-propanol/hexane 1:9, 1.0 mL/min; 
250 nm). retention times: 10.7 min (major enantiomer), 14.9 min (minor enantiomer). 
45a: 88%, e.e. 97%; [α]D25 -38.7 (c 2.0, CHCl3). The e.e. was determined by chiral HPLC 
(Chiralpak AD; 2-propanol/hexane 3:97; 1.0 mL/min, 250 nm); retention times: 16.6 min (major 
enantiomer), 17.1 min (minor enantiomer). The absolute configuration of the product was 
determined by comparison of its optical rotation with that of the known compound.40e 
45b: 89%, e.e. 99%; [α]D25 = -48.4 (c 1.5, CHCl3). The e.e. was determined by chiral 
HPLC (Chiralpak AD; 2-propanol/hexane 1:99, 0.8 mL/min, 250 nm); retention times: 8.3 min 
(minor enantiomer), 10.9 min (major enantiomer). The absolute configuration was assumed by 
analogy with compound 45a.  
47: 40%, e.e. 6%; [α]D25 =  +5.0 (c 1.1, CHCl3). The e.e. was determined by chiral GC: 
Megadex Chiral column (25 m, flow rate: 15mL/min, 50 °C (2 min), then 3 °C/min up to 190 °C, 
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 FID detection): retention times: 27.2 min (minor enantiomer), 27.3 min (major enantiomer). 
The absolute configuration of the product was determined by comparison of its optical 
rotation with that of the known compound. 
49: 85%, e.e. 28%, [α]D25 = +6.5 (c 1.2, CHCl3). The e.e. was determined by chiral GC 
(Megadex Chiral column (25 m, flow rate: 15mL/min, isotherm 65 °C, FID detection); 
retention times: 49.5 min (minor enantiomer), 51.6 min (major enantiomer). The absolute 
configuration of the product was determined by comparison of its optical rotation with that 
of the known compound.42 
51-52: The ratio was determined by GC-MS analysis. The e.e.s of 51 and 52 were 
determined by chiral HPLC (Chiralpak OD, 2-propanol/hexane 1:99, 0.5 mL/min, 250 nm); 
retention times of 52: 14.2 min (major enantiomer), 15.1 min (minor enantiomer); retention 
times of 51: 17.9 (minor enantiomer), 18.8 (major enantiomer). 
55: 83%, e.e. 27%; [α]D25 = -23.5 (c 1.6, CHCl3). The e.e. was determined by chiral 
HPLC (Chiralpak OD, 2-propanol/hexane 5:95, 0.4 mL/min, 250 nm); retention times: 13.7 min 
(minor enantiomer), 15.6 min (major enantiomer). The absolute configuration of the product 
was determined by comparison of its optical rotation with that of the known compound.43 
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 Chap. 2 – Asymmetric Synthesis of 2-(2-
Pyridyl)aziridines from 2-Pyridineimines Bearing 
Stereogenic N-Alkyl Substituents. 
N
N OH
N
N OH
+
N
N
O
NH
Py
O
 
2.1 – Introduction 
Aziridine chemistry has indeed been extensively exploited by organic synthetic 
chemists.1 In the last several decades, more than 200 research papers have been registered 
in the Chemical Abstracts database every year, and since 2001 the tally has been more than 
350 papers a year, which clearly shows a broad interest in the preparation and utilization of 
aziridines. Their incorporation into a wide variety of motifs, from drugs and biologically 
active molecules to ligands for asymmetric catalysis,2 underlines their importance to modern 
chemistry. 
Aziridines are the nitrogen analogues of epoxides and exhibit similar reactivity 
patterns as electrophilic reagents. The highly strained three membered ring readily opens 
with excellent stereo- and regio-control to afford a wide variety of more stable ring opened 
or ring expanded chiral amines. 
2.1.1 – Preparation of aziridine 
A literature survey reveals an extensive investigation of the synthesis and chemistry 
of aziridines since the first synthesis by Gabriel in 1888.3 Numerous methods have been 
reported for the synthesis of differently substituted aziridines. The range of synthetic 
methodology available for preparation of aziridines (summarized diagrammatically in Scheme 
1) is very wide and include nitrene addition to olefins, carbene and ylide addition to imines, 
and cyclization of 1,2-amino alcohols, 1,2-aminohalides, and 1,2-azido alcohols. 
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Scheme 1 
Nitrene methods4: ‘Classical’ methods for direct aziridination of alkenes have 
traditionally featured addition of nitrenes (reactive intermediates in which nitrogen bears 
only one substituent, one lone pair and two other electrons) to the unsaturated partner. The 
limitations to the method (often involving alkoxycarbonylnitrenes) are well-documented, with 
the necessity for harsh reaction conditions and the lack of stereoselectivity constituting two 
major factors which have limited the attractiveness of this methodology. 
Such nitrenes typically were generated by thermal or photochemical decomposition of 
the corresponding azides and these methods intrinsically lead to mixtures of (more reactive) 
singlet and (more stable) triplet nitrenes; only singlet nitrenes may be relied upon to react 
stereospecifically with 1,2-disubstituted alkenes. Triplet nitrenes react in a two-step 
process with alkenes (Scheme 2), in which an N–C bond is formed in each step, whereas 
singlet nitrenes are able to form both new bonds in a concerted process. 
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A useful method involves in situ generation of nitrenes, by means of oxidation of 
hydrazine derivatives. Of particular relevance is the methodology of Rees and his 
collaborators by which a range of N-amino aziridine derivatives were prepared by reaction of 
the corresponding hydrazine derivatives with alkenes in the presence of lead tetraacetate 
(Scheme 3) or with electrochemical processes for oxidation of hydrazine.5 
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Scheme 3 
The possibility of transferring nitrenes to olefins by means of transition metal 
catalysts (Cu, Mn, Rh, Ag) was recognized well before asymmetric catalysis was established. 
Thus, porphyrin6 and salen catalysts, known for their ability to aziridinate alkenes in the 
presence of the nitrene precursor N-tosyliminophenyliodinane, provided the inspiration for a 
new generation of copper-based catalytic processes. In particular, Evans,7 Jacobsen8 and 
Katsuki9 have described the utility of chiral bis-oxazolines and 1,2-diamines in 
enantioselective aziridination of a range of alkenes (Scheme 4). 
These reactions, though representing a major achievement in the synthesis of 
enantiopure aziridines, still retain some drawbacks, not least of which is the frequent 
requirement for the reactions to be conducted using a large excess (often 5 equivalents) of 
alkene. 
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Scheme 4 
Carbene methods: The synthesis of aziridines by reaction of nitrenes and nitrene 
equivalents with alkenes involves the roughly simultaneous formation of two new C–N bonds. 
If one performed an alternative synthetic analysis, one can immediately identify a method 
which is centred around the simultaneous formation of one C–N bond and  one C–C bond. 
Thus, if a  carbene or equivalent thereof (such as an ylid) were to react efficiently with an 
imine, a useful aziridination protocol would result. This area of research has only recently 
attracted the attention of synthetic organic chemists. 
Thus, Jacobsen and Finney reported that the metallocarbene derived from ethyl 
diazoacetate and copper(I)hexafluorophosphate adds with mediocre stereoselectivity to N-
arylaldimines. At best, diasteroeselectivities were acceptable (often > 10:1, in favour of the  
cis-isomers) but enantioselectivity was low (Scheme 5).10 
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Scheme 5 
The similar copper(I)-catalyzed reaction of trimethylsilyldiazomethane with N-
tosylimines in the presence of (R)-Tol-BINAP proceeded with better levels of enantiocontrol, 
but still falls short of the standards expected of modern asymmetric transformations 
(Scheme 6).11 
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Scheme 6 
The aza-Darzens reaction also falls into this category of aziridine-forming reaction. 
Several groups have investigated this route to aziridines, especially in the asymmetric 
manifold, in recent years. Thus, reactions of N-Dpp imines with (R)- and (S)-camphorsultam-
derived α-bromoenolates12 (Scheme 7) and of S-chiral sulfinylimines with achiral 
bromoenolates13 (Scheme 8) have been studied; in both cases, high levels of enantio- and 
diastereocontrol were observed. 
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Rong closure of 1,2-aminoalcohols, 1,2-aminohalides or 1,2-aminoazides: A 
conceptually  obvious synthesis of aziridines utilizes  1,2-amino alcohols as precursors: the 
reaction can be  readily achieved when the hydroxyl functional group is converted to a  good 
leaving group. Intramolecular nucleophilic displacement reaction by the amine lone pair then 
yields the aziridine ring. 
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 More recent methods exploit the conversion of the alcohol moiety of amino alcohols to  
oxyphosphonium species. As examples, treatment of an aminoalcohol with Ph3P plus either 
Br2,14 CCl415 or DEAD,16 have been  widely  employed to effect aziridine ring-closure. Other 
phosphorus reagents employed in such reactions are diphenylphosphinic chloride17 and 
diethoxytriphenylphosphine, [Ph3P(OEt)2].18  
By using enantiopure amino alcohols, enantiopure aziridines are obtained 
enantiomerically-pure 1,2-amino alcohols required are frequently form via the reduction of  
enantiopure 2-amino acids, which are commercially available;19 indeed, in many cases, the 
aminoalcohols themselves are commercially available. Where only the aminoacid  is available,  
the efficiency of aziridine formation is, in some cases, hampered by the difficulty in  
isolating the intermediate amino alcohols, due to formation of water soluble metal complexes. 
To circumvent this problem, the reduction of N-Ts amino acids (rather than the aminoacid 
itself) has been described; this modification allows the synthesis of enantiopure N-Ts 
aziridines  in a one-pot reaction.20 (Scheme 9). 
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Scheme 9 
Given the ready availability of enantiomerically-pure epoxides by a range of 
asymmetric processes, much use has been made of the multi-step preparation of aziridines 
from these precursors. In particular, the phosphine-mediated ring-closure of azidoalcohols 
(a Staudinger reaction), themselves obtained from chiral epoxides by ring-opening reaction 
using a range of azide sources, has attracted much interest. The pivotal reaction of this 
particular sequence revolves around the reaction of the hydroxyazide with trialkyl- or 
triarylphosphine, leading to oxazaphospholidines, which is rapidly formed and may be slowly 
converted to N-unsubstituted aziridine product upon heating in acetonitrile (Scheme 10). The 
reaction is reliable for a wide range of chiral and achiral epoxides and there is no issue of 
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 regiochemistry: both asymmetric centres are cleanly and predictably inverted during the 
process. 
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Scheme 10 
2.1.2 – Aziridine ring in biologically active compounds 
As powerful alkylating agents, aziridines have an inherent in vivo potency, often based 
primarily on toxicity rather than specific activity. There are, however, several classes of 
aziridine-containing natural products which marry potency with selectivity, of which perhaps 
the best-known are the Mitosanes (Scheme 11).21 The Mitosanes were first isolated from 
soil extracts of Streptomyces verticillatus and they exhibit both anti-tumour and antibiotic 
activity: structure–activity relationships have identified the aziridine ring as being essential 
for such anti-tumour activity, and a large amount of work has concentrated on synthesizing 
derivatives of these natural products with increased potency. 
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Scheme 11 
These natural bioactive compounds are powerful DNA alkylating agents. Thus, in the 
first step of the postulated mechanism of action, the natural products are converted from 
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 the native quinone form to the hydroquinone (Scheme 12); secondly, formation of 
indoloaziridine  occurs. The aziridine ring is next cleaved and DNA is first alkylated and then 
cross-linking occurs. The Mitosanes are one of the few classes of naturally-occurring 
antibiotics to exhibit the same mode of action  in vivo and  in vitro. 
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Scheme 12 
Related compounds which have also shown similar anti-cancer activity are the FR and 
FK compounds shown below.22 Consideration of the acetal-like core of these molecules 
reveals an intimate relationship with the Mitosanes (Scheme 13). 
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 A structurally-distinct class of naturally-occurring aziridine derivatives possessing 
potent biological activity, isolated from Streptomyces grieseofuscus S42227 by Nagaoka and 
co-workers, is the Azinomycin family (Scheme 14).23 This class of compounds possesses a 
wide range of activity against a range of cancers, including solid tumours, and Azinomycin-like 
structures have been shown to exert cytotoxicity against a variety of human tumour cell 
lines. The activity of all of these compounds again lies in their ability to act as DNA cross-
linking agents, via nucleophilic ring-opening of the aziridine and epoxide moieties by N-7 
positions of purines. It is not clear at present which ring-opening reaction takes precedence 
in the cross-linking event. 
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Scheme 14 
The PBI class of natural products (Scheme 15) represents another type of DNA-
alkylating aziridinyl quinone species.24 In these compounds, however, the aziridinenis directly 
attached to the quinone subunit and undergoes ring-opening by nucleophilic attack of the 
DNA phosphate backbone, rather than alkylation by a purine nitrogen atom, as in the case of 
the Mitosane. 
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Scheme 15 
Finally, in this section a range of synthetic aziridines has been examined for their 
suitability as pharmaceutical agents, based on the observations in the 1960s that nitrogen 
mustards (such as di(2-chloroethyl)methylamine) were able to reduce the rate of tumour 
growth in mice models. Nitrogen mustards (so-named due to their close structural 
resemblance to sulfur mustard, di(2-chloroethyl)sulfide, the ‘mustard gas’ of the First World 
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 War) are very active alkylating agents due to their ability to form aziridinium ions which are 
rapidly alkylated by DNA (Scheme 16). 
In particular, N-mustard-based ADEPT (antibody-directed enzyme pro-drug therapy) 
strategies (in which a protected form of the mustard is directed with high selectivity to a 
tumour site) have attracted great interest in recent years as potential cancer 
chemotherapies.25 
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Scheme 16 
2.1.3 - Aziridines as chiral ligands 
Enantiopure aziridines have gained considerable importance over a number of years as 
chiral ligands in transition metal-catalyzed asymmetric syntheses.1,2 The concentrated 
density of stereochemical information located close to a good  σ-donor nitrogen makes chiral 
aziridines attractive ligands for asymmetric catalysis. In an extension of Corey’ s chiral 
oxazaborolidines for the enantioselective reduction of prochiral ketones, aziridine 2-
carbinols (2S,3R)-1 have been used as precatalysts to prepare oxazaborolidines (2S,3R)-2 
(Scheme 17).26 When used with borane-dimethylsulfide complex for the reduction of 
acetophenone to  (R)-phenylethyl alcohol, enantioselectivities were greater than 90%. 
A range of aziridine 2-carbinols have been screened as catalysts for the 
enantioselective addition of diethylzinc to aldehydes and aziridine (S,S)-3 gave up to 97% ee 
and good yields.27 An equally effective N-trityl aziridine has been studied and the 
corresponding polymer supported catalyst  (S)-4 prepared.28,29 High enantioselectivity was 
retained and the catalyst was recycled without significant loss in enantioselectivity.  
C2-Symmetric bis-aziridines have been studied as ligands in a number of metal 
mediated asymmetric reactions.30 A two carbon tether between the aziridine nitrogens was 
optimal, regardless of the metal used, to allow five membered chelate formation, and the 
other aziridine side chains were varied for steric and electronic requirements. Bis-aziridine 
 
-52- 
 (2S,3S,2’S,3’S)-5 generally showed the best performance. This bisaziridine gave good results 
osmium catalysed asymmetric dihydroxylation of trans-stilbene and in the palladium 
catalysed allylic alkylation. A range of chiral bis-aziridine disulfide as (2R,2’R)-6 was 
prepared by Braga and co-workes31 and they have been screened as catalysts for the 
enantioselective addition of diethylzinc to aldehydes with good results (e.e. > 99%). 
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Dogan and co-workes recently developed a new set of chiral ligands, ferrocenyl-
substituted aziridinylmethanols (Fam), and used them in diethylzinc addition reactions to 
aldehydes32 to obtain secondary alcohols with up to 99% e.e., to enones33 to obtain β-
ethylated ketones in up to 80% e.e. and in alkynylation of aldehyde catalysed by titanium 
isopropoxyde (Scheme 18).34 
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 2.2 – Asymmetric synthesis of 2-(2’-pyridyl)aziridines 
Following our previous studies on enantioselective Pd-catalyzed allylic substitution 
reactions using 1-(2-pyridyl)alkyl aziridines as ligands (see chapter 1),35 we directed our 
interest to the asymmetric synthesis of 2-(2-pyridyl)aziridines 8 from chiral 2-
pyridineimines 7 bearing a stereogenic center at the nitrogen atom (Scheme 19), aiming to 
assess their potential as bidentate ligands in a variety of enantioselective catalytic 
transformations. The envisioned route involved the addition of halomethylmetal reagents to 
the imine function. 
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Scheme 19 
The same approach as been recently followed by different authors. The N-(tert-
butylsulfinyl)aziridine 10 (R = (R)-t-BuSO) has been prepared by the the Corey-Chaykovsky 
sulfonium ylide aziridination protocol (Scheme 20).36 Moreover, an N-substituted-2-phenyl-
3-(2-pyridyl)aziridine was obtained by Darzens-type reaction of lithiated 2-
(chloromethyl)pyridine with (R)- and (S)-N-benzylidene-O-methyl-phenylglycinol (Scheme 
20).37 However, in both reports removal of the aziridine nitrogen substituent (chiral 
auxiliary) has not been described. Apparently, this is a difficult task, that should be 
accomplished by selective procedures to preserve the integrity of the aziridine ring and the 
configuration of the benzylic stereocenter. In this regard, it should be underlined that the 
aziridine 8 can easily undergo ring-opening by hydrogenolysis and nucleophilic attack, 
especially through N-activation by protic or Lewis acids. Hence, in order to prepare the N-
unsubstituted 2-(2-pyridyl)aziridine 8 (R = H), it should be possible to remove the N-(tert-
butyl)sulfinyl substituent R in the aziridine 8 by treatment with methyllithium at low 
temperature,38 rather than by the usual treatment with HCl/dioxane or HCl/methanol. 
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Scheme 20 
2.2.1 - Addition of “carbenoid” reagents to chiral aromatic imines 
Initial reactions were performed on the known imine 13, which is available by 
condensation of 2-pyridinecarboxaldehyde with (S)-valinol and subsequent protection of the 
hydroxyl function as its trimethylsilyl ether.39 As a matter of fact, our previous studies on 
the asymmetric synthesis of enantiopure 1-(2-pyridyl)alkylamines showed that O-
trimethylsilyl valinol is the preferred chiral auxiliary for the diastereoselective addition of 
organometallic reagents to 2-pyridineimines, providing the desired amines with higher 
diastereoselectivities compared to valine esters and phenylglycinol.39 Hence, a number of 
halogenomethylmetal reagents were added to the imine 13 under different experimental 
conditions, in order to optimize the synthesis of the 1,2-disubstituted aziridine 14, which 
was isolated following routine desilylation procedures (Scheme 21). 
It should be observed that electron-withdrawing N-substituents are generally 
required to achieve the addition of carbenoid reagents to the azomethine function. We 
hoped, however, that the electron-withdrawing pyridine ring would provide sufficient 
activation of the imine 13. So, in the first experiment, we used the zinc reagent that is 
formed in situ from diethylzinc and chloroiodomethane, and was previously used for the 
cyclopropanation of alkenes.40 This reagent was added to the TMSO-protected imine 13 at 
−30 °C, but no desired product was formed, even allowing the reaction mixture to reach room 
temperature (Table 1, entry 1). Even replacing chloroiodomethane with diiodomethane no 
reaction was observed (entry 2). We then moved to reagents that have previously been used 
for the preparation of halohydrins from aldehydes. We observed that a smooth reaction 
occurred at room temperature using the samarium reagent formed in situ by reaction of 
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 samarium with diiodomethane;41 the desired aziridine 14 was isolated in good yield but very 
low diastereoselectivity (entry 3) after desilylation of the crude reaction product with 
ammonium fluoride and column chromatography. No improvement was achieved by carrying 
out the reaction at 0 °C, as the yield and diastereomeric ratio (d.r.) were slightly lower 
(entry 4). The use of chloroiodomethane in place of diiodomethane in the samarium-mediated 
procedure gave a complex mixture of products (entry 5). 
 
Scheme 21 
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Table 1 
Entry 
Reagents 
(equivalents) 
T (°C) 
Time 
(h) 
14 
(Yield %)[a] 
14 
(S,S):(R,S)[b] 
1 Et2Zn (2), CH2ICl (4)[c] -30 to 20 3 0[d] - 
2 Sm (3), CH2I2 (2) 20 3 72 56:44 
3 Sm (3), CH2I2 (2) 0 3 70 52:48 
4 Sm (3), CH2ICl (2) 20 3 e - 
5 MeLi (2), CH2I2 (2) -78 to 0 4 e - 
6 MeLi (1.8), CH2ICl l (1.8), LiBr (1) -78 to 20 8 93[f] 87:13 
7 MeLi (3.6), CH2ICl (3.6), LiBr (2) -78 to 20 8 95[f] (65)[g] 92:8(>99:1)[g] 
[a] Yield of the crude reaction product. [b] Determined by GC-MS and 1H NMR analyses. [c] The reaction was 
performed in toluene. [d] The starting imine was recovered. [e] A complex mixture of products was obtained.  [f] 
The O-methyl derivative of 14 (ca 8% yield) was observed  by GC-MS analysis in the reaction mixture. [g] Yield and 
d.r. of 14 after column chromatography (SiO2). 
 
The reagent formed in situ, in the presence of the imine, from diiodomethane and 
methyllithium42 also gave a mixture of products, that was abandoned (entry 6). Good results 
were instead obtained with chloromethyllithium, which was formed in situ by the addition of 
methyllithium to a mixture of chloroiodomethane and lithium bromide in THF at –78 °C in the 
presence of the imine 13,43 then slowly raising the temperature to 20 °C. In this case, the 
aziridine 14 was obtained with excellent yield and high stereocontrol (d.r. 87:13, entry 7), 
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 following desilylation with ammonium fluoride in a MeOH-H2O mixture. The positive influence 
of lithium bromide on the stability of the carbenoid reagent should be similar to that of 
lithium dialkylamides, which, on the basis of DFT calculations,44 form mixed dimer 
aggregates with chloromethyllithium in THF solution. Better diastereoselectivity (d.r. 92:8) 
was finally obtained by using a greater excess of reagents (3.6 equivalents) with respect to 
the imine, and the pure diastereomer (S,S)-14 was isolated in 65% yield following 
chromatography on a silica gel column (entry 8). In the latter reactions (entries 7 and 8), 
small amounts (up to 8%) of the O-methyl ether of 14 were detected by GC-MS analysis and 
this compound was isolated by repeated chromatography of the impure compound obtained by 
pooling enriched chromatographic fractions coming from different reaction runs. 
Unfortunately, removal of the nitrogen substituent from the aziridine 14 to give the 
1-unsubstituted aziridine 16 proved to be impossible by the routine procedures generally 
used to cleave β-aminoalcohols. In fact, the aziridine 14 was unreactive towards oxidizing 
agents, such as periodic acid/methylamine and lead tetraacetate, in different solvents and 
experimental conditions (Scheme 22). In our opinion, this failure can be ascribed to the 
strain associated with the formation of the intermediate iminium ion 15, which features an 
exocyclic N=C double bond. This hypothesis is supported by the recent observation of the 
peculiar reactivity of 1-alkenylaziridines, which do not display nucleophilic character at the 
exocyclic C2-alkenyl carbon as is usually observed in enamines.45 
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Scheme 22 
2.2.2 – Variation of aromatic ring  
The scope of the described aziridination procedure exploiting chloromethyllithium was 
then investigated on a range of different aromatic imines derived from the same chiral 
auxiliary, (S)-valinol (Scheme 23). We readily recognized that the presence of the 2-
pyridineimine moiety is a requisite for the successful aziridination. As a matter of fact, the 
2-quinolineimine 17 proved to be less reactive than the 2-pyridineimine 13, as the 
corresponding aziridine 18 was obtained with low yield (51%) and the benzaldimine 19 did not 
react at all. 
 
-57- 
 N
OTMS
no reaction
19
N
N
OTMS N
N
OH
17 18
1) CH2ICl, LiBr,
THF, -78 °C
2) MeLi, -78
to 20 °C
3) NH4F,
MeOH-H2O
"
1) CH2ICl, LiBr,
THF, -78 °C
2) MeLi, -78
to 20 °C
3) NH4F,
MeOH-H2O  
Scheme 23 
Surprisingly, the reactions of the 3- and 4-pyridineimines 20a and 20b, respectively, 
lead to the secondary amines 21a,b, which were isolated in small amounts and identified by 
comparison with authentic specimen, and mainly the tertiary amines 22a,b. All the products 
21a,b and 22a,b were obtained with complete diastereoselectivity. 
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Scheme 24 
It is noteworthy that the competitive attack of methyllithium on the imine 13 was not 
observed. Moreover, when quenching the reaction mixture at low temperature, we did not 
detect the presumed intermediate β-chloro amine. The outcome of a modified experimental 
procedure was also instructive. When methyllithium was added to the mixture of 
chloroiodomethane and lithium bromide in THF at −78 °C, then the imine 13 was added to the 
cold mixture after 15 min, no product was formed after allowing the temperature to slowly 
reach room temperature. This result demonstrated that the actual reagent must be formed 
in situ in the presence of the imine. 
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Scheme 25 
The proposed rationale for the different behaviour of the 2- and 3-pyridineimines in 
this reaction is described in Scheme 25. The reactivity of the bidentate imines 13 and 17 
can be associated to their chelating ability, allowing formation of the stable chelate complex 
23 with the organometallic reagent ClCH2Li generated in situ. At the same time, the 
bidentate ligand (imine) enhances the nucleophilic character of the organolithium reagent and 
promotes the intramolecular C-C bond forming reaction leading to the β-chloro lithium amide 
24. Then, this intermediate undergoes intramolecular substitution to give the aziridine 14, 
after deprotection of the hydroxyl group. 
On the other hand, when methyllithium is added to the mixture of chloroiodomethane 
and 3-pyridineimine 20, it reacts with both of them at comparable rates. Apparently, the 
chloromethyllithium generated in situ is less reactive or unreactive towards the imine 20. 
The amide 25, formed by attack of methyllithium on the imine 20, is converted to the 
secondary amine 21 by proton quenching and desilylation, and to the tertiary amine 22 by 
reaction with methyl iodide, which is formed in the first halogen-metal exchange step, and 
desilylation. 
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Scheme 26 
2.2.3 – Different chiral auxiliaries 
We also examined the effect of different chiral auxiliaries, either β-aminoalcohols or 
α-aminoesters available from the "chiral pool", on the reactivity/diastereoselectivity of the 
corresponding 2-pyridineimines (Scheme 27). The imine 27 derived from 1,1-diphenylvalinol 
was found to be unreactive, presumably owing to the bulkiness of the N-substituent, and the 
(+)-norephedrine-derived imine 28 reacted sluggishly to give a mixture of products 
containing the diastereomeric aziridines 29 in 44% yield and 77:23 ratio (GC-MS). Moreover, 
the imine 30 prepared from (R)-phenylglycinol, gave the expected aziridine 31 with low 
diastereoselectivity and the major (R,R)-diastereomer was isolated in 25% yield after column 
chromatography. As found for aziridine 16, the N-substituent in 30 could not be removed by 
oxidative procedures, and hydrogenolysis over different Pd-catalysts was unsatisfactory due 
to concomitant cleavage of the pyridyl-substituted aziridine C-N bond. 
 
 
-60- 
 N
N
Ph
OTMS
SiO2
N
N
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Scheme 27 
Then we checked (S)-valine methyl ester as the chiral auxiliary and carried out the 
aziridination procedure on the derived imine 32 (Scheme 28). In this way, we obtained the 
product 33, coming from organometallic additions to both the imine and ester functions, in 
good yield and d.r. 87:13. Selective attack to the azomethine functionality could not be 
accomplished by working with equimolar amounts of reagents (imine, chloroiodomethane and 
methyllithium), as the same product 33 was formed, albeit in low yield. This result apparently 
demonstrates that chloromethyllithium, rather than a carbene, is the active intermediate in 
the reaction. Moreover, products coming from the attack of methyllithium to the ester 
function were not observed either in the crude reaction mixture or in chromatographic 
fractions. Similarly, the 2-quinolineimine 34 gave the corresponding aziridine-α-chloroketone 
35, in comparable yield and d.r. 88:12. 
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Scheme 28 
2.2.4 – Removal of N-substituent 
Further efforts were devoted to find alternative procedures for the removal of the 
N-substituent in the aziridine 14, through modification of the hydroxyl functionality. Initial 
attempts were directed to the transformation of the primary alcohol to halides (36) or 
phenylsulfide (37) by Mitsunobu procedures, because these compounds were expected to 
undergo β-amide elimination by treatment with a metal or a reducing agent (e.g. LiDBB and 
SmI2).46 Unfortunately, we met with no success, because the reaction mixtures were 
generally complex and the desired product was never isolated by column chromatography. 
Even the preparation of the bromide via the tosylate in different experimental conditions 
failed, probably because of the instability of any eventual bromide formed. 
N
N
OH
PhSSPh,
Et3P
THF N
N
SPh
N
NH
PhS
N
N
Br
N
NH
DEAD
Ph3P
MgBr2
THF
LiDBB
SmI2
X
X
14
36
37  
Scheme 29 
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 Treatment of the chloroketone 33 with tributylstannyl hydride in refluxing benzene 
in the presence of AIBN gave the ketone 38 (Scheme 30), on which Wolff-Kishner reactions 
with hydrazine or phenylhydrazine and KOH in ethylene glycol or dimethylsulfoxide at high 
temperature were carried out; however, the expected fragmentation of the hydrazones to 
give the free aziridine we did not occur contrary to previous reports of α-heterosubstituted 
hydrazones.47 Instead, new isomeric products (39a and 40a) were formed by rearrangement 
of 38 in the basic medium (vide supra). 
benzene,
AIBN, 80 °C
Bu3SnH
N
N
38
O
33
N
N
O
Cl
N
N OH
N
N OH
+
39a
40a
NH2NH2
DMSO
reflux
KOH
 
Scheme 30 
Swern oxidation of the aziridine-alcohol 14 smoothly led to the aziridine-aldehyde 41 
(Scheme 31), which was reduced with SmI2 at low temperature. β-Fragmentation of the 
intermediate ketyl radical anion was expected to occur, thus giving the desired NH-aziridine. 
Instead, several unidentified products were observed by TLC analysis, presumably due to 
competitive side reactions, probably including pinacol coupling and most likely cleavage of the 
aziridine C-N bond. Indeed, it has been reported that acetoxymethylpyridine can be coupled 
with carbonyl compounds through cleavage of the benzylic C-O bond, driven by chelation of 
samarium to the pyridine nitrogen and the acetate.48 
 
Et3N, CH2Cl2
-70 °C N
N
41
O
14
DMSO, (COCl)2,
DMAP
N
N
OH
SmI2 Complex
Mixture
 
Scheme 31 
The aziridine-ketone 38 reacted in basic medium (methanolic KOH at the reflux 
temperature of methanol) to give a highly prevalent compound, to which the structure 39a 
(Scheme 32) was tentatively assigned on the basis of mass-spectrometric and spectroscopic 
analyses, as a matter of fact, only the depicted structure fits with all the analytical data. In 
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 particular, the stereochemistry of the two ring stereocenters was determined by a NOE 
experiment: irradiation of the pyridyl-substituted ring proton only caused a response of the 
adjacent methylene hydrogen, not the ring methyl substituent. Although another compound, 
probably the diastereomer 40a, was present (ca 15% by 1H NMR) in the crude reaction 
mixture, it was not isolated by column chromatography, perhaps because it underwent 
dehydration more readily.  
We suggest that compound 39a is formed by the concerted mechanism depicted in 
structure 42, featuring the cleavage of the aziridine C-N bond, wherein the two electrons 
unusually move from nitrogen to carbon. We assume that the configuration of the pyridyl-
substituted stereocenter is maintained throughout this rearrangement. This supposition is in 
agreement with the reported stereoselective rearrangement of a 1,2,3-trisubstituted 
aziridine to 1-pyrroline by generation of a carbanion at the propargyl N-substituent.49 
Analogously, when aldehyde 41 was subjected to the same conditions a 55:45 mixture of two 
compounds was observed, presumably the diastereomers 39b and 40b, as evidenced by the 1H 
NMR spectrum of the crude reaction mixture. However, only the major product was isolated 
by column chromatography, as the minor one probably decomposed by dehydration. 
Conversely, no product was formed by heating the sodium alkoxide derived from the 
aziridine-alcohol 14 in THF.  
 
38, 41
39 a: R = Me
b: R = H
40
KOH
N
N R OH
N
N OHR
+
42
NH
Py
O
R
MeOH, 82 °C
 
Scheme 32 
2.2.5 – Use of the 2-(2-pyridyl)aziridines as chiral ligand 
We thought that the new 2-(2-pyridyl)aziridines synthesed in this work could be used 
a chiral ligands in asymmetric catalysis. We tested them in standard palladium catalyzed 
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 Asymmetric Allylic Alkylation (AAA) reaction of the carbonate 43 (Scheme 33), and found 
that the reactions with dimethyl malonate proceed with in the standard reaction conditions 
(BSA, allylpalladium chloride dimer, tetrahydrofuran). However with our great 
disappointment, low to moderate levels of enantioselectivity where obtained (Table 2). The 
ligand 14 with the S,S configurations of the two stereocenter showed the higher 
enantioselectivity (e.e. 62%) and its diasteroisomer gave the product with the same 
configuration but with only the 20% of e.e.. This results indicated that the configuration of 
stereocenter in the benzylic position is more important for the stereocontrol, we also tested 
the aziridine 18 and 31 but with low e.e.. 
 
Scheme 33 
Ph Ph
OCO2Et
(allylPdCl)2 (5 mol%),
L* , NaH, THF
Ph Ph
MeO2C CO2MeCH2(CO2Me)2
43 44  
Table 2 
L* Yield 44 (%) e.e. 44 (%) 
14 (S, S) 85 62 (R) 
14 (R, S) 89 20 (R) 
18 (S, S) 82 33 (R) 
31 (R, R) 85 20 (S) 
 
Finally we tested the 2-(2-pyridyl)aziridine 14 in the enantioselective addition of 
dietylzinc to aromatic aldehydes (Scheme 34). The reaction proceeded very smoothly, and 
was complete in only 2.5 hours at room temperature (Table 3), affording the addition product 
with 50% e.e.. Increasing the realative amount of the chiral ligand did not increase the 
enantioselectivity. 
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 Scheme 34 
R H
O
R
OH
Et2Zn, Toluene 25°C
N
N
14
OH
45 46
 
Table 3 
R L (mol%) Conversion 46 (%) e.e. 46 (%) 
Ph 5 100 50 
Ph 10 100 51 
2-Naphtyl 5 100 47 
4-Br-Ph 5 100 50 
 
2.3 – Experimental section 
2.3.1 – General protocol for the preparation of Imines 
The imines 20a, 20b, 28 and 34 were prepared from the corresponding aldehydes and 
enantiopure amines in almost quantitative yield by the procedures previously described for 
the preparation of the 2-pyridineimines 14, 17, 30 and 32.35,39 All the crude imines >95% 
pure by 1H NMR analysis) and were used immediately as obtained avoiding purification. 
However, the imine 34, being obtained as a solid, could be easily purified for analytical 
purpose by crystallization from Et2O-pentane mixture. 
 
N
N
OTMS
 
N-(3-Pyridylmethylidene)-O-trimethylsilyl-(S)-valinol (20a): Yellow oil; [α]D20 = -20.8 (c 
1.0, CHCl3); IR (neat): ν = 2958, 2929, 2868, 1646, 1591, 1575, 1470, 1422, 1388, 1250, 1026, 
839, 805, 708; 1H NMR (300 MHz, CDCl3): δ = 8.87 (s, 1 H), 8.63 (d, J = 4.7 Hz, 1 H), 8.24 (s, 
1 H), 8.12 (dt, J = 1.8 Hz, J = 7.9 Hz, 1 H), 7.33 (dd, J = 4.8 Hz, J = 7.8 Hz, 1 H), 3.87 (dd, J = 
3.9 Hz, J = 10.3 Hz, 1 H), 3.66 (dd, J = 8.2 Hz, J = 10.3 Hz, 1 H), 3.02 (m, 1 H), 1.95 (sept, J = 
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 6.8 Hz, 1 H), 0.93 (d, J = 6.8 Hz, 3 H), 0.92 (d, J = 6.8 Hz, 3 H), 0.03 (s, 9 H); 13C NMR (75 
MHz, CDCl3): δ = 157.8 (C=N), 151.2, 150.2, 134.5, 134.5, 131.9, 123.5, 78.8, 64.2, 29.9, 20.0, 
18.6, 0.4; MS (EI): m/z = 264 (M+, 6), 249 (5), 221 (4), 161 (100), 73 (27), 55 (16). 
 
N
N
OTMS 
N-(4-Pyridylmethylidene)-O-trimethylsilyl-(S)-valinol (20b): Yellow oil; [α]D20 = −43.0 (c 
0.4, CHCl3); IR (neat): v = 3081, 3032, 2958, 2872, 1650, 1593, 1462, 1405, 1251, 1115, 882, 
841; 1H NMR (300 MHz, CDCl3): δ = 8.67 (dd, J = 1.6 Hz, J = 4.5 Hz, 1 H), 8.18 (s, 1 H), δ = 
7.60 (dd, J = 1.6 Hz, J = 4.5 Hz, 1 H), 3.86 (dd, J = 3.6 Hz, J = 10.5 Hz, 1 H), 3.64 (dd, J = 
7.8 Hz, J = 10.5 Hz, 1 H), 3.03 (dd, J = 3.6 Hz, J = 7.8 Hz, 1 H), 1.95 (sept, J = 6.9 Hz, 1 H), 
0.93 (d, J = 6.9 Hz, 3 H), 0.91 (d, J = 6.9 Hz, 3 H), 0.02 (s, 9 H); 13C NMR (75 MHz, CDCl3): 
δ = 158.8, 150.3, 143.1, 121.9 (PyH), 78.7, 64.0, 29.9, 19.9, 18.6, −0.4; MS (EI): m/z = 264 (M+, 
11), 249 (10), 221 (3), 161 (100), 131 (4), 103 (9), 73 (35). 
 
N
N
Me
OTMS
Ph
 
N-(2-Pyridylmethylidene)-O-trimethylsilyl-1(R),2(S)-norephedrine (28): Colourless oil; 
[α]D20 +98.0 (c 1.9, CHCl3); IR (neat): v = 3054, 2958, 2872, 1650, 1588, 1568, 1468, 1436, 
1367, 1251, 1107, 973, 878, 774; 1H NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 0.9 Hz, J = 1.7 
Hz, J = 4.9 Hz, 1 H), 8.08 (s, 1 H), 7.90 (dt, J = 1.0 Hz, J = 7.9 Hz, 1 H), 7.69 (ddt, J = 1.0 Hz, 
J = 1.7 Hz, J = 7.9 Hz, 1 H), 7.15-7.33 (m, 6 H), 4.78 (d, J = 6.4 Hz, 1 H), 7.90 (quint, J = 6.4 
Hz, 1 H), 1.33 (d, J = 6.4 Hz, 3 H), 0.07 (s, 9 H); 13C NMR (75 MHz, CDCl3): δ = 159.4, 153.6, 
150.1, 138.0, 136.8, 128.4, 128.0, 127.2, 126.5, 123.8, 78.5, 65.8, 16.2, 2.1; MS (EI) m/z = 297 
(6), 179 (100), 133 (44), 92 (19), 73 (48). 
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N-(2-Quinolylmethylidene)-(S)-valine Methyl Ester (34): White powder; m.p. = 57-58 °C 
(Et2O-pentane); [α]D20 −113.7 (c 1.1, CHCl3); IR (Nujol): v = 1735, 1639, 1595, 1463, 1376, 
1193, 1142, 975, 842, 760, 734; 1H NMR (300 MHz, CDCl3): δ = 8.52 (s, 1 H), 8.28 (d, J = 8.5 
Hz, 1 H), 8.21 (d, J = 8.6 Hz, 1 H), 8.14 (d, J = 8.5 Hz, 1 H), 7.87 (d, J = 8.0 Hz, 1 H), 7.77 (dt, 
J = 1.4 Hz, J = 8.1 Hz, 1 H), 7.77 (dt, J = 1.4 Hz, J = 8.0 Hz, 1 H), 3.86 (d, J = 7.0 Hz, 1 H), 
3.78 (s, 3 H), 2.45 (dsept, J = 6.8 Hz, J = 7.0 Hz, 1 H), 1.01 (d, J = 6.8 Hz, 3 H), 0.98 (d, J = 
6.8 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 172.0, 164.7, 154.2, 147.7, 136.4, 129.7, 129.5, 
128.8, 127.6, 127.5, 118.6, 79.8, 51.9, 31.8, 19.4, 18.5; MS (EI): m/z = 270 (M+, 2), 255 (2), 
238 (3), 227 (14), 212 (15), 211 (100), 195 (30), 169 (28), 168 (25), 142 (42), 128 (13), 115 
(15). Anal. Calcd forC16H18N2O2: C, 71.09; H, 6.71; N, 10.36. Found C, 71.15; H, 6.73; N, 10.34. 
2.3.2 - Reaction of imines with methyllithium/chloroiodomethane. 
General procedure: Lithium bromide (0.66 g, 7.6 mmol) and chloroiodomethane (0.99 
mL, 13.6 mmol) were added to the solution of the imine 13 (1.00 g, 7.6 mmol) in anhydrous 
THF (20 mL) under an inert atmosphere. The magnetically stirred mixture was cooled at 78 
°C and MeLi (1.6 M in Et2O, 8.5 mL, 13.6 mmol) was slowly added, meanwhile the mixture 
assumed a dark red colour. The temperature was allowed to rise to 20 °C over 6 h, then the 
mixture was quenched with saturated aqueous sodium hydrogen carbonate (20 mL). The 
organic phase was extracted with Et2O (3 x 20 mL), and the combined organic layers were 
concentrated at reduced pressure. For reactions of imines derived from O-TMS-β-
aminoalcohols, the residue was taken up in MeOH-H2O (1:1, 20 mL) and NH4F (2.5 g) was 
added, the mixture was stirred overnight, then NaOH pellets were added until pH 11 was 
achieved, MeOH was removed at reduced pressure, and the organic phase was extracted 
with Et2O (3 x 20 mL). The combined organic layers was washed with brine (20 mL), dried 
(Na2SO4) and concentrated at reduced pressure. The dark oily residue was purified via SiO2 
column chromatography eluting with 20:80 cyclohexane/EtOAc, then with 90:10 EtOAc 
/MeOH mixtures. 
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3-Methyl-2(S)-[2(S)-(2-pyridyl)-1-aziridinyl]-1-butanol (14): 0.509 g, 65%, red 
oil; [α]D20 −105.6 (c 0.5, CHCl3); IR (neat): v = 3373, 2960, 1595, 1570, 1479, 1436, 1387, 
1077, 762; 1H NMR (300 MHz, CDCl3): δ = 8.54 (ddd, J = 1.0 Hz, J = 1.8 Hz, J = 4.8 Hz, 1 H), 
7.63 (dt, J = 1.2 Hz, J = 7.8 Hz, 1 H), 7.24 (dt, J = 0.9 Hz, J = 7.8 Hz, 1 H), 7.16 (ddd, J = 1.2 
Hz, J = 4.9 Hz, J = 7.5 Hz, 1 H), 3.83 (d, J = 3.6 Hz, 2 H), 2.69 (dd, J = 3.2 Hz, J = 6.6 Hz, 1 
H), 2.07 (d, J = 3.2 Hz, 1 H), 2.04 (sept, J = 6.9 Hz, 1 H), 1.95 (d, J = 6.5 Hz, 1 H), 1.66 (bs, 1 
H), 1.50 (q, J = 3.6 Hz, 1 H), 0.98 (d, J = 6.9 Hz, 3 H), 0.96 (d, J = 6.9 Hz, 6 H); 13C NMR (75 
MHz, CDCl3): δ = 159.5, 149.9, 136.5, 121.9, 120.3, 75.6, 63.3, 42.9, 35.6, 29.9, 19.5, 19.4; MS 
(ES): m/z = 207.3 (M + H)+, 229.2 (M + Na)+, 413.3 [(2 M + H)+], 435.3 (2 M + Na)+. Anal. Calcd 
for C12H18N2O: C, 69.87; H, 8.80; N, 13.58. Found C,  69.60; H, 8.85; N, 13.28. 
Whereas the minor diastereomer of 14 was not isolated by column chromatography, a 
sample of the O-methyl ether of 14 was obtained by column chromatography of several 
pooled fractions containing it, coming from different reaction runs: red oil; [α]D20 −82.6 (c 
4.6, CHCl3); IR (neat): v = 2968, 1590, 1578, 1482, 1431, 1391, 1075, 767; 1H NMR (300 MHz, 
CDCl3): δ = 8.49 (ddd, J = 0.7 Hz, J = 1.6 Hz, J = 4.9 Hz, 1 H), 7.59 (dt, J = 1.4 Hz, J = 7.9 Hz, 
1 H), 7.24 (d, J = 7.9 Hz, 1 H), 7.12 (ddt, J = 0.9 Hz, J = 4.7 Hz, J = 7.9 Hz, 1 H), 3.55 (d, J = 
6.7 Hz, 1 H), 3.54 (d, J = 4.5 Hz, 1 H), 3.38 (s, 3 H), 2.56 (dd, J = 3.3 Hz, J = 6.5 Hz, 1 H), 
2.02 (d, J = 3.3 Hz, 1 H), 2.00 (d, J = 6.5 Hz, 1 H), 1.94 (sept, J = 6.9 Hz, 1 H), 1.65 (dd, J = 
4.5 Hz, J = 6.7 Hz, 1 H), 0.95 (d, J = 6.9 Hz, 3 H), 0.94 (d, J = 6.9 Hz, 6 H); 13C NMR (75 
MHz, CDCl3): δ = 160.1, 148.9, 136.4, 120.7, 120.0, 74.4, 73.8, 59.0, 41.9, 30.1, 19.2, 18.9; MS 
(EI): m/z = 220 (M, 1), 219 (2), 175 (31), 145 (22), 133(10), 119 (100), 106 (69), 92 (55), 79 
(21), 65(16). Anal. Calcd for C13H20N2O: C, 70.87; H, 9.15; N, 12.72. Found C, 70.58; H, 9.18; 
N, 12.42. 
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3(S)-Methyl-2-[2(S)-(2-quinolyl)-1-aziridinyl]-1-butanol (18): it was obtained from the 
imine 17 (1.1 g, 3.5 mmol), 0.457 g (51%); red oil; [α]D20 −115.7 (c 1.6, CHCl3); IR (neat): v = 
3370, 2964, 1589, 1574, 1428, 1388, 1070, 770; 1H NMR (300 MHz, CDCl3): δ = 8.10 (d, J = 
8.5 Hz, 1 H), 8.07 (d, J = 8.5 Hz, 1 H), 7.80 (d, J = 8.1 Hz, 1 H), 7.71 (ddd, J = 1.5 Hz, J = 6.9 
Hz, J = 8.4 Hz, 1 H), 7.52 (ddd, J = 1.2 Hz, J = 7.0 Hz, J = 8.5 Hz, 1 H), 7.36 (d, J = 8.5 Hz, 1 
H), 3.86 (d, J = 3.9 Hz, 2 H), 2.92 (dd, J = 3.3 Hz, J = 6.8 Hz, 1 H), 2.13 (sept, J = 6.9 Hz, 1 
H), 2.10 (d, J = 3.3 Hz, 1 H), 2.05 (d, J = 6.8 Hz, 1 H),  1.58 (q, J = 4.0 Hz, 1 H), 0.98 (d, J = 
6.9 Hz, 3 H), 0.96 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 160.4, 147.6, 136.8, 
129.5, 128.8, 127.6, 127.5, 126.0, 117.9, 75.4, 63.5, 42.7, 35.7, 30.1, 19.7, 19.4; MS (ES): m/z 
= 256.4 (M + H)+, 279.3 (M + Na)+, 535.6 (2 M + Na)+. Anal. Calcd for C16H20N2O: C, 74.97; H, 
7.86; N, 10.93. Found C, 74.71; H, 7.88; N, 10.90. 
 
N
N
Me
OH
Ph
 
1(R)-Phenyl-2(S)-[2(R)- and 2(S)-(2-pyridyl)-1-aziridinyl]-1-propanol 29: The reaction 
of the imine 28 (0.936 g, 3 mmol) gave a mixture of the diastereomeric aziridines 29 (0.335 
g, 44%) with a 77:23 ratio (1H NMR), which could not be separated by column 
chromatography. The different absorptions for the two diastereomers were evidenced from 
enriched chromatographic fractions. Major diastereomer: yellow oil; 1H NMR (300 MHz, 
CDCl3): δ = 8.49 (m, 1 H), 7.60 (m, 2 H), 7.38-7.12 (m, 6 H), 4.95 (d, J = 3.9 Hz, 1 H), 4.55 (d, 
J = 6.3 Hz, 1 H,), 2.82 (dd, J = 3.9 Hz, J = 6.3 Hz, 1 H), 2.61 (dd, J = 3.3 Hz, J = 6.4 Hz, 1 H), 
2.06 (d, J = 3.3 Hz, 1 H), 1.86 (d, J = 6.6 Hz, 1 H), 1.00 (d,  J = 6.4 Hz, 1 H). Minor 
diastereomer: yellow oil; 1H NMR (300 MHz, CDCl3): δ = 8.60 (m, 1 H, PyH), 7.66 (m, 2 H), 
7.38-7.12 (m, 6 H), 4.88 (d, J = 3.9 Hz, 1 H), 4.39 (d, J = 6.5 Hz, 1 H), 2.84 (dd, J = 3.9 Hz, J 
= 6.5 Hz, 1 H), 2.61 (dd, J = 3.2 Hz, J = 6.6 Hz, 1 H), 2.17 (d, J = 3.3 Hz, 1 H), 1.91 (d, J = 6.6 
Hz, 1 H), 0.88 (d,  J = 6.5 Hz, 1 H). Anal. Calcd for C16H18N2O: C, 75.56; H, 7.13; N, 11.01. 
Found C, 75.98; H, 7.17; N, 10.98. 
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2(R)-Phenyl-2-[2(R)-(2-pyridyl)-1-aziridinyl]ethanol (31): it was obtained from the 
imine 30 (1.04 g, 3.5 mmol), 0.210 g (25%); red oil; [α]D20 −87.3 (c 0.7, CHCl3); IR (neat): v = 
3365, 3052, 3019, 2933, 2853, 1595, 1570, 1480, 1389, 1354, 1216, 1150, 1067, 756, 701; 1H 
NMR (300 MHz, CDCl3): δ = 8.51 (ddd, J = 0.9 Hz, J = 1.7 Hz, J = 4.9 Hz, 1 H), 7.61 (dt, J = 
1.9 Hz, J = 7.7 Hz, 1 H), 7.38 (dd, J = 1.6 Hz, J = 7.9 Hz, 1 H), 7.34-7.10 (m, 6 H), 4.01 (dd, J 
= 5.5 Hz, J = 11.3 Hz, 1 H), 3.94 (dd, J = 5.5 Hz, J = 11.3 Hz, 1 H), 2.95 (t, J = 5.5 Hz, 1 H); 
2.72 (bs, 1 H), 2.61 (dd, J = 3.2 Hz, J = 6.6 Hz, 1 H), 2.39 (d, J = 3.3 Hz, 1 H), 2.19 (d, J = 6.6 
Hz, 1 H); 13C NMR (75 MHz, CDCl3): δ = 159.1, 149.1, 139.9, 136.4, 128.3, 127.5, 127.4, 121.9, 
120.7, 75.6, 67.6, 39.7, 38.6; MS (EI): m/z = 312 (M+, 1), 297 (5), 177 (10), 144 (31), 119 (63), 
106 (100), 92 (30), 73 (43). Anal. Calcd for C15H16N2O: C, 74.97; H, 6.71; N, 11.66. Found C, 
75.12; H, 6.88; N, 11.48. 
 
N
N
O
Cl
 
 (S)-1-Chloro-4-methyl-3-[2(S)-(2-pyridyl)-1-aziridinyl]-2-pentanone (33): it was 
obtained from the imine 32 (0.792 g, 3.6 mmol): 0.60 g (75%); red oil; [α]D20 −59.3 (c 1.2, 
CHCl3); IR (neat): v = 2967, 2865, 1734, 1593, 1465, 1436, 1389; 1H NMR (300 MHz, CDCl3): 
δ = 8.44 (dd, J = 0.9 Hz, J = 4.8 Hz, 1 H), 7.58 (tt, J = 1.7 Hz, J = 7.8 Hz, 1 H), 7.19 (dd, J = 
0.9 Hz, J = 7.8 Hz, 1 H), 7.14 (ddt, J = 1.2 Hz, J = 4.8 Hz, J = 7.8 Hz, 1 H), 4.60 (d, J = 17.0 
Hz, 1 H), 4.51 (d, J = 17.0 Hz, 1 H), 2.68 (dd, J = 3.4 Hz, J = 6.7 Hz, 1 H), 2.25 (d, J = 6.5 Hz, 
1 H), 2.06 (dsept, J = 6.5 Hz, J = 6.6 Hz, 1 H), 2.00 (d, J = 3.4 Hz, 1 H), 1.68 (d, J = 6.7 Hz, 1 
H), 0.91 (d, J = 6.6 Hz, 3 H), 0.85 (d, J = 6.6 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 202.0, 
158.1, 148.9, 136.5, 122.2 , 119.9, 83.9, 47.6, 43.6, 34.9, 32.1, 19.1, 19.0; MS (ES) m/z = 253.2 
(M + H)+, 275.1 (M + Na)+. Anal. Calcd for C13H17ClN2O: C, 61.78; H, 6.78; Cl, 14.03; N, 11.08;  
Found C, 61.48; H, 6.88; Cl, 13.99; N, 11.03. 
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(S)-1-Chloro-4-methyl-3-[2(S)-(2-quinolyl)-1-aziridinyl]-2-pentanone (35): It was 
obtained starting from of the imine 34 (0.621 g, 2.3 mmol): 0.514 g (78%); red oil; [α]D20 
−71.2 (c 1.2, CHCl3); IR (neat): v = 3052, 2964, 2926, 2875, 1733, 1618, 1600, 1505, 1430, 
1428, 1389, 1313, 1030, 829, 756, 628; 1H NMR (300 MHz, CDCl3): δ = 8.13 (d, J = 8.6 Hz, 1 
H), 8.04 (d, J = 8.4 Hz, 1 H), 7.80 (d, J = 8.1 Hz, 1 H), 7.71 (dt, J = 1.4 Hz, J = 8.4 Hz, 1 H), 
7.57 (dt, J = 1.4 Hz, J = 8.0 Hz, 1 H), 7.35 (d, J = 8.5 Hz, 1 H), 4.68 (d, J = 16.7 Hz, 1 H), 
4.60 (d, J = 16.7 Hz, 1 H), 2.99 (dd, J = 3.3 Hz, J = 6.7 Hz, 1 H), 2.42 (d, J = 6.3 Hz, 1 H), 
2.19 (dsept, J = 6.3 Hz, J = 6.8 Hz, 1 H), 2.12 (d, J = 3.3 Hz, 1 H), 1.79 (d, J = 6.7 Hz, 1 H), 
1.00 (d, J = 6.8 Hz, 3 H), 0.96 (d, J = 6.8 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 201.1, 158.9, 
147.4, 136.9, 129.6, 128.6, 127.5, 127.4, 126.1, 117.0, 83.7, 47.7, 44.2, 35.2, 32.4, 19.2, 19.1; 
MS (ES): m/z = 303.1 (M + H)+, 325.0 (M + Na)+. Anal. Calcd for C17H19ClN2O: C, 67.43; H, 
6.32; Cl, 11.71; N, 9.25. Found C, 67.40; H, 6.36; Cl, 11.67; N, 9.20. 
2.3.3 – Dehalogenation of ketone 33 
N
N
O  
(S)-4-Methyl-3-[2(S)-(2-pyridyl)-1-aziridinyl]-2-pentanone (38): A solution of 
compound 33 (0.102 g, 0.4 mmol), tri(n-butyl)tin hydride (0.12 mL, 0.6 mmol) and AIBN (10 
mg) in benzene (5 mL) was heated at the reflux temperature under an inert atmosphere for 
3 h. Evaporation of the solvent at reduced pressure gave an oily residue that was subjected 
to chromatography on a SiO2 column eluting with cyclohexane-ethyl acetate (70:30) to obtain 
28 as a red-brown oil: 0.076 g (88%); red-brown oil: [α]D20 −20.2 (c 1.0, CHCl3); IR (neat): v = 
2936, 2932, 2874, 1710, 1594, 1565, 1436, 1353, 1212, 996, 776, 748; 1H NMR (300 MHz, 
CDCl3): δ = 8.50 (ddd, J = 1.0 Hz, J = 1.7 Hz, J = 4.9 Hz, 1 H), 7.62 (dt, J = 1.7 Hz, J = 7.7 Hz, 
1 H), 7.21 (td, J = 1.0 Hz, J = 7.7 Hz, 1 H), 7.14 (ddd, J = 1.2 Hz, J = 4.9 Hz, J = 7.7 Hz, 1 H), 
2.68 (dd, J = 3.3 Hz, J = 6.6 Hz, 1 H), 2.31 (s, 3 H), 2.12 (dsept, J = 6.2 Hz, J = 6.6 Hz, 1 H), 
2.07 (d, J = 6.2 Hz, 1 H), 2.02 (d, J = 3.3 Hz, 1 H), 1.69 (d, J = 6.6 Hz, 1 H), 0.97 (d, J = 6.6 
 
-72- 
 Hz, 3 H), 0.90 (d, J = 6.6 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 210.1, 159.0, 149.0, 136.6, 
122.1, 120.0, 85.9, 44.0, 34.7, 31.7, 27.1, 19.4, 19.2; MS (ES): m/z = 219.4 (M + H)+, 241.4 (M 
+ Na)+Anal. Calcd for C13H18N2O: C, 71.53; H, 8.31; N, 12.83. Found C, 71.21; H, 8.38; N, 12.64. 
2.3.4 – Oxidation of aziridine 14 
N
N
O 
(S)-3-Methyl-2-[2(S)-(2-pyridyl)-1-aziridinyl]butanal (41): To a solution of oxalyl 
chloride (68 mg, 45 μL, 0.53 mmol) in CH2Cl2 (2 mL) at −60 °C was added dropwise a solution 
of DMSO (83 mg, 76 μL, 1.1 mmol) in CH2Cl2 (2 mL). After 10 min, a solution of aziridine 14 
(100 mg, 0.49 mmol) in CH2Cl2 (2 mL) was added dropwise, followed, after 15 minutes, by 
triethylamine (246 mg, 0.34 mL, 2.4 mmol). The temperature was slowly raised to 20 °C and 
the mixture was further stirred for 2 h, then quenched with H2O (5 mL). The organic phase 
was extracted with CH2Cl2 (3 x 10 mL), and the combined organic phases was concentrated. 
The residue was subjected to chromatography on a SiO2 column eluting with EtOAc to give 
29 as a red oil: 74 mg (74%); [α]D20 −24.6 (c 0.33, CHCl3); IR (neat): v = 3059, 2964, 2919, 
2868, 1733, 1669, 1592, 1572, 1472, 1436, 1260, 1079, 804, 753; 1H NMR (300 MHz, CDCl3): 
δ = 9.78 (d, J = 2.8 Hz, 1 H), 8.48 (ddd, J = 0.9 Hz, J = 1.8 Hz, J = 4.9 Hz, 1 H), 7.61 (dt, J = 
1.8 Hz, J = 7.6 Hz, 1 H), 7.32 (d, J = 8.7 Hz, 1 H), 7.21 (ddd, J = 0.9 Hz, J = 3.9 Hz, J = 7.6 
Hz, 1 H), 2.64 (dd, J = 3.5 Hz, J = 6.7 Hz, 1 H), 2.25 (dsept,  J = 5.7 Hz, J = 6.6 Hz, 1 H), 
2.23 (d, J = 3.5 Hz, 1 H), 2.08 (dd, J = 2.8 Hz, J = 5.7 Hz, 1 H), 1.82 (d, 1 H, J = 6.7 Hz), 0.98 
(d, J = 6.8 Hz, 3 H), 0.95 (d, J = 6.8 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 202.9, 158.8, 
149.2, 136.6, 122.2, 120.2, 83.1, 42.3, 35.1, 30.6, 19.2, 18.9; MS (ES): m/z = 205.4 (M + H)+, 
227.3 (M + Na)+. Anal. Calcd for C12H16N2O: C, 70.56; H, 7.90; N, 13.71; Found C, 70.32; H, 
7.93; N, 13.66. 
 
2.3.5 – Tratament in basic mediun of ketone 38 and aldehyde 41 
N
N OH  
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 3(S),4(S)-3-Hydroxy-2-isopropyl-3-methyl-4-(2-pyridyl)-1-pyrroline (39a): To a 
solution of 38 (300 mg, 1.4 mmol) in MeOH (10 mL) was added KOH (0.118 g, 2.1 mmol). The 
mixture was heated at the reflux temperature for 2 h, then the solvent was evaporated at 
reduced pressure, H2O (5 mL) was added, and the organic phase was extracted with CH2Cl2 
(2 x 20 mL). The combined organic layers was washed with brine (10 mL), dried (Na2SO4) and 
concentrated at reduced pressure. The dark oily residue was subjected to chromatography 
on a SiO2 column eluting with EtOAc, then with a 90:10 EtOAc/MeOH mixture, to give 39a as 
a yellowish oil: 0.186 g (61%); [α]D20 −120.2 (c 0.9, CHCl3); IR (neat): v = 3245, 2967, 2931, 
2871, 1641, 1594, 1569, 1473, 1436, 1370, 1151, 1112, 987, 788, 751; 1H NMR (300 MHz, 
CDCl3): δ = 8.49 (d, J = 4.3 Hz, 1 H), 7.66 (t, J = 7.7 Hz), 7.19 (dd, J = 4.3 Hz, J = 7.7 Hz, 2 
H), 6.22 (bs, 1 H), 4.17 (dd, J = 7.9 Hz, J = 15.5 Hz, 1 H), 3.82 (dd, J = 6.9 Hz, J = 15.5 Hz, 1 
H), 3.22 (dd, J = 6.9 Hz, J = 7.9 Hz, 1 H), 2.82 (sept, J = 6.6 Hz, 1 H), 1.43 (s, 3 H), 1.29 (d, J 
= 6.9 Hz, 3 H), 1.22 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ = 185.3, 160.1, 148.4, 
137.1, 124.7, 121.8, 84.6, 64.0, 53.4, 28.0, 24.6, 21.8, 21.3; MS (EI): m/z = 218 (M, 4), 175 (5), 
149 (6), 120 (3), 121 (10), 106 (100), 92 (8), 78 (15); MS (ES): m/z = 219.3 (M + H)+, 241.4 (M 
+ Na)+. Anal. Calcd for C13H18N2O: C, 71.53; H, 8.31; N, 12.83. Found C, 71.56; H, 8.34; N, 
12.80. 
N
N H OH  
3(S),4(S)-3-Hydroxy-2-isopropyl-4-(2-pyridyl)-1-pyrroline (39b): this was obtained 
from 41 (0.300 g, 1.45 mmol) by the same procedure used for 39a: 148 mg (52%); yellowish 
oil; [α]D20 −98.7 (c 1.4, CHCl3); IR (neat): v = 3241, 2977, 2927, 2864, 1647, 1597, 1578, 1471, 
1430, 1378, 1141, 988, 784, 757; 1H NMR (300 MHz, CDCl3): δ = 8.54 (dt, J = 1.7 Hz, J = 4.6 
Hz, 1 H), 7.64 (td, J = 1.9 Hz, J = 7.7 Hz, 1 H), 7.17 (m, 2 H), 5.14 (d, J = 8.3 Hz, 1 H), 4.30 
(dt, J = 8.3 Hz, J = 14.9 Hz, 1 H), 3.76 (dt, J = 8.6 Hz, J = 14.9 Hz, 1 H), 3.50 (dt, J = 8.3 Hz, 
J = 8.4 Hz, 1 H), 2.87 (sept, J = 6.8 Hz, 1 H), 1.26 (d, J = 6.8 Hz, 3 H), 1.22 (d, J = 6.8 Hz, 3 
H); 13C NMR (75 MHz, CDCl3): δ = 183.4, 160.4 (Py), 149., 136.7, 123.9, 122.5, 83.0, 61.7, 55.6,  
29.4, 20.0, 19.0; the product decomposed during GC-MS analysis. Anal. Calcd for C12H16N2O: 
C, 70.56; H, 7.90; N, 13.71; Found C, 70.54; H, 7.93; N, 13.77. 
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2.3.6 – Catalysis reactions 
The reactions of AAA are conducted as see in the Chapter 1. 
 
General procedure for the addition of diethylzinc to aldehydes: To a solution of 
the ligand 14 (0.1 mmol, 0.021 g) in anhydrous toluene (5 ml) at 0°C a solution of diethylzinc 
(1 M in hexane, 2 mL) was added. After 30 minutes the benzaldehyde (1 mmol, 101 μL) was 
added and the temperature was rising at 25°C. After 2.5 hour the reaction mixture was 
cooled at 0°C and 1N HCl (5 ml) was added. The organic phase was extracted with CH2Cl2 (3 x 
10 mL), and the combined organic phases was concentrated. The residue was subjected to 
chromatography on a SiO2 column eluting column eluting with cyclohexane-ethyl acetate 
(90:10) to obtain 46 as oil. 
The enantiomeric eccess of the benzylic alcohols and their absolute configuration were 
determined as reported in literature.50 
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 Chap. 3 – Asymmetric Route to Pyridines Bearing 
a Highly Functionalized 2-Alkyl Substituent by 
Aziridine Ring Opening Reactions 
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H OHN
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3.1 – Introduction 
The aziridine ring is one of the most valuable building blocks in modern synthetic 
chemistry,1 because of its widely recognized versatility for chemical bond elaborations and 
functional group transformations. Its reactivity is dominated by the electrophilic nature at 
carbon atoms and generally involves cleavage of the strained three-membered ring, by a wide 
range of nucleophiles to give β-substituted amines. Its potency is the combination of Bæyer 
strain (estimated around 111 kJ/mol, comparable with that of oxirane) and the 
electronegativity of the heteroatom: this means that aziridines are willing to undergo ring-
cleavage reactions under relatively mild conditions. As might be expected, due to the 
diminished electronegativity of nitrogen compared to oxygen, ring-opening reactions of these 
hetero-cycles are less facile than the corresponding reactions of epoxides, but there is still a 
wealth of examples of such chemistry. There are several features of these reactions which 
are worthy of consideration. 
Where an aziridine is unsymmetrically-substituted (as would typically be the 
situation), reaction with a nucleophile can lead to two products of ring-opening (Scheme 1): 
one derived from nucleophilic attack at C2-carbon and one from the attack to C3-carbon. As 
would be expected most nucleophiles preferentially direct their attack to the site of lesser 
substitution, though electronic considerations (for instance in the ring-opening of 2-
arylaziridines) may perturb this preference. 
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Scheme 1 
Chiral aziridines undergo regio- and stereoselective ring opening to access to chiral 
amines with predictable α and β stereochemistry. The increasing synthetic accessibility of 
chiral aziridines2 has propelled their use in ring opening reactions in asymmetric organic 
synthesis. In general, two types of aziridine can be considered: activated and unactivated 
(Scheme 2). The former contain substituents capable of stabilising by coniugation the 
developing negative charge on nitrogen during nucleophilic ring opening. The latter, also known 
as simple aziridines are generally unsubstituted or with alkyl substitution on nitrogen and 
usually require acid catalysis (protonation or Lewis acid) to facilitate ring opening. 
 
N
R
"nonactivated"
R = H, alkyl, aryl
N
R
"activated"
R = COR', CO2R', SO2R'  
Scheme 2 
A large variety of nucleophiles have been employed successfully in asymmetric ring-
opening (ARO) reactions, with the majority of these being heteroatom-based such as azide, 
alcohols, thiols, amines, halides or carbon-based nucleophiles (Scheme 3). Nucleophilic ring 
opening of aziridine cover examples of broad applications for the synthesis of amino acids, 
aza-sugars, chiral ligands, biologically active compounds, natural products and other synthesis. 
In this introduction I desire to report some applications of chiral aziridine’s ring opening in 
the synthesis of chiral organic compounds. 
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Scheme 3 
Chloramphenicol (3) is one of the oldest antibacterial agents and only its (2R,3R) 
enantiomer is active. Wulff and co-workers reported the synthesis of this important 
antibiotic in enantiomerically pure form in only four steps,3 where one step consist in the 
regio- and stereoselective opening of the aziridine ring by heating with dichloroacetic acid 
(Scheme 4). The enantiopure aziridine (1) was synthetized by the reaction of  
ethyldiazoacetate and the N-benzyl-p-nitrobenzaldimine in the presence of the chiral 
catalyst prepared from tiphenylborate and (R)-VAPOL. The treatment of 1 with an excess of 
dichloroacetic acid under forcing condition resulted in the ring opening of the the protonated 
aziridine by the dichloroacetate anion with complete inversion of configuration. Under the 
reaction conditions the benzyl protecting group was removed and the amine was 
chloroacetilated to give the amide (2). Finally the ester function was reduced with sodium 
borohydride to give the (-)-chloramphenicol (3) with good yield. 
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Scheme 4 
 
The same author4 described the reductive ring opening of the aziridine 4 (Scheme 5) 
with borane-trimethylamine complex in the presence of TFA to give the amino ester 5. The 
amine 5 was converted into the compound 6 (BIRT-377), an antagonist of the leukointegrin 
LFA-1. 
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Scheme 5 
An interesting example of application of aziridine’s ring opening is found in the 
Harada’s preparation of chital diazepines 10 possessing highly potent 5-HT3 receptor 
antagonist activity (Scheme 6)5. The activated aziridine 7, derived from serine, was opened 
by the diamine 8 to give the aminoester 9, which was converted trought deprotection, 
cyclization and reduction to the diazepine 10. 
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Scheme 6 
The opening of chiral aziridino alcohols was applied to the enantioselective synthesis 
of some members of the important class of carbapenem antibiotics. For example the regio- 
and steroselective opening of the aziridino alcohol 11 (Scheme 7)6 by lithium diethylcuprate 
give the amino alcohol 12, precursor of the β-lactams 13, a intermediate of the PS5 
carbapenem 14. 
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Scheme 7 
Shibasaki and co-workers7 developed a new synthesis of Tamiflu (oseltamivir 
phosphate 18) an orally active anti-influenza drug that potently inhibits neuramidase, an 
enzyme crucial for the release and spread of the avian influenza virus from infected cells.8 
One of the first step of the synthesis consists of catalytic desymmetrization of meso-
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 aziridine (15) with TMSN3 using a Yittrium complex of chiral ligand 17 to give the azido amine 
16 with 96% of yield and 91% of e.e. (e.e. 99% after recrystalization). 
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Scheme 8 
Finally Hudlicky9 studied a new synthesis of 7-deoxypancratistatin (21), a compound 
highly active against many cancer cell lines, via region- and stereoselective intramolecular ring 
opening of the chiral aziridine 19 in presence of silica gel as Lewis acid. 
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Scheme 9 
I have reported in the Chapter 2 the synthesis of the 2-(2-pyridyl)-substituted 
aziridine 22 by the addition of chloromethyllithium to the pyridineimine derived from (S)-
valinol.10 Stimulated by the plethora of reports describing the ring-opening of unactivated 
aziridines by hetero-nucleophiles, we applied a few such procedures to the aziridine 22, 
aiming to assess the factors controlling the regioselectivity of the nucleophilic attack, 
providing the polyfunctional compounds 23 and/or 24 (Scheme 10). In particular, we planned 
to prepare the compounds 23, whose stuctural features are the homobenzylic amine moiety 
and the benzylic stereocenter. We envisaged that these compounds and those obtained by 
removal or transformation of the N-substituent can find use as chiral non-racemic 
polydentate ligands in enantioselective catalytic reactions. Moreover, this skeleton is present 
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 in a number of compounds, e.g. 2511 and 2612, which have been described in recent patents 
reporting their herbicide and fungicide properties. 
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Scheme 10 
3.2 - Results and discussion 
The protocols for the Lewis acid-promoted nucleophilic ring opening of analogous 
substituted aziridines, as described by other groups, were taken into account. A series of 
reactions with several hetero-nucleophiles in different experimental conditions demonstrated 
that it is possible to activate the aziridine ring and control the regioselectivity of the ring-
opening process by the proper choice of the reagent, Lewis acid and solvent.  
The reactions gave the products 23 (Scheme 11), coming from nucleophilic attack at 
the more substituted aziridine carbon, either exclusively or together with the alternative 
product 24 (Table 1). Initial attempts involved water as the nucleophile in the presence of a 
protic13 or Lewis acid catalyst.14 Heating a mixture of aziridine 22 and p-toluenesulfonic acid 
(20 mol%) in 9:1 acetonitrile-water at the reflux temperature for 6 h gave a mixture of the 
regioisomeric ring-opening products 23a and 24a (82:18), which were separated by column 
chromatography. Slightly better results were obtained using cerium trichloride heptahydrate 
(30 mol%) with other experimental conditions remaining constant; by this manner an improved 
regioselectivity (86:14) was obtained. 
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Scheme 11 
Then, efforts were devoted to optimize the reaction with sodium azide, with the aim 
of preparing the benzylic azide 23b. By using sodium azide as the nucleophile source, an 
acetonitrile-water mixture (9:1) was used as the solvent. Having observed no reactivity at the 
reflux temperature in the absence of a Lewis acid, we evaluated ceric ammonium nitrate 
(CAN) and cerium trichloride heptahydrate,15 which were both found to be effective 
catalysts in the same solvent mixture either at room temperature or at the reflux 
temperature. 
In both cases we obtained good results. As a matter of fact, the benzylic azide 23b was 
formed exclusively and isolated in high yield. A slightly lower yield of 24b was obtained using 
sodium azide (2 equivalents) and aluminum trichloride16 (10 mol%) in 1:1 EtOH-H2O after 24 h 
at 25 °C. On the other hand, trimethylsilyl azide,17 when used in aprotic solvents (THF, 
CH2Cl2), gave a mixture of the azides 23b (prevalent) and 24b. The reaction rate increased in 
the presence of tetrabutylammonium fluoride;17c,d in this case, the amount of the benzylic 
amine 24b was also increased, such that this compound could be isolated by column 
chromatography. 
 
 
 
 
 
 
 
-88- 
 Table 1 
Reagent 
(eq.) 
Additive 
(mol %) 
Solvent, T, t Ratio 23/24[a] 
23,yield 
(%)[b] 
24,yield 
(%)[b] 
H2O p-TsOH (20) 
CH3CN-H2O (9:1), 
reflux, 6 h 82:18 23a, 77 24a, 14 
H2O CeCl3·7H2O (30) 
CH3CN-H2O (9:1), 
reflux, 8 h 86:14 23a, 71 24a, 8 
NaN3 (1.5) - 
CH3CN-H2O (9:1), 
reflux, 6 h - - - 
NaN3 (1.1) CAN (10) 
CH3CN-H2O (9:1), 
25 °C, 24 h 100:0 23b, 91 - 
NaN3 (1.1) CAN (10) 
CH3CN-H2O (9:1), 
reflux, 5 h 100:0 23b, 94 - 
NaN3 (1.1) CeCl3·7H2O (10) 
CH3CN-H2O (9:1), 
25 °C, 18 h 100:0 23b, 92 - 
NaN3 (1.1) CeCl3·7H2O (10) 
CH3CN-H2O (9:1), 
reflux, 4 h 100:0 23b, 91 - 
NaN3 (2) AlCl3 (10) 
EtOH-H2O (1:1), 25 
°C, 24 h 100:0 23b, 62 - 
TMSN3 (2) - CH3CN , 25 °C, 20 h 91:9 23b, 87 24b[c] 
TMSN3 (2) - CH2Cl2 , 25 °C, 48 h 80:20 23b, 73 24b, 16 
TMSN3 (2) n-Bu4NF (20) THF, 25 °C, 20 h 65:35 23b, 58 24b, 31 
[a] Determined by 1HNMR analysis of the crude product. [b] Yield of product isolated by column chromatography 
(SiO2). [c] The product was not isolated. 
 
The reactions with the primary amines benzylamine and p-anisidine in different 
conditions always gave mixtures of the isomeric products 23c,d and 24c,d. The best ratio in 
favour of 23c (75:25) and 24d (71:29) was obtained in the presence of the hydrated ceric 
salt in acetonitrile-water. In comparison the use of anhydrous zinc triflate18 or lithium 
perchlorate18,19 in acetonitrile led to lower selectivities. Moreover, no reaction was observed 
with benzylamine and zinc triflate in dichloromethane. All the four compounds 23c,d and 
24c,d could be isolated, preferably from the properly enriched reaction mixtures. Similarly, 
the reaction with dibenzylamine in the optimal reaction coditions gave the two products 23e 
and 24e in almost 1:1 ratio, and they were separated chromatographically with some 
difficulty. 
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 Table 2 
Reagent (eq.) 
Additive 
(mol %) 
Solvent, T, t Ratio 23/24[a] 
23,yield 
(%)[b] 
24,yield 
(%)[b] 
PhCH2NH2 (2) 
CeCl3·7H2O 
(50) 
CH3CN-H2O (9:1), 
reflux, 6 h 75:25 2c, 67  24c
c 
PhCH2NH2 (2) 
Zn(OTf)2 
(10) CH3CN, reflux, 8 h 51:49 23c, 38 24c, 40 
PhCH2NH2 (2) 
Zn(OTf)2 
(10) CH2Cl2, reflux, 6 h - -  - 
PhCH2NH2 (2) LiClO4 (10) CH3CN, reflux, 8 h 40:60 23c[c]  24c[c] 
4-CH3OC6H4NH2 
(1.2) LiClO4 (10) CH3CN, reflux, 24 h 69 :31
[d] 23d, 62 24d, 27 
4-CH3OC6H4NH2 
(1.2) 
CeCl3·7H2O 
(50) CH3CN, reflux, 24 h 71 :29
 23d, 51 24d , 24 
(PhCH2)2NH (2) 
CeCl3·7H2O 
(50) 
CH3CN-H2O (9:1), 
reflux, 5 h 53:47 23e, 48 24e, 41 
2-NaphthylSH 
(1.1) 
CeCl3·7H2O 
(30) 
CH3CN-H2O (9:1), 
reflux, 2 h 100:0 23f, 92 - 
2-NaphthylSH (3) - CH3CN-H2O (9:1), reflux, 5 h 75:25 23f, 57 24f, 18 
2-NaphthylSH (3) - CH2Cl2, 25 °C, 24 h 70:30 23f, 54 24f, 19 
PhSH (1.1) CeCl3·7H2O (30) 
CH3CN-H2O (9:1), 
reflux, 4 h 96:4 23g, 84 24g, 3 
PhSH (3) - CH2Cl2, 25°C, 2 h 50:50 23g, 42 24g, 45 
PhCH2SH (1.1) 
CeCl3·7H2O 
(30) 
CH3CN-H2O (9:1), 
reflux, 2 h 70:30 23h, 65 24h, 23 
n-BuSH (1.1) CeCl3·7H2O (30) 
CH3CN-H2O (9:1), 
reflux, 4 h -
[e] 23i, 57; 23a, 12 - 
t-BuSH (1.1) CeCl3·7H2O (30) 
CH3CN-H2O (9:1), 
reflux, 4 h 81:19 23a, 62 24a, 9 
t-BuSH (1.1) p-TsOH (50) CH3CN-H2O (9:1), reflux, 4 h 85:15 23a, 79 24a,
 11 
[a] Determined by 1HNMR analysis of the crude product. [b] Yield of product isolated by column chromatography 
(SiO2). [c] The product was not isolated. [d] The reaction was incomplete (about 60% conversion of 1c). [e] A complex 
mixture of products was observed, only 23i and 23a were isolated by column chromatography (SiO2).  
 
The positive effect of both the protic solvent and the cerium salt was particularly 
evident in the reactions of the aziridine 22 with aromatic thiols. In the case of 2-
naphthalenethiol (1.1 equiv.), the benzylic sulfide 23f was obtained exclusively with high yield 
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 after heating in the presence of the hydrated ceric salt in 9:1 acetonitrile-H2O at the reflux 
temperature for 2 h.20 On the other hand, lower reaction rates and mixtures of 23f and 24f 
were observed in the absence of the catalyst in the same solvent mixture and in 
dichloromethane.21 Similar results were obtained in the case of thiophenol, whereas the 
reaction with benzylthiol gave a mixture of the products 23h and 24h (70:30) in the 
optimized conditions. The reaction with n-butylthiol was even less satisfactory, as it afforded 
a mixture, from which only the prevalent sulfide 23i and the alcohol 24a were isolated by 
column chromatography. Finally, t-butylthiol was ineffective, as we only obtained the alcohols 
23a and 24a, coming from the competitive ring opening by water. 
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Scheme 12 
A few of the compounds 23 and 24 were subjected to routine oxidative cleavage of 
the N-substituent to obtain the corresponding homobenzylic and benzylic amines, which were 
immediately converted to the benzamides 25 and 26 with good overall yields (Scheme 12). 
Moreover, the azide 23b was converted to the 1-(2-pyridyl)-1,2-diamine 27 by the three-step 
sequence described in Scheme 13, avoiding purification of the intermediates. In particular, 
after the usual oxidative cleavage of the N-substituent, we tried the reduction of  the azide 
group with lithium aluminum hydride at 0 °C, but a complex mixture of products was obtained. 
Alternatively, the β-azido amine was treated with triphenylphosphine, then hydrolysis of the 
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 intermediate ylide gave the primary diamine 27. It should be observed that the analogous 
process carried out on the isomeric azide-amine 24b would give the enantiomer of the amine 
27. 
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Scheme 13 
 
Other methodologies to achieve ring opening reactions of the aziridine ring in the 
aziridine-alcohol 22 were then studied (Scheme 14). The secondary amine 28 was obtained by 
hydrogenolysis of the more substituted C-N bond of the aziridine-alcohol 22 in the presence 
of Pd(OH)2/C. Surprisingly, treatment of 22 with an excess of hydroiodic acid gave the same 
amine 28. A literature survey showed that hydroiodic acid displays reducing properties 
towards many organic compounds.22 In particular, reductions of α-halo ketones by iodide ion 
and hydroiodic acid have been reported.23 Based on these reports, we propose that ring-
opening occurs first to give the iodide 29, which is then reduced by iodide attack (Scheme 
15). 
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Scheme 14 
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 The reactions of aziridine-alcohol 22 with an excess of both carbonyldiimidazole 
(CDI) and reactive alkyl halides were then carried out, as these reactions were expected to 
give halogenated products coming from the ring opening of the aziridine by halide ion.24 
Presumably, the halide ion is generated by N-alkylation of one imidazole ring of CDI or a 
reaction intermediate.25 However, when methyl iodide was used the only product observed 
was the imidazolidinone 30, which was also prepared by reaction of the amino alcohol 28 with 
CDI. In order to account for this result, the iodide 31 is proposed as an intermediate in the 
formation of 30 from 22. 
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Scheme 15 
The bromide 32 was obtained by reaction of 22 with CDI and an excess of allyl 
bromide in acetonitrile at room temperature (Scheme 16). The diastereomeric bromide was 
detected in 10% in the crude reaction mixture. It showed the 1H NMR absorption of the 
CHBr proton at lower field with respect to the major diastereomer, and its amount increased 
to 33% when the reaction was carried out at reflux temperature. Interestingly, analogous 
reactions of 2-(2-hydroxyalkyl)aziridines described in the literature gave compounds coming 
from attack of halide ions to the unsubstituted aziridine carbon.24 The bromine in 32 could be 
easily substituted by reaction with sodium azide in refluxing DMF to give the azido-
oxazolidinone 33 as a single stereoiosomer. The complete or very high stereoselectivity 
observed in the described transformations of both the aziridine 22 and the bromide 32 
involving cleavage of the benzylic C-N and C-Br bonds, respectively, points to an SN2 
mechanism operating with inversion of configuration. 
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Scheme 16 
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 Finally, reaction of 22 with two equivalents of acetyl chloride gave the polyfunctional 
compound 34 by N,O-diacetylation and concomitant aziridine ring-opening by chloride ion 
(Scheme 17). 
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Scheme 17 
In conclusion, the ring-opening reaction of the 2-(2-pyridyl)aziridine 22 with hetero-
nucleophiles in optimized experimental conditions, i.e. in acetonitrile-water mixture as the 
solvent, and in the presence of a catalytic amount of ceric trichloride heptahydrate, proved 
to be a useful route to a variety of laterally di-functionalized pyridines. 
3.3 – Experimental section 
3.3.1 – General protocol for ring opening reaction of 22 
CeCl3.7H2O-catalyzed hydrolytic ring-opening of aziridine 22. Preparation of pyridine-
amine-diols 23a and 24a. CeCl3.7H2O (0.054 g, 0.15 mmol) was added to the solution of the 
aziridine 22 (0.100 g, 0.48 mmol) in 1:1 CH3CN-H2O mixture (20 mL). The mixture was stirred 
at the reflux temperature for 8 h: T.L.C. analysis showed that the starting material was 
totally consumed and two products were formed. Saturated aqueous solution of NaHCO3 (10 
mL) was added and the organic materials were extracted with Et2O (3 x 20 mL). The 
collected ethereal layers were dried over Na2SO4 and concentrated to leave a brown oily 
residue which was subjected to chromatography eluting with EtOAc/MeOH/30% NH4OH 
(98:2:1) mixture. 
CeCl3.7H2O-Catalyzed ring-opening of the aziridine 1 by hetero-nucleophiles. 
Preparation of laterally poly-functionalized pyridines 23b-i and 24b-d,f-h. Typical 
procedure: Sodium azide (0.034 g, 0.52 mmol) and CeCl3.7H2O (0.090 g, 0.24 mmol) were 
added to the solution of the aziridine 22 (0.100 g, 0.48 mmol) in a 9:1 CH3CN-H2O mixture 
(20 mL). The mixture was stirred at the reflux temperature for 2 h: T.L.C. analysis showed 
that the starting material was totally consumed. The organic materials were extracted with 
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 EtOAc (3 × 20 mL). The collected ethereal layers were dried over Na2SO4 and concentrated 
to leave 23a as a yellowish oil: Pure 23b (0.109 g, 71%) was obtained by column 
chromatography on a short SiO2 column eluting with cyclohexane/EtOAc mixture. 
 
N
H
N
OH
OH  
(S)-2-[(R)-2-Hydroxy-2-(2-pyridyl)ethylamino]-3-methyl-1-butanol (23a): Yellow oil; 
[α]D20 +24.2 (c 1.3, CHCl3). IR (neat): v = 3406, 2962, 2925, 1658, 1597, 1413, 1260, 1049, 
794, 751. 13H NMR (300 MHz, CDCl3): δ = 8.55 (ddd, J = 0.7, J = 1.3, J = 4.7, 1 H), 7.72 (dt, J 
= 1.7, J = 7.6, 1 H), 7.38 (dt, J = 0.9, J = 7.9, 1 H), 7.23 (ddd, J = 0.7, J = 4.7, J = 7.6, 1 H), 
4.86 (dd, J = 3.6, J = 7.5, 1 H), 3.65 (dd, J = 4.1, J = 10.8, 1 H), 3.38 (dd, J = 7.7, J = 10.8, 1 
H), 3.06 (dd, J = 3.6, J = 12.0, 1 H), 2.97 (bs, 3 H), 2.90 (dd, J = 7.5, J = 12.0, 1 H), 2.43 (ddd, 
J = 4.1, J = 6.7, J = 7.7, 1 H), 1.81 (sept, J = 6.9, 1 H), 0.97 (d, J = 6.8, 3 H), 0.90 (d, J = 6.8, 6 
H). 13C NMR (75 MHz, CDCl3): δ = 160.3, 148.3, 136.9, 122.6, 120.6, 72.3, 64.8, 61.0, 54.0, 29.1, 
19.5, 18.5. GC-MS m/z 207 (2), 193 (26), 181(8), 175 (10), 121(44), 116 (60), 109 (100), 108 
(24), 94 (25), 79 (19), 69 (11); MS (ES) m/z 225.4 (M + H)+. Anal. Calcd for C12H20N2O2: C, 
64.26; H, 8.99; N, 12.49. Found C, 64.06; H, 9.01; N, 12.44. 
 
N
H
N
N3
OH  
(S)-2-[(R)-2-Azido-2-(2-pyridyl)ethylamino)-3-methyl-1-butanol (23b): Red oil; [α]D20 
+76.8 (c 1.7, CHCl3). IR (neat): v = 3380, 2956, 2922, 2102, 1592, 1472, 1436, 1155, 1117. 1H 
NMR (300 MHz, CDCl3): δ = 8.61 (ddd, J = 0.9, J = 1.8, J = 4.7, 1 H), 7.74 (dt, J = 1.8, J = 7.7, 1 
H), 7.38 (dt, J = 0.9, J = 7.7, 1 H), 7.26 (ddd, J = 1.1, J = 4.7, J = 7.5, 1 H), 4.64 (dd, J = 5.0, J 
= 7.6, 1 H), 3.59 (dd, J = 4.1, J = 10.8, 1 H), 3.31 (dd, J = 7.7, J = 10.8, 1 H), 3.30 (dd, J = 5.0, 
J = 12.5, 1 H), 3.19 (dd, J = 7.6, J = 12.5, 1 H), 2.39 (dd, J = 4.1, J = 7.7, 1 H), 2.14 (bs, 2 H) 
1.77 (sept, J = 6.9, 1 H), 0.94 (d, J = 6.9, 3 H), 0.88 (d, J = 6.9, 3 H). 13C NMR (75 MHz, 
CDCl3): δ = 157.5, 149.6, 137.0, 123.2, 121.9, 66.7, 64.8, 61.0, 51.1, 29.2, 19.4, 18.4. MS (ES) 
m/z 250.2 (M + H)+, 272.1 (M + Na)+. Anal. Calcd for C12H19N5O: C, 57.81; H, 7.68; N, 28.09; O, 
6.42. Found C, 57.55; H, 7.70; 27.99. 
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(S)-2-[(R)-2-(Benzylamino)-2-(2-pyridyl)ethylamino]-3-methy-1-lbutanol (23c): Yellow 
oil; [α]D20 +30.8 (c 1.7, CHCl3); IR (neat): v = 3308, 3061, 3028, 2956, 2921, 2864, 1591, 1570, 
1454, 1434, 1366, 1121, 1048, 749, 699. 1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 0.8, J = 
1.8, J = 4.8, 1 H), 7.63 (td, J = 1.8, J = 7.7, 1 H), 7.35 (m, 5 H), 7.28 (m, 1 H), 7.23 (ddd, J = 
1.2, J = 4.8, J = 7.5, 1 H), 3.87 (dd, J = 5.9, J = 7.2, 1 H), 3.72 (d,  J = 12.9, 1H), 3.61 (d,  J = 
12.9, 1 H), 3.59 (dd, J = 4.0, J = 10.7, 1 H), 3.35 (dd, J = 7.8, J = 10.7, 1 H), 2.91 (m, 2 H), 2.53 
(bs, 3 H), 2.39 (dd, J = 4.0, J = 7.8, 1 H), 1.78 (sept, J = 6.8, 1 H), 0.86 (d, J = 6.8, 3 H), 0.88 
(d, J = 6.8, 3 H). 13C NMR (75 MHz, CDCl3): δ = 161.7, 149.5, 140.1, 136.4, 128.3, 128.2, 126.9, 
122.7, 122.3, 64.6, 63.2, 52.8, 51.6, 29.4, 19.5, 18.7. MS (ES) m/z 314.3 (M + H)+. Anal. Calcd 
for C19H27N3O: C, 72.81; H, 8.68; N, 13.41. Found C, 72.88; H, 8.71; N, 13.37. 
 
N
H
N
NH
OH
MeO
 
(S)-2-[(R)-2-(4-Methoxyphenylamino)-2-(2-pyridyl)ethylamino]-3-methyl-1-butanol 
(23d): Red oil; [α]D20 +21.1 (c 1.3, CHCl3). IR (neat): v = 3333, 2957, 2928, 2872, 2828, 1592, 
1512, 1465, 1435, 1239, 1039. 13H NMR (300 MHz, CDCl3): δ = 8.58 (ddd, J = 0.8, J = 1.7, J = 
4.8, 1 H), 7.63 (dt, J = 1.7, J = 7.6, 1 H), 7.36 (dt, J = 0.8, J = 7.8, 1 H), 7.18 (ddd, J = 1.2, J = 
4.8, J = 7.6, 1 H), 6.72 (d, J = 9.1, 2 H), 6.60 (d, J = 9.1, 2 H), 4.54 (dd, J = 4.8, J = 7.1, 1 H), 
3.78 (s, 3 H), 3.62 (dd, J = 4.1, J = 10.8, 1 H), 3.38 (dd, J = 7.5, J = 10.8, 1 H), 3.13 (dd, J = 
4.8, J = 11.9, 1 H), 3.05 (dd, J = 7.1, J = 11.9, 1 H), 2.73 (bs, 2 H), 2.43 (ddd, J = 4.1, J = 6.5, J 
= 7.5, 1 H), 1.81 (sept, J = 6.8, 1 H), 0.93 (d, J = 6.8, 3 H), 0.87 (d, J = 6.8, 6 H). 13C NMR (75 
MHz, CDCl3): δ = 161.2, 152.4, 149.3, 141.4, 136.8, 122.4, 121.8, 115.5, 114.7, 64.8, 60.9, 60.3, 
55.6, 52.4, 28.9, 19.4, 18.4; MS (ES) m/z 330.2 (M + H)+. Anal. Calcd for C19H27N3O2: C, 69.27; 
H, 8.26; N, 12.76. Found C, 69.52; H, 8.30; N, 12.71. 
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(S)-2-((R)-2-(dibenzylamino)-2-(pyridin-2-yl)ethylamino)-3-methylbutan-1-ol (23e): Red 
oil; [α]D20 +24.3 (c 1.4, CHCl3). IR (neat): v = 3357, 3061,3028, 2959, 2925, 1589, 1453, 1434, 
1261, 1072, 1027, 698. 1H NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 0.8, J = 1.7, J = 4.9, 1 H), 
7.71 (td, J = 1.9, J = 7.6, 1 H), 7.36 (m, 9H), 7.23 (m, 3H), 3.96 (dd, J = 6.7, J = 6.9, 1 H), 3.84 
(d, J = 13.8 2H), 3.64 (dd, J = 4.1, J = 10.8, 1 H), 3.42 (d, J = 13.8 2 H), 3.37 (m, 2 H), 3.20 
(dd, J = 7.4, J = 11.6, 1 H), 2.38 (dd, J = 4.1, J = 6.9, 1 H), 1.76 (sept, J = 6.8, 1 H), 0.95 (d, J = 
6.8, 3 H), 0.89 (d, J = 6.8, 6 H). 13C NMR (75 MHz, CDCl3) δ= 159.4, 148.8, 139.8, 136.1, 128.7, 
128.3, 127.0, 124.5, 122.2, 64.5, 62.2, 60.9, 54.3, 45.5, 29.5, 19.6, 18.9. MS (ES) m/z 404.5 
(M+H)+. Anal. Calcd for C26H33N3O: C, 77.38; H, 8.24; N, 10.41. Found C, 77.10; H, 8.27; N, 
10.37. 
N
H
N
S
OH  
(S)-2-[(R)-2-(2-Naphthylthio)-2-(2-pyridyl)ethylamino]-3-methyl-1-butanol (23f): 
Yellowish oil; [α]D20 +51.8 (c 1.7, CHCl3). IR (neat): v = 3412, 3330, 3055, 3009, 2954, 1584, 
1565, 1474, 1432, 1105, 1044, 748, 692. 1H NMR (300 MHz, CDCl3): δ = 8.56 (ddd, J = 0.9, J = 
1.9, J = 4.8, 1 H), 7.71 (m, 2 H), 7.69 (m, 2 H), 7.59 (dt, J = 1.8, J = 7.7, 1 H), 7.46 (m, 2 H), 
7.39 (dd, J = 1.8, J = 8.5, 1 H),  7.28 (dt, J = 0.9, J = 7.8, 1 H), 7.16 (ddd, J = 1.1, J = 4.9, J = 
7.8, 1 H), 4.61 (dd, J = 6.4, J = 6.6, 1 H), 3.60 (dd, J = 4.1, J = 10.8, 1 H), 3.40 (dd, J = 6.4, J = 
12.3, 1 H), 3.33 (dd, J = 7.4, J = 10.8, 1 H), 3.29 (dd, J = 6.4, J = 12.2, 1 H), 2.65 (bs, 2 H), 
2.42 (ddd, J = 4.1, J = 6.4, J = 7.4, 1 H), 1.78 (sept, J = 6.8, 1 H), 0.93 (d, J = 6.8, 3 H), 0.88 
(d, J = 6.8, 3 H). 13C NMR (75 MHz, CDCl3): δ = 159.8, 149.4, 136.6, 133.5, 132.3, 131.4, 130.9, 
129.4, 128.4, 127.6, 127.4, 126.5, 126.2, 123.1, 122.4, 64.7, 60.8, 54.8, 50.5, 29.2, 19.6, 18.6. 
MS (ES) m/z 367.3 (M + H)+, 389.1 (M + Na)+. Anal. Calcd for C22H26N2OS: C, 72.09; H, 7.15; 
N, 7.64. Found C, 71.83; H, 7.16; N, 7.62. 
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S
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(S)-2-[(R)-2-(Phenylthio)-2-(2-pyridyl)ethylamino]-3-methyl-1-butanol (23g): Yellow oil; 
[α]D20 +87.7 (c 1.2, CHCl3). IR (neat): v = 3419, 3332, 3056, 3006, 2957, 2925, 2871, 1589, 
1569, 1471, 1434, 1385, 1109, 1049, 1025, 747, 691. 1H NMR (300 MHz, CDCl3): δ = 8.57 (ddd, 
J = 0.9, J = 1.8, J = 4.8, 1 H), 7.74 (dt, J = 1.8, J = 7.7, 1 H), 7.33 (m, 3 H), 7.25 (m, 3 H), 7.17 
(ddd, J = 0.9, J = 4.8, J = 7.4, 1 H),  4.47 (dd, J = 6.7, J = 6.9, 1 H), 3.60 (dd, J = 4.1, J = 10.7, 
1 H), 3.35 (dd, J = 6.7, J = 12.3, 1 H), 3.31 (dd, J = 7.6, J = 10.7, 1 H), 3.26 (dd, J = 6.9, J = 
12.3, 1 H), 2.48 (bs, 2 H), 2.31 (ddd, J = 4.1, J = 7.1, J = 7.6, 1 H), 1.77 (sept, J = 6.9, 1 H), 
0.93 (d, J = 6.8, 3 H), 0.89 (d, J = 6.8, 6 H). 13C NMR (75 MHz, CDCl3): δ = 159.9, 149.3, 136.5, 
134.1, 132.2, 128.8, 127.3, 123.0, 122.2, 64.5, 60.8, 55.2, 50.6, 29.2, 19.5, 18.6. MS (ES) m/z 
317.1 (M + H)+. Anal. Calcd for C17H23N2OS: C, 67.29; H, 7.64; N, 9.23. Found C, 67.01; H, 7.65; 
N, 9.21. 
N
H
N
S
OH
 
(S)-2-[(R)-2-(Benzylthio)-2-(2-pyridyl)ethylamino]-3-methyl-1-butanol (23h): Yellow oil; 
[α]D20 +143.0 (c 1.2, CHCl3). IR (neat): v = 3383, 3061, 3028, 2956, 2925, 1590, 1494, 1471, 
1453, 1434, 1049, 749, 702. 1H NMR (300 MHz, CDCl3): δ = 8.56 (ddd, J = 0.8, J = 1.6, J = 4.8, 
1 H), 7.74 (dt, J = 1.8, J = 7.8, 1 H), 7.29 (m, 5 H), 7.18 (m, 2 H), 3.97 (dd, J = 6.8, J = 6.8, 1 
H), 3.79 (d, J = 13.3, 1 H), 3.60 (d, J = 13.3, 1 H),  3.54 (dd, J = 4.1, J = 10.7, 1 H), 3.24 (dd, J 
= 7.6, J = 10.7, 1 H), 3.21 (dd, J = 6.7, J = 12.1, 1 H), 3.11 (dd, J = 7.0, J = 12.1, 1 H), 2.40 (bs, 2 
H), 2.31 (dd, J = 4.1, J = 7.6, 1 H), 1.71 (sept, J = 6.9, 1 H), 0.89 (d, J = 6.8 , 3 H), 0.84 (d, J = 
6.8, 6 H). 13C NMR (75 MHz, CDCl3): δ = 160.6, 149.3, 137.9, 136.7, 128.9, 128.5, 127.0, 122.9, 
122.2, 64.5, 60.8, 51.2, 50.6, 35.4, 29.2, 19.5, 18.6. GC-MS m/z 105 (100), 91 (93), 93 (70), 
104 (40), 78 (31), 65 (30), 226 (26), 124 (26), 194 (25), 226 (18), 207 (16), 51 (16), 136 (12). 
Anal. Calcd for C19H26N2OS: C, 69.05; H, 7.93; N, 8.48. Found C, 69.16; H, 7.95; N, 8.46. 
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(S)-2-[(R)-2-(Butylthio)-2-(2-pyridyl)ethylamino]-3-methyl-1-butanol (23i): Yellow oil; 
[α]D20 +36.8 (c 1.0, CHCl3). IR (neat): v = 3346, 2957, 2926, 2872, 1590, 1569, 1468, 1434, 
1049, 788, 748. 1H NMR (300 MHz, CDCl3): δ = 8.54 (ddd, J = 0.8, J = 1.8, J = 4.7, 1 H), 7.67 
(dt, J = 1.8, J = 7.7, 1 H), 7.39 (dt, J = 0.8, J = 7.7, 1 H),  7.17 (ddd, J = 1.0, J = 4.7, J = 7.7, 1 
H),  4.06 (dd, J = 7.1, J = 7.1, 1 H), 3.59 (dd, J = 4.2, J = 10.7, 1 H), 3.30 (dd, J = 7.5, J = 10.7, 
1 H), 3.24 (dd, J = 7.1, J = 12.1, 1 H), 3.16 (dd, J = 7.1, J = 12.1, 1 H), 2.60 (bs, 2 H), 2.43 (dd,  
J = 6.8, J = 7.2, 2 H), 2.39 (dd,  J = 4.2, J = 7.5, 1 H), 1.78 (sept, J = 6.9, 1 H), 1.47 (m, 2 H), 
1.31 (m, 2 H), 0.92 (d, J = 6.9, 3 H), 0.88 (d, J = 6.9, 3 H), 0.84 (t, J = 7.3, 3 H). 13C NMR (75 
MHz, CDCl3): δ = 160.9, 149.1, 136.7, 122.8, 122.1, 64.6, 60.8, 51.6, 50.6, 31.6, 30.4, 29.2, 21.9, 
19.5, 18.6, 13.6. MS (ES) m/z 297.2 (M + H)+. Anal. Calcd for C16H28N2OS: C, 64.82; H, 9.52; 
N, 9.45. Found C, 64.73; H, 9.52; N, 9.43. 
 
N
N
H OH
HO
 
(S)-2-[(R)-2-Hydroxy-1-(2-pyridyl)ethylamino]-3-methyl-1-butanol (24a): Yellow oil; 
[α]D20 +38.6 (c 1.2, CHCl3). IR (neat) v = 3330, 2957, 2921, 2873, 1670, 1595, 1571, 1468, 
1436, 1049, 774, 751. 1H NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 0.8, J = 1.6, J = 4.9, 1 H), 
7.75 (dt, J = 1.8, J = 7.7, 1 H), 7.34 (dt, J = 0.9, J = 7.7, 1 H), 7.28 (m, 1 H), 4.12 (dd, J = 4.2, 
J = 6.6, 1 H), 3.96 (dd, J = 4.2, J = 11.3, 1 H), 3.84 (dd, J = 6.6, J = 11.3, 1 H), 3.81 (dd, J = 3.7, 
J = 11.6, 1 H), 3.65 (dd, J = 6.1, J = 11.6, 1 H), 2.47 (dd, J = 3.7, J = 6.1, 1 H), 1.81 (sept, J = 
6.8, 1 H), 0.95 (d, J = 6.8, 3 H), 0.90 (d, J = 6.8, 6 H). 13C NMR (75 MHz, CDCl3) δ= 159.7, 
149.1, 137.1, 123.1, 122.7, 65.6, 64.1, 62.8, 61.1, 29.3, 19.3, 18.9. MS (ES) m/z 225.4 (M + H)+. 
Anal. Calcd for C12H20N2O2: C, 64.26; H, 8.99; N, 12.49. Found C, 64.10; H, 9.02; N, 12.45. 
N
N
H OH
N3
 
(S)-2-[(S)-2-Azido-1-(2-pyridyl)ethylamino]-3-methyl-1-butanol (24b): Yellow oil; [α]D20 
+52.8 (c 1.1, CHCl3). IR (neat): v = 3378, 2950, 2923, 2106, 1594, 1470, 1438, 1153, 1112. 1H 
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 NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 0.9, J = 1.7, J = 4.8, 1 H), 7.72 (dt, J = 1.8, J = 7.7, 
1 H), 7.30 (dt, J = 0.9, J = 7.7, 1 H), 7.26 (ddd, J = 0.9, J = 4.8, J = 7.7, 1 H), 3.98 (dd, J = 
6.5, J = 6.5, 1 H), 3.69 (dd, J = 3.9, J = 11.1, 1 H), 3.63 (dd, J = 6.5, J = 12.1, 1 H), 3.55 (dd, J = 
6.57.1, J = 12.1, 1 H), 3.50 (dd, J = 5.4, J = 11.1, 1 H), 2.54 (bs, 2 H), 2.31 (dd, J = 3.9, J = 5.4,1 
H), 1.69 (sept, J = 6.8, 1 H), 0.86 (d, J = 6.8, 3 H), 0.82 (d, J = 6.8, 3 H). 13C NMR (75 MHz, 
CDCl3): δ = 161.7, 149.7, 136.6, 122.9, 122.7, 63.2, 31.6, 30.9, 29.5, 19.4, 18.7. MS (ES) m/z 
250.2 (M + H)+. Anal. Calcd for C12H19N5O: C, 57.81; H, 7.68; N, 28.09; O, 6.42. Found C, 
57.58; H, 7.71; 28.00. 
N
N
H OH
H
N
 
(S)-2-[(S)-2-Benzylamino-1-(2-pyridyl)ethylamino]-3-methyl-1-butanol (24c): Yellow oil. 
[α]D20 +22.3 (c 1.7, CHCl3). IR (neat): v = 3308, 3062, 2955, 2915, 2866, 2850, 1590, 1454, 
1434, 1366, 1120, 749, 698. 1H NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 0.8, J = 1.6, J = 4.8, 
1 H), 7.68 (dt, J = 1.8, J = 7.6, 1 H), 7.32 (m, 5 H), 7.15 (m, 1 H), 7.18 (ddd, J = 0.8, J = 4.8, J = 
7.6, 1 H), 3.91 (dd, J = 4.6, J = 8.5, 1 H), 3.69 (d, J = 12.7, 1 H), 3.64 (dd, J = 4.6, J = 11.1, 1 
H), 3.63 (d, J = 12.7, 1 H), 3.42 (dd, J = 7.7, J = 11.1, 1 H), 3.03 (dd, J = 4.4, J = 12.0, 1 H), 
2.90 (dd, J = 8.6, J = 12.0, 1 H), 2.67 (bs, 3 H), 2.43 (dd, J = 4.6, J = 7.7, 1 H), 1.82 (sept, J = 
6.9, 1 H), 0.97 (d, J = 6.9, 3 H), 0.91 (d, J = 6.9, 3 H). 13C NMR (75 MHz, CDCl3): δ = 161.9, 
149.2, 140.1, 136.4, 128.3, 128.2, 127.1, 127.1, 126.7, 122.7, 122.3, 64.7, 62.5, 61.7, 60.3, 54.5, 
53.6, 30.2, 19.3, 18.7. MS (ES) m/z 314.3 (M + H)+. Anal. Calcd for C19H27N3O: C, 72.81; H, 
8.68; N, 13.41. Found C, 73,15; H, 8.71; N, 13.38. 
 
N
N
H OH
H
NMeO
 
(S)-2-[(S)-2-(4-Methoxyphenylamino)-1-(2-pyridiyl)ethylamino]-3-methyl-1-butanol 
(24d): Yellow oil; [α]D20 −38.8 (c 1.0, CHCl3). IR (neat): v = 3372, 2956, 2922, 2104, 1598, 
1464, 1116. 1H NMR (300 MHz, CDCl3) δ= 8.61 (ddd, J = 0.9, J = 1.8, J = 4.8, 1 H), 7.66 (dt, J = 
1.8, J = 7.7, 1 H), 7.22 (m, 2 H), 6.78 (d, J = 9.0, 2 H), 6.62 (d, J = 9.0, 2 H),  4.02 (dd, J = 5.6, 
J = 7.3, 1 H), 3.75 (s, 3 H), 3.61 (dd, J = 3.9, J = 11.0, 1 H), 3.43 (dd, J = 5.4, J = 11.0, 1 H), 
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 3.40 (dd, J = 5.6, J = 12.5, 1 H), 3.29 (dd, J = 7.3, J = 12.5, 1 H), 2.69 (bs, 3 H), 2.26 (dd, J = 
3.9, J = 5.4,1H), 1.66 (sept, J = 6.8, 1 H), 0.84 (d, J = 6.9, 3 H), 0.80 (d, J = 6.9, 3 H). 13C NMR 
(75 MHz, CDCl3): δ= 161.4, 152.3, 149.6, 142.1, 136.5, 122.8, 122.5, 114.9, 114.7, 63.1, 61.1, 
60.4, 55.7, 50.9, 29.5, 19.4, 18.9. MS (ES) m/z = 330.2 (M + H)+. Anal. Calcd for C19H27N3O2: 
C, 69.27; H, 8.26; N, 12.76. Found C, 69.49; H, 8.29; N, 12.73. 
N
N
H OH
N
 
(S)-2-((S)-2-(dibenzylamino)-1-(pyridin-2-yl)ethylamino)-3-methylbutan-1-ol (24e): 
Yellow oil. [α]D20 −24.7 (c 1.7, CHCl3). IR (neat): v = 3320, 3085, 3062, 3027, 2959, 1593, 
1453, 1364, 1261, 1118, 1027, 780, 746, 698. 1H NMR (300 MHz, CDCl3): δ = 8.52 (ddd, J = 1.0, 
J = 1.8, J = 5.0, 1 H), 7.63 (dt, J = 1.9, J = 7.7, 1 H), 7.23 (td, J = 1.0, J = 7.7, 1 H), 7.18 (ddd, 
J = 1.0, J = 4.9, J = 7.5, 1 H), 3.93 (dd, J = 7.2, J = 7.2, 1 H), 3.73 (d, J = 13.5, 2 H), 3.66 (dd, 
J = 4.0, J = 10.9, 1 H), 3.58 (d, J = 13.5, 2 H), 3.45 (dd, J = 4.9, J = 11.0, 1 H), 2.73 (d, J = 7.0, 
2 H), 2.18 (dd, J = 4.0, J = 4.9, 1 H), 2.09 (bs, 2H), 1.61 (sept, J = 6.8, 1 H), 0.80 (d, J = 6.8, 3 
H), 0.77 (d, J = 6.8, 3 H). 13C NMR (75 MHz, CDCl3): δ = 162.9, 149.1, 138.9, 136.0, 128.0, 
128.9, 128.2, 127.0, 126.9, 122.0, 62.6, 60.8, 60.7, 60.1, 59.2, 29.7, 19.2, 19.0. MS (ES) m/z = 
404.3 (M + H)+. Anal. Calcd for C26H33N3O: C, 77.38; H, 8.24; N, 10.41. Found C, 77.10; H, 8.27; 
N, 10.37. 
 
N
N
H OH
S
 
(S)-2-[(R)-2-(2-Naphthylthio)-1-(2-pyridyl)ethylamino]-3-methyl-1-butanol (24f): 
Yellowish oil; [α]D20 +30.7 (c 1.2, CHCl3). IR (neat): v = 3421, 3342, 3052, 2951, 1581, 1463, 
1434, 1043, 1014, 742, 692. 1H NMR (300 MHz, CDCl3): δ = 8.56 (ddd, J = 1.2, J = 1.7, J = 4.7, 
1 H), 7.78 (m, 2 H), 7.74 (m, 2 H), 7.62 (dt, J = 1.8, J = 7.7, 1 H), 7.47 (m, 2 H), 7.39 (dd, J = 
1.8, J = 8.7, 1 H),  7.17 (m, 2 H), 3.96 (dd, J = 6.2, J = 6.4, 1 H), 3.61 (dd, J = 3.8, J = 11.1, 1 H), 
3.45 (dd, J = 5.0, J = 11.1, 1 H), 3.43 (dd, J = 6.4, J = 13.2, 1 H), 3.37 (dd, J = 6.2, J = 13.2, 1 
H), 2.81 (bs, 2 H), 2.42 (ddd, J = 3.8, J = 4.8, J = 5.0, 1 H), 1.62 (sept, J = 6.9, 1 H), 0.76 (d, J 
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 = 6.9, 3 H), 0.79 (d, J = 6.9, 3 H). 13C NMR (75 MHz, CDCl3): δ = 160.1, 149.7, 136.4, 133.7, 
133.4, 131.7, 128.5, 127.7, 127.4, 127.1, 127.0, 126.5, 125.7, 122.9, 122.8, 63.3, 61.1, 60.4, 40.4, 
29.3, 19.4, 18.7. GC-MS (EI) m/z 262 (100), 230 (55), 263 (51), 115 (46), 78 (27), 104 (15), 
264 (12). MS (ES) m/z 367.3 (M + H)+, 389.0 (M + Na)+. Anal. Calcd for C22H26N2OS: C, 72.09; 
H, 7.15; N, 7.64. Found C, 72.15; H, 7.17; N, 7.61. 
 
N
N
H OH
S
 
(S)-2-[(R)-2-Phenylthio-1-(2-pyridyl)ethylamino]-3-methyl-1-butanol (24g): Yellow oil; 
[α]D20 +11.4 (c 0.9, CHCl3). IR (neat): v = 3424, 3345, 3057, 2959, 2925, 2972, 1643, 1589, 
1467, 1436, 1258, 1042, 1013, 743, 690. 1H NMR (300 MHz, CDCl3): δ = 8.61 (dt, J = 1.6, J = 
4.4, 1 H), 7.66 (dt, J = 1.8, J = 7.8, 1 H), 7.38 (m, 1 H), 7.31 (m, 2 H), 7.21 (m, 2 H), 3.92 (dd, J 
= 6.3, J = 7.2, 1 H), 3.62 (dd, J = 3.8, J = 11.1, 1 H), 3.46 (dd, J = 5.0, J = 11.1, 1 H), 3.35 (dd, J 
= 7.2, J = 13.2, 1 H), 3.29 (dd, J = 6.3, J = 13.2, 1 H), 2.55 (bs, 2 H), 2.21 (ddd, J = 3.8, J = 5.0, 
J = 6.4, 1 H), 1.63 (sept, J = 6.9, 1 H), 0.82 (d, J = 6.9, 3 H), 0.78 (d, J = 6.9, 6 H). 13C NMR 
(75 MHz, CDCl3): δ = 161.3, 149.7, 136.3, 129.4, 128.9, 126.1, 122.7, 122.6, 63.0, 61.1, 60.6, 
41.1, 29.4, 19.4, 18.8. GC-MS m/z 193 (100), 107 (39), 214 (35), 106 (17), 175 (12), 92 (12), 119 
(11), 78 (10), 136 (9), 285 (3). Anal. Calcd for C17H23N2OS: C, 67.29; H, 7.64; N, 9.23. Found C, 
67.58; H, 7.67; N, 9.22. 
N
N
H OH
S
 
(S)-2-[(R)-2-Benzylthio-1-(2-pyridyl)ethylamino]-3-methyl-1-butanol (24h): Yellow oil; 
[α]D20 −23.4 (c 1.2, CHCl3). IR (neat): v = 3382, 3060, 3030, 2951, 2922, 1590, 1491, 1472, 
1044, 741, 702. 1H NMR (300 MHz, CDCl3): δ = 8.57 (ddd, J = 0.9, J = 1.7, J = 4.9, 1 H), 7.63 
(dt, J = 1.7, J = 7.6, 1 H), 7.32 (m, 5 H), 7.26 (ddd, J = 0.9, J = 4.9, J = 7.6, 1 H), 7.13 d, J = 
7.6, 1 H), 3.77 (dd, J = 6.3, J = 6.3, 1 H), 3.68 (s, 2 H), 3.61 (dd, J = 3.7, J = 11.1, 1 H), 3.46 
(dd, J = 5.1, J = 11.1, 1 H), 2.86 (dd, J = 6.3, J = 13.3, 1 H), 2.77 (dd, J = 6.3, J = 13.3, 1 H), 
2.36 (bs, 2 H), 2.39 (dd, J = 3.7, J = 5.1, 1 H), 1.62 (sept, J = 7.0, 1 H), 0.80 (d, J = 7.0, 3 H), 
0.77 (d, J = 7.0, 6 H). 13C NMR (75 MHz, CDCl3): δ = 159.7, 149.6, 138.3, 136.3, 128.9, 128.5, 
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 127.0, 122.4, 122.5, 63.0, 61.4, 60.6, 38.8, 37.1, 29.4, 19.4, 18.8. GC-MS m/z 91 (100), 193 
(92), 107 (31), 106 (31), 228 (16), 124 (14), 65 (14), 281 (12), 136 (12), 78 (12), 175 (11), 51 
(10), 299 (4), 207 (3). Anal. Calcd for C19H26N2OS: C, 69.05; H, 7.93; N, 8.48. Found C, 69.26; 
H, 7.96; N, 8.45. 
 
3.3.2 - Oxidative cleavage of the N-auxiliary. Preparation of the β-substituted primary 
amines and benzamides 25b,e,f,h,i and 26b,e,f,h. 
Typical procedure: To the valinol derivative 23b (0,240 g, 0.96 mmol) dissolved in MeOH (5 
mL) were added 40% MeNH2 in water (1.2 mL), then a solution of H5IO6 (0.768 g) in H2O (5 
mL) was added dropwise. After stirring for 2 h at room temperature, the reaction was 
complete, as determined by T.L.C. analysis. Most of the solvent was evaporated at reduced 
pressure, then the organic materials were extracted with Et2O (3 × 20 mL). The collected 
ethereal layers were dried over Na2SO4 and concentrated to leave the primary amine as a 
yellow oil. This was dissolved in acetone (5 mL), then Na2CO3 (0.200g), H2O (5 mL) and benzoyl 
chloride (167 μl, 1.44 mmol) were added while magnetically stirring. After stirring for 12 h, 
the organic materials were extracted with Et2O (3 x 20 mL). The collected ethereal layers 
were dried over Na2SO4 and concentrated to leave the benzamide 25b as a yellow oil. The 
product was subjected to column chromatography (SiO2) eluting with a 1:1 mixture 
cyclohexane-EtOAc to give pure 25b as a yellow oil: 0.205 g (81%). 
 
N
NH2
N3
 
(R)-2-azido-2-(2-pyridyl)ethanamine: Red oil; IR (neat): v = 3365, 2962, 2923, 2102, 1590, 
1571, 1472, 1436, 1260, 1094, 1020, 798. 1H NMR (300 MHz, CDCl3): δ = 8.60 (d, J = 4.7, 1 H), 
7.72 (dt, J = 1.6, J = 7.9, 1 H), 7.35 (d, J = 7.9, 1 H), 7.24 (ddd, J = 1.6, J = 4.7, J = 7.9, 1 H), 
4.55 (dd, J = 5.5, J = 13.3, 1 H), 3.18 (dd, J = 5.5, J = 13.3, 1 H), 3.06 (dd, J = 7.1, J = 13.3, 1 
H), 1.76 (bs, 2 H). 13C NMR (75 MHz, CDCl3): δ = 157.4, 149.6, 136.9, 123.0, 121.7, 69.0, 46.3. 
MS (ES) m/z 164.3 (M + H)+. 
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NH2
S
 
(R)-2-(2-Naphthylthio)-2-(2-pyridyl)ethanamine: Yellowish oil; 1H NMR (300 MHz, 
CDCl3): δ = 8.56 (ddd, J = 0.9, J = 1.8, J = 4.9, 1 H), 7.79 (m, 2 H), 7.71 (m, 2 H), 7.61 (td, J = 
1.9, J = 7.8, 1 H), 7.44 (m, 4 H), 7.32 (dt, J = 0.9, J = 7.7, 1 H), 7.14 (ddd, J = 1.1, J = 4.8, J = 
7.8, 1 H), 4.49 (dd, J = 6.1, J = 7.2, 1 H), 3.39 (dd, J = 7.2, J = 13.5, 1 H), 3.27 (dd, J = 6.1, J = 
13.5, 1 H). 13C NMR (75 MHz, CDCl3): δ = 159.5, 149.4, 136.5, 134.1, 130.5, 128.8, 127.5, 127.3, 
126.9, 126.6, 126.3, 126.0, 125.5, 122.9, 122.2, 57.7, 46.0. GC-MS (EI) m/z 262 (100), 230 
(49), 263 (44), 115 (42), 78 (31), 51 (14), 217 (11), 160 (8). 
 
N
NH2
S
 
(R)-2-(2-Phenylthio)-2-(2-pyridyl)ethanamine: Yellow oil; 1H NMR (300 MHz, CDCl3): δ = 
8.56 (ddd, J = 1.0, J = 1.8, J = 4.8, 1 H), 7.61 (dt, J = 1.8, J = 7.7, 1 H), 7.33 (m, 2 H), 7.29 (m, 
2 H), 7.19 (m, 2 H), 7.16 (m, 1 H), 4.33 (dd, J = 6.1, J = 7.2, 1 H), 3.31 (dd, J = 7.2, J = 13.4, 1 
H), 3.19 (dd, J = 6.1, J = 13.4, 1 H). 13C NMR (75 MHz, CDCl3): δ = 170.8, 159.6, 149.4, 136.5, 
134.1, 131.9, 128.8, 128.6, 124.6, 122.9, 122.2, 57.8, 46.0. GC-MS (EI) m/z 168 (100), 201 (99), 
124 (20), 65 (17), 78 (16), 94 (15), 212 (9), 109 (9), 186 (4). 
 
N
NH2
S
 
(R)-2-(Benzylthio)-2-(2-pyridyl)ethanamine: Yellow oil; 13H NMR (300 MHz, CDCl3): δ = 8.60 
(d, J = 4.4, 1 H), 7.68 (dt, J = 1.8, J = 7.6, 1 H), 7.30 (m, 7 H), 3.90 (dd, J = 6.3, J = 7.0, 1 H), 
3.72 (d, J = 13.2, 1 H), 3.64 (d, J = 13.2, 1 H), 3.25 (dd, J = 7.0, J = 13.4, 1 H), 3.16 (dd, J = 
6.3, J = 13.4, 1 H), 1.94 (bs, 2 H). 13C NMR (75 MHz, CDCl3): δ = 160.4, 149.3, 136.7, 130.3, 
128.9, 128.5, 127.0, 122.9, 122.1, 54.0, 45.8, 35.3. GC-MS m/z 124 (100), 91 (28), 215 (16), 122 
(14), 105 (11), 106 (10), 65 (10), 79 (9), 227 (2). 
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(R)-2-(2-Naphthylthio)-1-(2-pyridyl)ethanamine: Yellowish oil; 1H NMR (300 MHz, 
CDCl3): δ = 8.59 (m, 1 H), 7.80 (m, 2 H), 7.76 (dt, J = 1.8, J = 7.7, 1 H), 7.49 (m, 3 H), 7.33 (m, 
2 H), 7.18 (ddd, J = 0.7, J = 4.8, J = 7.7, 1 H), 4.23 (dd, J = 5.4, J = 8.2, 1 H), 3.57 (dd, J = 
5.4, J = 13.4, 1 H), 3.32 (dd, J = 8.2, J = 13.3, 1 H), 2.44 (bs, 2 H). 13C NMR (75 MHz, CDCl3): 
δ = 162.5, 149.7, 136.9, 133.9, 129.2, 128.8, 127.9, 127.8, 127.7, 127.4, 126.8, 126.7, 126.1, 
122.8, 121.9, 56.2, 42.7. 
 
N
NH2
S
 
(R)-2-Benzylthio-1-(2-pyridyl)ethanamine: Yellow oil; 1H NMR (300 MHz, CDCl3): δ = 8.57 
(m, 1 H), 7.67 (m, 1 H), 7.31 (m, 6 H), 7.21 (m, 1 H), 4.56 (dd, J = 6.8, J = 7.8, 1 H), 3.67 (s, 2 
H), 3.12 (dd, J = 6.8, J = 12.9, 1 H), 2.75 (dd, J = 6.8, J = 12.9, 1 H), 2.14 (bs, 2 H). 13C NMR 
(75 MHz, CDCl3): δ = 162.4, 149.4, 136.5, 135.7, 129.7, 129.4, 129.0, 126.2, 122.4, 121.6, 55.9, 
42.7. GC-MS (EI) m/z 107 (100), 80 (20), 213 (4), 136 (4), 230 (2), 183 (2). 
 
N
N3 H
N
O  
(R)-N-[2-Azido-2-(2-pyridyl)ethyl]benzamide (25b): Red oil; [α]D20 +55.5 (c 1.1, CHCl3). IR 
(neat): v = 3288, 3068, 2937, 2104, 1638, 1540, 1321, 772, 707. 1H NMR (300 MHz, 
CDCl3): δ = 8.64 (dt, J = 0.7, J = 4.8, 1 H), 8.11 (d, J = 6.9, 1 H), 7.77 (m, 2 H), 7.48 (m, 1 H), 
7.42 (m, 3 H), 7.31 (ddt, J = 0.8, J = 4.9, J = 7.6, 1 H), 7.16 (m, 1 H), 4.90 (t, J = 6.1, 1 H), 4.07 
(ddd, J = 6.1, J = 6.9, J = 12.4,  1 H), 3.87 (ddd, J = 6.1, J = 6.9, J = 12.4, 1 H). 13C NMR (75 
MHz, CDCl3): δ = 167.7, 149.4, 137.5, 134.1, 133.2, 131.6, 129.9, 128.5, 128.3, 126.9, 123.6, 
122.6, 64.1, 43.3. GC-MS (280 °C) m/z 105 (100), 218 (67), 77 (61), 262 (56), 263 (29), 115 
(26), 219 (24), 230 (23), 384 (13), 160 (12). MS (ES) m/z 268.2 (M + H)+, 290.1 (M + Na)+, 
557.2 (2 M + Na)+. Anal. Calcd for C14H13N5O: C, 62.91; H, 4.90; N, 26.20. Found C, 63.10; H, 
4.92; N, 26.12. 
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(R)-N-[2-(2-Naphthylthio)-2-(2-pyridyl)ethyl]benzamide (25f): White crystals. (from 
Et2O); m.p. = 122.0-122.5 °C; [α]D20 +58.7 (c 1.9, CHCl3). IR (KBr): v = 3326, 3046, 3003, 2926, 
1843, 1710, 1638, 1578, 1523, 1436, 1271, 822, 745, 701. 1H NMR (300 MHz, CDCl3): δ = 8.56 
(ddd, J = 0.7, J = 1.6, J = 4.9, 1 H), 7.93 (s, 1 H), 7.73 (m, 5 H), 7.58 (dt, J = 1.9, J = 7.8, 1 H),  
7.45 (m, 5 H), 7.32 (m, 3 H), 7.16 (ddd, J = 0.7, J = 4.9, J = 7.8, 1 H), 4.85 (t, J = 6.6, 1 H), 
4.21 (ddd, J = 6.1, J = 6.6, J = 13.5, 1 H), 4.15 (ddd, J = 6.1, J = 6.6, J = 13.5, 1 H). 13C NMR 
(75 MHz, CDCl3): δ = 167.4, 158.9, 149.0, 136.9, 133.5, 132.2, 131.2, 131.0, 129.2, 128.5, 128.3, 
127.5, 127.4, 126.8, 126.4, 126.2, 123.6, 122.5, 52.3, 43.2. GC-MS (EI) (280 °C) m/z 384 (4), 
263 (30), 230 (29), 211 (18), 160 (8), 136 (16), 115 (13), 105 (100), 77 (38). MS (ES) m/z = 
385.1 (M + H)+, 791.0 (2 M + Na)+. Anal. Calcd for C24H20N2OS: C, 74.97; H, 5.24; N, 7.29. 
Found C, 75.05; H, 5.26; N, 7.28. 
 
N
S H
N
O  
(R)-N-[2-Phenylthio-2-(2-pyridyl)ethyl]benzamide (25g): Red oil; [α]D20 +51.8 (c 2.0, 
CHCl3). IR (neat): v = 3323, 3058, 2925, 2853, 1644, 1579, 1537, 1484, 1436, 1292, 1075, 
749, 692.  1H NMR (300 MHz, CDCl3): δ = 8.61 (d, J = 4.6, 1 H), 7.74 (m, 2 H), 7.68 (td, J = 1.7, 
J = 7.7, 1 H),  7.49 (m, 2 H), 7.44 (m, 3 H), 7.32 (m, 2 H), 7.24 (m, 2 H), 4.72 (dd, J = 6.1, J = 
6.9, 1 H), 4.16 (m, 2 H). 13C NMR (75 MHz, CDCl3): δ = 167.4, 159.0, 149.1, 137.0, 134.4, 133.5, 
132.5, 131.4, 129.0, 128.5, 127.7, 126.9, 123.8, 122.4, 52.5, 43.0. GC-MS (EI) m/z 105 (100), 
77 (73), 168 (61), 213 (38), 201 (49), 334 (20), 180 (16), 225 (14), 119 (8). Anal. Calcd for 
C20H18N2OS: C, 71.83; H, 5.42; N, 8.38. Found C, 71.58; H, 5.43; N, 8.35. 
 
N
H
N
S
O  
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 (R)-N-[2-Benzylthio-2-(2-pyridyl)ethyl]benzamide (25h): Colourless oil; [α]D20 +26.1 (c 1.0, 
CHCl3). IR (neat): v = 3320, 3060, 2923, 1644, 1537, 1471, 1434, 1290, 697.  1H NMR (300 
MHz, CDCl3): δ = 8.59 (ddd, J = 1.0, J = 1.9, J = 4.9, 1 H), 7.76 (m, 2 H), 7.69 (dt, J = 1.9, J = 
7.8, 1 H), 7.47 (m, 5 H), 7.32 (m, 4 H), 7.25 (m, 1 H), 4.23 (dd, J = 6.7, J = 9.7, 1 H), 4.17 (ddd, 
J = 4.6, J = 6.7, J = 13.1, 1 H), 3.97 (ddd, J = 4.6, J = 9.7, J = 13.1, 1 H), 3.89 (d, J = 13.5, 1 H), 
3.75 (d, J = 13.5, 1 H). 13C NMR (75 MHz, CDCl3): δ = 167.4, 159.7, 148.6, 137.9, 137.3, 134.5, 
131.4, 129.0, 128.6, 128.5, 127.1, 127.0, 123.8, 122.5, 48.7, 42.4, 35.7. GC-MS (EI) m/z 105 
(100), 124 (76), 226 (74), 77 (49), 91 (45), 257 (41). Anal. Calcd for C21H20N2OS: C, 72.38; H, 
5.79; N, 8.04. Found C, 72.40; H, 5.80; N, 8.02. 
 
N
H
N
nBuS
O  
(R)-N-[(2-Butylthio-2-(2-pyridyl)ethyl]benzamide (25i): Yellow oil; [α]D20 +27.4 (c 1.0, 
CHCl3); 3314, 3057, 2913, 1647, 1534, 1477, 1297, 694. 1H NMR (300 MHz, CDCl3): δ = 8.58 
(ddd, J = 0.9, J = 1.7, J = 4.9, 1 H), 7.74 (m, 2 H), 7.71 (dt, J = 1.7, J = 7.4, 1 H), 7.47 (m, 1 H), 
7.42 (m, 2 H), 7.23 (ddd, J = 0.9, J = 4.7, J = 7.5, 1 H),  4.29 (dd, J = 5.8, J = 7.4, 1 H), 4.11 
(ddd, J = 6.2, J = 7.4, J = 13.6, 1 H), 4.01 (ddd, J = 5.8, J = 11.2, J = 13.6, 1 H), 2.57 (m, 2 H), 
1,54 (m, 2 H), 1,38 (m, 2 H), 0.87 (t, J = 7.3, 3 H). 13C NMR (75 MHz, CDCl3): δ = 167.4, 160.0, 
148.7, 137.4, 134.4, 133.3, 131.4, 130.1, 128.5, 128.4, 126.9, 123.7, 122.5, 49.2, 42.8, 31.6, 
30.9, 21.9, 13.6. MS (EI) m/z 314 (4), 257 (16), 181 (11), 160 (18), 124 (57), 105 (100), 93 (14), 
77 (55). MS (ES) m/z = 315.2 (M + H)+, 651.3 (2 M + Na)+. Anal. Calcd for C18H22N2OS: C, 
68.75; H, 7.05; N, 8.91. Found C, 68.38; H, 7.08; N, 8.89.  
 
N
N3
N
H
O
 
N-((S)-2-azido-1-(pyridin-2-yl)ethyl)benzamide (26b): Yellow oil; [α]D20 +13.4 (c 1.2, 
CHCl3); IR (neat): v = 3282, 3071, 2932, 2108, 1631, 1547, 1315, 778.  1H NMR (300 MHz, 
CDCl3): δ = 8.63 (ddd, J = 0.8, J = 1.6, J = 4.8, 1 H), 7.88 (m, 2 H), 7.75 (dd, J = 1.9, J = 7.7, 1 
H), 7.45 (m, 3 H), 7.38 (dt, J = 0.8, J = 1.6, 1 H), 7.30 (ddd, J = 1.9, J = 4.8, J = 7.4, 1 H), 5.46 
(ddd, J = 4.9, J = 5.7, J = 7.3, 1 H), 3.85 (dd, J = 4.9, J = 12.2,  1 H), 3.80 (dd, J = 5.7, J = 
12.2, 1 H). 13C NMR (75 MHz, CDCl3): δ = 167.0, 156.4, 149.3, 13.1, 134.0, 131.8, 128.6, 127.1, 
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 127.0, 123.2, 122.6, 55.0, 53.5. MS (ES) m/z = 268.2 (M + H)+. Anal. Calcd for C14H13N5O: C, 
62.91; H, 4.90; N, 26.20. Found C, 63.21; H, 4.92; N, 26.18. 
 
N
S
N
H
O
 
(R)-N-[2-Naphthylthio)-1-(2-pyridyl)ethyl]benzamide (26f): White crystals (from Et2O); 
m.p. = 119.5-120 °C. [α]D20 −22.7 (c 1.3, CHCl3). IR (Nujol): v = 3310, 1638, 1518, 1468, 1370, 
810, 729. 1H NMR (300 MHz, CDCl3): δ = 8.58 (ddd, J = 0.8, J = 1.6, J = 4.8, 1 H), 8.12 (d, J = 
7.0, 1 H); 7.81 (m, 2 H), 7.75 (m, 3 H), 7.63 (m, 2 H), 7.47 (m, 3 H), 7.38 (m, 2 H), 7.20 (m, 2 
H), 5.56 (dd, J = 5.2, J = 6.8, 1 H), 3.82 (dd, J = 5.2, J = 13.6, 1 H), 3.51 (dd, J = 7.8, J = 13.6, 
1 H). 13C NMR (75 MHz, CDCl3): δ = 166.8, 157.6, 149.0, 136.9, 133.7, 133.5, 131.5, 130.1, 128.5, 
128.4, 127.6, 127.2, 127.1, 126.5, 125.7, 123.4, 123.6, 123.1, 53.9, 38.5. MS (ES) m/z 385.1 (M 
+ H)+, 791.0 (2 M + Na)+. Anal. Calcd for C24H20N2OS: C, 74.97; H, 5.24; N, 7.29. Found C, 
75.10; H, 5.26; N, 7.27. 
N
S
N
H
O
 
 (R)-N-[2-Phenylthio-1-(pyridyl)ethyl]benzamide (26g): Red oil; [α]D20 −19.2 (c 0.4, CHCl3). 
IR (neat): v = 3321, 3054, 2927, 2852, 1642, 1572, 1533, 1482, 1431, 1290, 1078, 747, 691. 1H 
NMR (300 MHz, CDCl3): δ = 8.58 (ddd, J = 0.9, J = 1.7, J = 4.9, 1 H), 7.82 (m, 2 H), 7.68 (dt, J 
= 1.8, J = 7.8, 1 H), 7.49 (m, 3 H), 7.42 (m, 3 H), 7.33 (dt, J = 0.9, J = 7.8, 1 H), 7.27 (m, 2 H), 
7.15 (dt, J = 1.2, J = 6.5, 1 H), 5.48 (dd, J = 5.1, J = 7.2, J = 8.0, 1 H), 3.72 (dd, J = 5.1, J = 
13.6, 1 H), 3.44 (dd, J = 8.0, J = 13.6, 1 H). 13C NMR (75 MHz, CDCl3): δ = 166.7, 157.5, 137.1, 
134.1, 131.6, 129.2, 129.0, 128.5, 127.1, 126.1, 123.6, 123.1, 53.6, 38.7. GC-MS (EI) m/z 105 
(100), 77 (69), 213 (68), 136 (47), 211 (31), 212 (26), 180 (11), 281 (5), 334 (4). Anal. Calcd for 
C20183N2OS: C, 71.83; H, 5.42; N, 8.38. Found C, 71.98; H, 5.41; N, 8.36. 
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(R)-N-[2-(Benzylthio)-1-(2-pyridyl)ethyl]benzamide (26h): Colourless oil; [α]D20 −17.1 (c 
0.5, CHCl3). IR (neat): v = 3320, 3060, 2923, 1645, 1589, 1536, 1434, 1290, 696. 1H NMR (300 
MHz, CDCl3):  δ = 8.60 (ddd, J = 0.8, J = 1.7, J = 4.9, 1 H), 7.89 (m, 2 H), 7.48 (m, 2H), 7.39 (m, 
2 H), 7.29 (m, 7 H), 5.46 (dd, J = 5.9, J = 7.5,  1 H), 3.65 (s, 2 H), 3.14 (dd, J = 5.7, J = 13.5, 1 
H) 3.04 (ddd, J = 7.5, J = 13.6, 1 H). 13C NMR (75 MHz, CDCl3): δ = 168.5, 158.9, 147.8, 137.7, 
137.2, 134.7, 131.7, 129.0, 128.6, 127.3, 127.2, 123.6, 122.4, 53.1, 36.7, 29.7. GC-MS (EI) m/z 
105 (100), 257 (52), 77 (36), 91 (20), 136 (18), 211 (10), 258 (8). Anal. Calcd for C21H20N2OS: 
C, 72.38; H, 5.79; N, 8.04. Found C, 72.11; H, 5.80; N, 8.03. 
3.3.3 - Preparation of the diamine 27 
To the valinol derivative 25b (0,202 g, 0.81 mmol) dissolved in MeOH (5 mL) were added 40% 
MeNH2 in water (1.0 mL), then a solution of H5IO6 (0.648 g) in H2O (5 mL) was added 
dropwise. After stirring for 2 h at room temperature, the reaction was complete, as 
determined by T.L.C. analysis. Most of the solvent was evaporated at reduced pressure, then 
the organic materials were extracted with Et2O (3 × 20 mL). The collected ethereal layers 
were dried over Na2SO4 and concentrated to leave the primary amine as a yellow oil. This was 
dissolved in THF (5 mL) and was cooled to 0 °C and PPh3 (0.177 mg, 0.67 mmol) was added. 
Then 2h the solution was warm at room temperature ad water (2 mL) was added. After 16h 
NaHCO2 (sat. solution, 5mL) was added and the organic materials were extracted with CH2Cl2 
(3 x 20 mL) the collected organic layers were dried over Na2SO4 and concentrated to leave a 
red solid. Pure 27 (0.074 g, 67%) was obtained by column chromatography on a short neutral 
Al2O3 column eluting with EtOAc/MeOH (9/1) mixture. 
 
 
N
NH2
NH2
 
(R)-1-(2-Pyridyl)ethane-1,2-diamine (27): Yellow oil; [α]D20 −45.6 (c 0.7, CHCl3). IR (neat): 
v = 3361, 2968, 2922, 2101, 1476, 1435, 1092, 1016, 794. 1H NMR (300 MHz, CDCl3): δ = 8.54 
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 (ddd, J = 0.7, J = 1.7, J = 7.9, 1 H), 7.69 (dt, J = 1.7, J = 7.8, 1 H), 7.32 (d, J = 7.9, 1 H), 7.21 
(ddd, J = 0.9, J = 4.7, J = 7.9, 1 H), 3.99 (dd, J = 5.2, J = 7.0, 1 H), 3.08 (dd, J = 5.2, J = 12.7, 
1 H), 2.93 (dd, J = 7.0, J = 12.7, 1 H), 1.83 (bs, 4 H). 13C NMR (75 MHz, CDCl3): δ = 158.7, 
149.2, 137.0, 122.8, 121.7, 59.6, 54.8. MS (ES) m/z 138.2 (M + H)+. Anal. Calcd for C7H11N3: C, 
61.29; H, 8.08; N, 30.63. Found C, 60.99; H, 8.11; N, 30.50. 
3.3.4 - Reaction with H2-Pd(OH)2/C 
The mixture of the aziridine 22 (50 mg, 0.24 mmol) and 20% Pd(OH)2/C (5 mg) in 
MeOH-AcOH (85:15, 3 mL) was magnetically stirred under a H2 atmosphere for 3 h. The 
mixture was filtered through a pad of celite. 1 N NaOH was added until pH 11 was reached, 
then most of the MeOH was evaporated at reduced pressure and the organic phase was 
extracted with CH2Cl2 (3 x 5 mL). The combined organic layers was dried (Na2SO4) and 
concentrated to leave pure 33 as an oil: 0.45 g (91%). 
3.3.5 - Reaction with HI 
The aziridine 6 (0.100 g, 0.48 mmol) was dissolved in 47% HI (5 mL) and the solution 
was stirred for 12 h, then NaOH pellets were cautiously added until pH 11 was reached. The 
organic phase was extracted with Et2O (3 x 5 mL) and the combined ethereal layers were 
washed with aq Na2S2O3, then dried (Na2SO4) and concentrated to leave a residue consisting 
of a white solid and a yellow oil. Chromatography on a small SiO2 column eluting with 
cyclohexane-EtOAc (1:9), then with EtOAc-MeOH-Et3N (8:1:1) gave the compound 33: 62 mg 
(62%).  
 
N
H
N
OH
 
N-[2-(2-Pyridyl)]ethyl-(S)-valinol (28). This was obtained from the aziridine 22 by 
hydrogenation over Pd(OH)2/C (91% yield) and by reduction with HI (62% yield): [α]D20 +16.8 
(c 2.0, CHCl3); IR (neat): v = 3334, 2962, 2925, 2872, 1651, 1589, 1467, 1427, 1384, 1274, 
1070, 813, 716;  1H NMR (300 MHz, CDCl3): δ = 8.49 (ddd, J = 1.0 Hz, J = 1.8 Hz, J = 4.9 Hz, 1 
H), 7.59 (ddt, J = 1.3 Hz, J = 1.8 Hz, J = 7.7 Hz, 1 H), 7.59 (dd, J = 0.9 Hz, J = 7.8 Hz, 1 H), 
7.11 (ddd, J = 1.3 Hz, J = 4.9 Hz, J = 7.7 Hz, 1 H), 3.63 (dd, J = 4.1 Hz, J = 10.9 Hz, 1 H), 3.34 
(dd, J = 7.5 Hz, J = 10.9 Hz, 1 H), 2.90 (bs, 2 H, OH + NH), 3.15-2.92 (m, 4 H), 2.40 (dd, J = 
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 4.1 Hz, J = 10.9 Hz, 1 H), 1.76 (sept, J = 6.7 Hz, 1 H), 0.90 (d, J = 6.7 Hz, 3 H), 0.85 (d, J = 
6.7 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 160.1 (Py), 149.0, 136.5, 123.4, 121.3, 64.6, 60.8, 
46.5, 38.0, 29.1, 19.4, 18.5; MS (EI): m/z = 204 (6), 191 (8), 177 (46), 165 (21), 135 (11), 121 
(10), 106 (55), 94 (100), 84 (20), 78 (15). Anal. Calcd for C12H20N2O: C, 69.19; H, 9.68; N, 
13.45. Found C, 69.41; H, 9.83; N, 13.42. 
 
3.3.6 – Preparation of compound 30 
To a solution of 28 (50 mg, 0.24 mmol) in dry CH2Cl2 (10 mL) was added CDI (40 mg, 
0.24 mmol) in one portion. After stirring overnight, H2O (5 mL) was added. The organic phase 
was extracted with CH2Cl2 (3 x 10 mL), and the combined organic phases was dried (Na2SO4) 
and concentrated at reduced pressure. The red oily residue was subjected to chromatography 
on a SiO2 column, eluting with EtOAc then with a 90:10 EtOAc/MeOH mixture to give 30 as a 
red oil: 0.047 g (84%). 
N
N
OO
 
(S)-3-[2-(2-Pyridyl)ethyl]-1,3-oxazolidin-2-one (30): [α]D20 +29.0 (c 1.9, CHCl3); IR 
(neat): v = 2961, 2929, 2869, 1733, 1593, 1566, 1427, 1259, 1009, 759; 1H NMR (300 MHz, 
CDCl3): δ = 8.52 (d, J = 4.9 Hz, 1 H, PyH), 7.62 (td, J = 1.8 Hz, J = 7.7 Hz, 1 H), 7.23 (d, J = 
7.8 Hz, 1 H), 7.15 (dd, J = 4.9 Hz, J = 7.8 Hz, 1 H), 4.11 (dd, J = 8.8 Hz, J = 8.9 Hz, 1 H), 4.01 
(dd, J = 5.4 Hz, J = 8.9 Hz, 1 H), 3.87 (ddd, J = 6.9 Hz, J = 7.1 Hz, J = 14.4 Hz, 1 H), 3.61 
(ddd, J = 3.6 Hz, J = 5.4 Hz, J = 8.8 Hz, 1 H), 3.42 (ddd, J = 6.2 Hz, J = 7.9 Hz, J = 14.4 Hz, 1 
H), 3.07 (m, 2 H), 2.87 (dsept, J = 3.5 Hz, J = 6.8 Hz, 1 H), 0.83 (d, J = 7.0 Hz, 3 H), 0.84 (d, 
J = 7.0 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 158.5, 157.5, 149.3, 136.6, 136.6, 123.5, 121.7, 
62.7, 59.3, 41.5, 35.9, 27.4, 17.6, 14.1; MS (ES): m/z = 235.2 (M + H)+, 491.1 (2 M + Na)+. Anal. 
Calcd for C13H18N2O2: C, 66.64; H, 7.74; N, 11.96. Found C, 66.72; H, 7.77; N, 11.92. 
 
3.3.7 – Preparation of compound 32 
To the aziridine 22 (0.100 g, 0.48 mmol) dissolved in anhydrous MeCN (10 mL) were 
added, in order, CDI (0.080 g, 0.48 mmol) and allyl bromide (0.21 mL, 2.4 mmol). The mixture 
was stirred at room temperature for 2 h, then quenched with H2O (10 mL). The organic phase 
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 was extracted with Et2O (2 x 10 mL) and CH2Cl2 (2 x 10 mL). The combined organic phases 
was washed with saturated aq NaHCO3, then combined, dried (Na2SO4) and concentrated at 
reduced pressure. The oily residue was subjected to chromatography on a SiO2 column eluting 
with cyclohexane-EtOAc (1:1) to give 32 as a whitish solid: 0.108 g (72%). 
 
N
Br
N
OO
 
3-[2(R)-Bromo-2-(2-pyridyl)ethyl]-4(S)-isopropyl-1,3-oxazolidin-2-one (32): m.p. = 107-
108 °C; [α]D20 +41.5 (c 1.2, CHCl3); IR (KBr): v = 3050, 3013, 2953, 2874, 1728, 1588, 1487, 
1436, 1258, 1159, 1050, 932, 788, 751, 706, 597; 1H NMR (300 MHz, CDCl3):  δ =  8.57 (ddd, J 
= 0.9 Hz, J = 1.7 Hz, J = 4.8 Hz, 1 H), 7.59 (dt, J = 1.8 Hz, J = 7.7 Hz, 1 H), 7.38 (td, J = 0.9 
Hz, J = 7.8 Hz, 1 H), 7.22 (ddd, J = 1.0 Hz, J = 4.8 Hz, J = 7.7 Hz, 1 H), 5.21 (dd, J = 6.3 Hz, J 
= 9.0 Hz, 1 H), 4.12 (dd, J = 6.3 Hz, J = 14.2 Hz, 1 H), 3.89 (m, 3 H), 3.08 (ddd, J = 1.0 Hz, J = 
6.1 Hz, J = 7.6 Hz, 1 H), 2.09 (dsept, J = 3.6 Hz, J = 6.9 Hz, 1 H), 0.76 (d, J = 6.9 Hz, 3 H), 
0.72 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 158.1, 157.2, 149.5, 137.1, 123.6, 
123.5, 62.8, 59.1, 48.0, 46.4, 27.1, 17.3, 14.0; MS (ES); m/z = 313.2 (M + H)+, 336.9 (M + H + 
Na)+. Anal. Calcd for C13H17BrN2O2: C, 49.85; H, 5.47; Br, 25.51; N, 8.94. Found C, 49.98; H, 
5.41; Br, 25.43; N, 8.90. 
3.3.8 – Preparation of compound 33 
N
N
N3
OO
 
The bromide 32 (40 mg, 0.13 mmol) was dissolved in dry DMF (5 mL) and sodium azide 
(48 mg, 0.73 mmol) was added. The mixture was heated at the reflux temperature for 8 h, 
then brine (5 mL) and EtOAc (10 mL) were added. The organic phase was extracted with 
EtOAc (3 x 10 mL), and the combined organic phases was concentrated at reduce pressure. 
The yellowish residue was subjected to chromatography on a SiO2 column eluting with 
cyclohexane, then with a 80:20 cyclohexane/EtOAc mixture to give the azide 38 as a 
yellowish oil: 28 mg (78%). 
3-[2(S)-Azido-2-(2-pyridyl)ethyl]-4(S)-isopropyl-1,3-oxazolidin-2-one (33): [α]D20 +12.8 
(c 1.1, CHCl3); IR (neat) v = 2964, 2935, 2874, 2102, 1738, 1597, 1560, 1425, 1268, 1001, 757; 
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1H NMR (300 MHz, CDCl3): δ =  8.62 (ddd, J = 0.8 Hz, J = 1.6 Hz, J = 4.6 Hz, 1 H), 7.74 (dt, J 
= 1.8 Hz, J = 7.7 Hz, 1 H), 7.39 (d, J = 7.8 Hz, 1 H), 7.28 (ddd, J = 0.8 Hz, J = 4.9 Hz, J = 7.7 
Hz, 1 H), 4.95 (dd, J = 4.6 Hz, J = 9.1 Hz, 1 H), 4.27 (dd, J = 8.8 Hz, J = 8.9 Hz, 1 H), 4.09 
(dd, J = 4.8 Hz, J = 8.8 Hz, 1 H), 3.97 (ddd, J = 3.5 Hz, J = 4.8 Hz, J = 8.8 Hz, 1 H), 3.85 (dd, 
J = 4.6 Hz, J = 14.6 Hz, 1 H), 3.45 (dd, J = 9.1 Hz, J = 14.5 Hz, 1 H), 2.16 (dsept, J = 3.5 Hz, J 
= 6.9 Hz, 1 H), 0.89 (d, J = 6.9 Hz, 3 H), 0.82 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, CDCl3): 
δ = 158.3, 155.7, 149.8 (PyH), 137.2, 123.6, 122.3, 64.4, 63.1, 60.4, 45.4, 27.4, 17.6, 14.1; MS 
(ES): m/z = 276.1 (M + H)+, 298.2 (M + Na)+. Anal. Calcd for C14H21N5O2: C, 57.71; H, 7.27; N, 
24.04. Found C, 57.56 ; H, 7.29; N, 23.94. 
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Chap. 4 – Asymmetric Synthesis of              
1-(2-Pyrrolyl)alkylamines by Addition of 
Organometallic Reagents to Chiral               
2-Pyrroleimines 
N
H HN
OH
Y
R
N
H N Y
Y = Ph, i -Pr
RM
OH
N
H N
R
Ph
N
H NH-Z
R
Z = Bn, Bz
 
4.1 – Introduction 
4.1.1 – 1-(2-Pyrrolyl)alkylamino moiety 
The chiral 1-(2-pyrrolyl)alkylamino moiety highlighted in structure 1 (Scheme 1), 
bearing a stereocenter at the benzylic carbon (one configuration is shown), is a common 
structural motif in non-cinchona indole alkaloids,1 and terpene-indole alkaloids,2 which 
display potent biological and physiological properties. Mytosene aziridines are also important 
compounds containing this skeleton fragment.3 In Scheme 1 we report some examples of 
these molecules. The hydrochloride of Yohimbine (1) is a selective and competitive α2-
adrenergic receptor antagonist and it has been used to treat erectile dysfunction, Ajmaline 
(2) and Raumacline (3) are antiarhythmic agents. Eudistomine L (4) have strong antiviral and 
antitumour activity, Fumitremorgin C (5) is a potent and specific inhibitor of the breast 
cancer resistance protein (BCRP/ABCG2), Geissoschizine (6) is a vasorelaxant. The 
pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxides (PBTDs) (7) as potent non-nucleoside 
inhibitors of the HIV-1 reverse transcriptase.4 7-aminoleucoaziridinomitosene 8) and 1,4-
aziridomitosene (9) have shown activity against various tumor model systems.5 
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Scheme 1 
Given their enormous importance, synthetic methods have been developed for these 
compounds, but efficient asymmetric procedures for the construction of the heterobenzylic 
stereocenter are still lacking. In principle, this goal can be accomplished during the 
formation of any of the four bonds involved. Three of these possibilities, concerning the 
formation of bonds a, b and c are described in Scheme 2. 
N
N
N
N
R
N
N
110 11
a c
b
H(R)R
 
Scheme 2 
 
-118- 
 For example, the a bond in compounds 1 can be formed by the inter- or intramolecular 
attack of the nucleophilic pyrrole C2 carbon at the electrophilic carbon of an azomethine 
compound, generally activated by a Lewis acid  and an electron-withdrawing N-substituent, or 
an iminium ion, possibily formed in situ (three-component Mannich reaction).6 For example, 
the BF3-mediated addition of pyrrole to (S)-N-trifluoromethylidene-1-phenylethylamine 12 
(Scheme 3) occurred with good yield but only moderate diastereoselectivity (d.r. 78:22) to 
give amine 13, whereas indole reacted (at C3) with complete stereocontrol.6d On the other 
hand, an allylic 3-methylene-2,3-dihydro-2-indolylindium 16 species generated by a Pd-In 
bimetallic cascade process from 2-iodo-N-allenylaniline 14 added to enantiopure N-[(R)-t-
butylsulfinyl] glyoxylate imine 15 with complete stereocontrol.6f 
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Scheme 3 
The 1-2-(indolyl)alkylamino moiety has been commonly prepared by the intramolecular 
version of this approach, i.e. the Pictet-Spengler reaction, which has been a key step in the 
synthesis of a large number of alkaloids.1s,t,7,8 In this reaction, an imine or iminium ion 
function, that is formed in situ by N-functionalization of tryptamine and its substituted 
derivatives by reaction with an aldehyde (e.g. 17), undergoes intramolecular attack by the 
indole-C2 carbon (Scheme 4) to give tricyclic compound (18). Although the reaction often 
gives mixtures of diastereomers, a number of highly stereoselective reactions have been 
reported, relying on the asymmetric induction of the stereocenter(s) present in the 
tryptamine aliphatic chain, or in the aldehyde, or in the amine substituent (chiral auxiliary). 
To our knowledge, the Pictet-Spengler reaction has rarely been applied to a pyrrole 
derivative. One example is the reaction developed by Dodd7s between the chiral amine 19 and 
acetaldehyde to give the product 20. 
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Alternatively, the stereocenter in structure 1 can be constructed via formation of 
bond b (Scheme 2) from the azomethine compounds 11.7t,9 For example, quinolizidine 
alkaloids have often been prepared by a sequence of steps where a tetracyclic quaternary 2-
indolyliminium ion (R-substituted N-charged cyclic structure 11) was formed by the Bischler-
Napieralski reaction between indole and lactam rings, then submitted to catalytic 
hydrogenation or hydride reduction (Scheme 5). 
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More recently, novel polycyclic indolyldiamines have been prepared by completely 
diastereoselective reductions of chiral, optically pure 2-indolylenamines (Scheme 6).9f  
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 The construction of bond c (Scheme 2) involves the addition of a carbon nucleophile or 
an organometallic reagent to a 2-pyrrolealdimine 11. However, 2-pyrrole- and 2-indoleimines 
are less electrophilic than other aromatic imines, owing to the electron-donating effect of 
the pyrrole/indole ring. For example, 9-benzyl-3,4-dihydro-β-carboline was unreactive 
towards a laterally metalated pyridine, although a successful reaction was observed when the 
imine was preliminarily activated by addition of trimethylsilyl trifluoromethanesulfonate.1d 
Similarly, the Lewis acid promoted addition of a ketene silyl acetal to a β-carboline 
hydrochloride derived from L-tryptophan1r (21) and the addition of allyltrimethylsilane to 
iminium ions derived from D-tryptophan have been described (Scheme 7).10 Benzylic and 
allylic organometallic reagents reacted smoothly with analogous imines bearing N-aryl or N-
benzenesulfonyl substituents.11 
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Recently, the chiral auxiliary approach has been exploited for the asymmetric 
synthesis of 2-(1-aminoalkyl)indoles. The addition of laterally metallated 3-cyano-4-
methylpyridine (25) to a 1,3-disubstituted-2-indoleimine derived from optically pure 
sulfinamides (26), gave the product 27 with a d.e. of 82% (Scheme 8).12 Recently, a ring-
substituted 2-pyrroleimine prepared from (R)-phenylglycinol (28) underwent highly 
diastereoselective addition of isopropylmagnesium chloride (4-5 equivalents) to give product 
29, whereas the addition of allylzinc bromide to an analogous imine prepared from (R)-phenyl 
glycineamide was unsatisfactory.13 
 
-121- 
 N
Bn
N
OBn
S
p-Tolyl
O
N
CN N
CN
HN
NBn
BnO
S
p-Tolyl
O
+
25 26 27
N
H
OMe
O
OEtN
Ph
HO
N
H
OMe
O
OEt
H
N
Ph
HOi PrMgCl
THF
28 29  
Scheme 8 
In the addition of an optically pure allylsilane to an acylhydrazone derived from 2-
pyrrolealdehyde the yield and e.e. were found to be dependent on the pyrrole N-substitution: 
a lower yield (49%) but higher e.e. (92%) was obtained with the N-Boc-pyrrole imine, with 
respect to the unprotected imine (e.e. 48%).14 Interestingly, tricyclic pyrrole-pyrazine-
oxazole structures (31) were prepared from 2-formylpyrroles derived from (S)-α-amino 
esters and (+)- or (−)-norephedrine15 (30). However, the potential of such compounds as 
precursors of chiral iminium ions, suitable substrates for the addition of Grignard reagents, 
eventually leading to 2-(1-aminoalkyl)pyrroles, has not been considered yet. 
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Another widely exploited method for the asymmetric synthesis of polycyclic indole 
alkaloids by construction of the bond c (Scheme 2) is the Diels-Alder cycloaddition of β-
carbolines and 2-indoleimine with 1,4-dienes.16,17 Notably, a chiral 2-pyrroleimine failed to 
react with 1,3-butadiene.18 For the sake of completeness, the C-N bond can also be formed 
by nucleophilic substitution of oxygen-substituted compounds. For example, 
dihydropyrrolizine esters gave the corresponding amines by reaction with ammonia and alkyl 
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 amines, but loss of the stereochemical integrity of the stereocenter was observed, pointing 
to an SN1 mechanism for these reactions.19 
Following this extensive literature search, we observed that the asymmetric synthesis 
of 1-(2-pyrrolyl)alkylamines was scarcely explored, as compared to the analogous indole 
derivatives. So, we were prompted to study the auxiliary-induced diastereoselective addition 
of organometallic reagents to 2-pyrroleimines, so filling a gap in our long term investigation 
on the asymmetric synthesis of benzylic and heterobenzylic amines from chiral imines.20 It 
should also be observed that optimization of this route would open an avenue to optically 
pure compounds with the pyrrolidine, pyrrolizidine and indolizidine skeletons,21 including 
alkaloids and pharmacologically interesting molecules, taking advantage of the possible 
hydrogenation of the pyrrole nucleus22 and the nucleophilicity of the pyrrole/pyrrolidine 
nitrogen atom. 
4.2 - Results and discussion 
4.2.1 - Addition of organometallic reagents to chiral pyrrole imines derived from (S)-valinol 
and (S)-phenylglycinol 
Optically pure phenylglycinol and valinol are among the most used chiral auxiliaries for 
the diastereoselective addition of organometallic reagents to imines.23 In particular, we 
described that the addition of organolithium reagents to 2-pyridineimines derived from (S)-
valinol and (S)-phenylglycinol occured effectively and with very highly diastereoselectivity 
following protection of the OH function as its trimethylsilyl ether.20 Hence, we began our 
investigation on the N,O-disilylated imine 34, which was prepared in two steps and almost 
quantitative yield from 2-pyrrolealdehyde and (S)-phenylglycinol through the intermediate 
unprotected imine 32. (Scheme 10). 
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 The addition of organolithium reagents to the imine 32 was carried out in diethyl 
ether at −15 or 0 °C, as no reaction was observed at lower temperatures. By using 2-3 
equivalents of organometallic reagents, good yields of the β-hydroxyamines 35 (Scheme 11) 
were obtained after protonolysis and desilylation of organometallic adducts with ammonium 
fluoride in the biphasic system THF/H2O (Table 1). The (S,S)-configuration of the prevalent 
diastereomer in products 35 was assumed on the basis of the sense of asymmetric induction 
previously determined in organometallic reactions of analogous aromatic and heteroaromatic 
imines.20 
 
N
N
OTMS
PhTMS
N
H HN
OH
Ph
R1) RM
2) NH4F
34 35
a: R = Me
b: R = n-Bu
e: R = Allyl
 
Scheme 11 
Very high diastereoselectivity (d.r. >95%) was observed in the formation of amines 
35a and 35b with MeLi and nBuLi, respectively, and the main diastereomer (S,S)-35a,b were 
isolated with good yields after column chromatography. The homoallylic amine 35e was then 
prepared using either allylzinc bromide or allylmagnesium chloride in tetrahydrofuran, but a 
better diastereoselectivity was obtained with the magnesium reagent (d.r. 90:10 versus 
>96:4). Instead, no reaction was observed with vinylmagnesium bromide. 
  
Table 1 
RM 
(equivalents) 
Solvent D.r.[a] 
(S,S)-35 
Yield %[b] 
MeLi (3) Et2O >95:5 35a, 87 
nBuLi (3) Et2O >95:5 35b, 82 
AllylZnBr (2) THF >90:10 35e, 81 
AllylMgCl (2) THF >96:4 35e, 83 
VinylMgCl (3) Et2O - no reaction 
[a] Determined by 1H NMR analysis. [b] The crude product was treated with 
NH4F (3 equiv.) and a catalytic amount of TBAF in THF-H2O (1:1), then 
submitted to column chromatography (SiO2). 
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 Subsequently, taking into account a recent report,13 we wished to check the reactivity 
of the unprotected imines 32 and 33 derived from (S)-phenylglycinol and (S)-valinol, 
respectively (Scheme 12). This choice required the use of an excess of the orgamometallic 
reagent, the first two equivalents being quenched by the acidic OH and NH functions. 
Moreover, it was expected that the negatively charged pyrrole substituent would decrease 
the reactivity of the imine function. As a matter of fact, the addition of MeLi (4 equivalents) 
to the imine 32 in THF occurred smoothly at −15 to 0 °C to give the amine 35a with 96% 
yield and d.r. >95 (Table 2). Similarly, the reaction with nBuLi in the same conditions gave the 
amine 35b in high yield and with (almost) complete diastereoselectivity, only one 
diastereomer being observed by 1H NMR analysis of the crude reaction product. Similarly, 
the addition of iPrMgCl proceeded smoothly to give 35c in 92% yield and with complete 
diastereoselectivity. 
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Scheme 12 
On the other hand, the addition of t-BuLi occurred with quite poor 
diastereoselectivity, although the two diastereomers of 35d could be seperated by column 
chromatography. A low conversion of the imine 32 was observed by TLC and GC analyses 
after addition of allylzinc bromide, however, the use of allylmagnesium chloride allowed the 
homoallylic amine 35e to be obtained with good yield and high diastereoselectivity (dr >95:5); 
higher yield and complete stereocontrol were then obtained using 4 equivalents of the 
allyldiethylzincate prepared by the addition of allylmagnesium chloride to diethylzinc.23 
Aiming to reduce the overall excess of organometallic reagents, we subsequently developed a 
more economic protocol that involved the preliminary addition of diethylzinc (2 equivalents) 
to the imine 32, followed by the addition of allylmagnesium chloride (2 equivalents); in this 
way, the homoallylic amine 35e was obtained with almost identical yield and complete 
stereocontrol. Good results were also obtained using benzylmagnesium chloride, providing 
access to the amines 35f in high yield and with d.r. >95:5. No reaction was observed with 
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 vinylmagnesium bromide and phenylmagnesium bromide, however, phenyllithium proved to be 
more reactive and gave the desired amine 35h. Unfortunately, the crude amine 35h, 
decomposed upon attempted purification by column chromatography, perhaps owing to the 
acidity of the methine proton linked to the carbon stereocenter. 
 
Table 2 
Imine Y 
RM 
(equivalents) 
D.r.[a] 
(S,S)-35, (S,S)-36, 
Yield %[b] 
32 Ph MeLi (4) >95:5 35a, 96 
32 Ph nBuLi (4) >99:1 35b, 91 
32 Ph iPrMgCl (4) >95:5 35c, 92 
32 Ph tBuLi (4)[c] 55:45 
(S,S)-35d, 31; 
(R,S)-35d, 28 
32 Ph AllylZnBr (4) - 35e, 10[a],[d] 
32 Ph AllylMgCl (4) >95:5 35e, 87 
32 Ph AllylEt2ZnMgCl (4) >99:1 35e, 89 
32 Ph 1) Et2Zn (2), 2) AllylMgCl (2) >99:1 5e, 86 
32 Ph BnMgCl (4) >95:5 35f, 91 
32 Ph VinylMgBr (4) - 35g, 0 
32 Ph PhMgBr (4) - 35h, 0 
32 Ph PhLi (4) >95:5 35h, 95[e] 
     
33 iPr MeLi (4) >99:1 36a, 91 
33 iPr nBuLi (4) >99:1 36b, 87 
33 iPr 1) Et2Zn (2), 2) AllylMgCl (2) >99:1 36e, 89 
33 iPr AllylMgCl (4) >99:1 36e, 78 
33 iPr BnMgCl (4) >99:1 36f, 90 
33 iPr 1) MeLi (2), 2) VinylLi (2) >99:1 36g, 92[e] 
33 iPr PhLi (4) >95:5 36h, 91[e] 
[a] Determined by 1H NMR analysis. [b] Yield of the pure (S,S)-diastereomer which was isolated by column 
chromatography (SiO2). [c] The reaction was performed in Et2O. [d] The product was not isolated. [e] The 
product decomposed during chromatography on a SiO2 column. 
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 Then we moved to evaluate the degree of asymmetric induction offered by the (S)-
valinol-derived 2-pyrroleimine 33 in the same organometallic reactions carried out on the 
imine 32. We were delighted to observe that even better results were obtained, as complete 
stereocontrol was achieved in the preparation of the amines 36a,b,e-h (Table 2). These 
results are in line with the previously observed evidence that a better stereocontrol was 
provided by valinol as the chiral auxiliary for imines with respect to phenylglycinol.20 The 
reaction with t-butyllithium was not carried out, as we had no chance to improve significantly 
the diastereoselectivity previously obtained with the imine 32. The β-aminoalcohols 36g,h 
were obtained using vinyllithium and phenyllithium, respectively. Vinyllithium was prepared by 
reaction of tri(n-butyl)vinyltin and n-BuLi, however, we found more convenient to initially add 
two equivalents of MeLi to the imine 33, since the first two equivalents of organometallic 
reagent are consumed by the acidic NH and OH groups, and then add two equivalents of 
vinyllithium. As previously observed with the amine 35h, the novel amines 36g,h underwent 
decomposition during attempted chromatographic purification. Nevertheless, it is likely that 
the crude amines 35h and 36g,h, being obtained with satisfactory purity, could be used as 
such in subsequent steps involving transformation of the alkene function.  
 
4.2.2 - Addition of organometallic reagents to chiral pyrrole imines derived from valine 
methyl ester 
 
We also prepared the imine 38 (Scheme 13) derived from 2-pyrrolecarboxaldehyde 
and (S)-valine methyl ester following protection of the NH function as its trimethylsilyl 
derivatives. 
The addition of allylzinc bromide to the imine 38 gave a mixture of two products: the 
desire product 39 with only the 51% of yield and the product 40 derivate from a double 
addition of the organometallic reagent to the ester function (Table 3). Increasing the 
temperature and using allylmagnesium chloride gave only the product 40 with good yields. 
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Table 3 
RM 
(equivalents) 
T (°C) D. r. of 38[a] 
39 
Yield(%) 
40 
Yield(%) 
AllylZnBr (3) -78 ? -10 92:8 51[b] 15[a] 
AllylZnBr (3) 0 ? 25 - - 84[b] 
AllylMgCl (3) 0 ? 25 - - 90[b] 
[a] Determined by 1H NMR analysis. [b] After cromatographic purification (SiO2).  
4.2.3 – Elaboration of amines 35 and 36 
At this point we assessed the possibility of using the β-aminoalcohol 35 and 36 for 
the construction of new optically active, pyrrole-containing molecules, such as aziridines by 
intramolecular cyclization and secondary amines through oxidative cleavage of the chiral 
auxiliary (Scheme 14). For the first goal we followed the same protocol previously applied for 
the synthesis of analogous 1-(2-pyridyl)alkylaziridines.20b,c As a matter of fact, the pyrrole-
aziridines 41a,b,f were successfully obtained in high yields by treatment of the β-
hydroxyamines 35a,b,f with triphenylphosphine and diethylazodicarboxylate (DEAD) in THF 
at room temperature.  
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Scheme 14 
On the other hand, hydrogenolysis of 35a with ammonium formate and Pd/C in ethanol 
at the reflux temperature gave disappointing results, as a complex mixture of products was 
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 obtained. Instead, the oxidative procedure making use of periodic acid and methylamine in 
THF-H2O was successful; however, starting from the β-aminoalcohols 35b,c,e the 
benzaldimines 42b,c,e were isolated, apparently being stable towards hydrolysis in the 
reaction conditions. In particular the imine 42c was isolated as a solid and could be purified 
simply by washing with pentane. Both the crude imines 42b,c,e were readily reduced to the 
corresponding benzylamines 43b,c,e by sodium borohydride in methanol (Scheme 15). It is 
worthy of note that this procedure is more convenient than the usual stepwise removal of 
the chiral auxiliary followed by N-benzylation. 
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Scheme 15 
On the other hand, the primary amines were formed by carrying out the oxidative 
procedure on the valinol derivatives 36 (Scheme 16); in this case the crude compounds were 
preferably treated with benzoyl chloride and potassium carbonate in acetone-H2O mixture, 
so easily obtaining the corresponding pure N-benzoyl derivatives 44a,b,e,f in good yields. 
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Scheme 16 
In conclusion, we have developed a convenient asymmetric route to 1-[2-
(pyrrolyl)]alkylamines exploiting the highly diastereoselective addition of organometallic 
reagents to chiral 2-pyrroleimines derived from (S)-phenylglycinol and (S)-valinol. Although a 
larger excess of organometallic reagents was needed, better diastereoselectivities were 
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 obtained working on the imines with unprotected N-H and O-H functions. Complete or 
excellent stereocontrol was achieved, especially with the (S)-valinol-derived imine. Removal 
of the chiral auxiliaries was achieved by an oxidative procedure to give the corresponding 
imines or primary amines, from which the N-benzyl and N-benzoylamines could be easily 
prepared. Pyrrole-aziridines were also prepared by cyclization of the (S)-phenylglycinol 
derived secondary amines. Future efforts in our laboratory will be devoted to converting the 
unsaturated amines 35h and 36g,h into bicyclic compounds by linking the pyrrole-NH and 
alkene functions. 
 
4.2.4 – Use of the synthesized compounds as chiral ligands 
 
Finally we tested the imine 32 and the aziridines 41a,f in the enanatioselctive 
addition of diethylzinc to benzaldehyde 45 (Scheme 17). The reaction proceeded slowly, 
moderate to good yield was obtained only after 24 hours at room temperature (Scheme 17), 
to gave the addition product 46 with low e.e.. 
 
Scheme 17 
Ph H
O
Ph
OH
Et2Zn, Toluene 25°C
L
45 46  
Table 4 
L Conversion 46 (%) e.e. 46 (%) 
32 75 9 
41a 96 21 
41f 88 15 
 
4.3 – Experimental section 
Melting points are uncorrected. Optical rotations were measured on a digital 
polarimeter in a 1-dm cell and [α]D-values are given in 10−1 deg cm3 g−1. 1H NMR spectra were 
recorded on Varian Inova and Gemini instruments for samples in CDCl3 which was stored over 
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 Mg: 1H chemical shifts are reported in ppm relative to CHCl3 (δH 7.27), J-values are given in 
Hz. and in the assignments s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, m = 
multiplet, bs = broad singlet, dd = doublet of doublets and dt = doublet of triplets. Infrared 
spectra were recorded on a Nicolet FT-380 spectrometer and IR assignments are reported 
in wavenumbers (cm−1). MS spectra were taken at an ionising voltage of 70 eV on a Hewlett-
Packard 5975 spectrometer with GLC injection. Molecular weight was determined on an 
Agilent Technologies MS 1100 instrument. Chromatographic separations were performed on 
columns of SiO2 (Merck, 230-400 mesh) at medium pressure. All the organic, inorganic and 
organometallic reagents and reactants and anhydrous solvents were purchased from Aldrich. 
4.3.1 – General protocol for the preparation of Imines 32, 33 
To a solution of (S)-phenylglycinol (0.823 g, 6 mmol) or (S)-valinol (0.618 g, 6 mmol) in 
anhydrous CH2Cl2 (30 mL) was added anhydrous MgS04 (5 g) and 2-pyrrolecarboxaldehyde 
(0.571 g, 6 mmol) and the mixture was stirred overnight. The solid was filtered off through a 
pad of Celite and the organic phase was concentrated at reduced pressure. The residue was 
crystallized from pentane:CH2Cl2 mixture (5:1) to give the imine, which was used in the 
following step avoiding purification. 
 
N
H N Ph
OH 
(S)-N-(2-Pyrrolmethylidene)phenylglycinol (32): 1.262 g (98%); white solid, mp 109-109.6 
°C. [α]D20 +24.3 (c 1.1, CHCl3). IR (KBr): νmax = 3331, 3113, 3061, 2921, 2854, 1640, 1425, 
1366, 1313, 1073, 1061, 1043, 813, 737, 701. 1H NMR (300 MHz, CDCl3): δ = 4.03 (dd, J = 3.6, 
J2 = 12.2, 1 H), 4.20 (dd, J = 9.9, J = 12.2, 1 H), 4.46 (dd, J = 3.6, J = 9.9, 1 H), 6.20 (m, 2 H), 
6.99 (m, 1 H), 7.38 (m, 5 H), 7.75 (s, 1 H). 13C NMR (75 MHz, CDCl3): δ = 67.9, 76.6, 109.6, 
117.7, 122.9, 126.9, 127.4, 128.6, 128.9, 140.7, 154.6. GC-MS m/z: 183 (100), 156 (12), 214 (7), 
80 (7). Anal. Calcd for C13H14N2O (214.11): C, 72.87; H, 6.59; N, 13.07. Found: C, 72.57; H, 
6.62; N, 13.10. 
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 N
H N
OH  
(S)-N-(2-Pyrrolmethylidene)valinol (33): 1.051 g (97%); white solid, mp 122.4-123 °C. [α]D20 
+121.5 (c 0.5, CHCl3). IR (KBr): νmax = 3239, 3114, 3085, 2966, 2924, 2868, 2843, 1633, 
1473, 1419, 1373, 1359, 1317, 1217, 1131, 1075, 1053, 1035, 934, 824, 761, 735. 1H NMR (300 
MHz, CDCl3): δ = 0.86 (d, J = 6.9, 3 H), 0.92 (d, J = 6.9, 3 H), 1.81 (sept, J = 6.9, 1 H), 2.92 
(dd, J = 3.5, J = 8.8, 1 H), 3.83 (dd, J = 3.5, J = 11.8, 1 H), 3.96 (dd, J = 8.8, J = 11.8, 1 H), 
6.16 (dd, J = 2.6, J = 3.6, 1 H), 6.26 (m, 1 H), 6.89 (m, 1 H), 7.66 (s, 1 H). 13C NMR (75 MHz, 
CDCl3): δ =  19.0, 19.6, 30.7, 64.5, 78.3, 109.3, 116.7, 122.3, 129.0, 153.7. GC-MS m/z: 149 
(100), 80 (47), 137 (38), 68 (26), 106 (24), 180 (23). Anal. Calcd for C10H16N2O (180.13): C, 
66.63; H, 8.95; N, 15.54. Found: C, 66.31; H, 8.98; N, 15.51. 
4.3.2 – Preparation of Imine 34 
N
N
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(S)-N-[(1-Trimethylsilylpyrrol-2-yl)methylidene]phenylglycinol trimethylsilyl ether 34: 
The crude imine 32 (1.26 gr, 5.9 mmol) was dissolved in CH2Cl2 (20 mL) and triethylamine 
(1.23 g, 12 mmol) and chlorotrimethylsilane (1.30 g, 12 mmol) were added to the solution 
cooled at 0 °C. After 3 h the solvent was removed at reduced pressure. A solution of 
cyclohexane/diethyl ether (1:1, 50 mL) was added and the solid precipitate was filtered off 
through a pad of Celite. The organic solvent was evaporated under reduced pressure to leave 
the imine 34 which was used in the following step avoiding purification: 2.074 gr (98%); white 
solid, m.p. 94.2-94.9 °C (from pentane:Et2O 5:1). [α]D20 −48.1 (c 0.5, CHCl3). IR (KBr): νmax = 
3105, 3062, 2962, 2908, 2857, 1640, 1451, 1425, 1247, 1122, 1084, 1051, 916, 902, 842, 739, 
700. 1H NMR (300 MHz, CDCl3): δ = 0.11 (s, 9 H), 0.58 (s, 9 H), 3.93 (d, J = 6.7, 2 H), 4.37 (t, 
J = 6.7, 1 H), 6.36 (dd, J = 2.6, J = 3.3, 1 H), 6.78 (dd, J = 1.5, J = 3.3, 1 H), 7.05 (m, 1 H), 
7.37 (m, 2 H), 7.51 (m, 3 H), 8.26 (s, 1 H). 13C NMR (75 MHz, CDCl3): δ = -0.5, 1.6, 67.6, 77.3, 
100.4, 120.5, 127.1, 127.8, 128.2, 129.5, 141.4, 153.0. GC-MS m/z: 255 (100), 73 (34), 183 
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 (22), 150 (19), 343 (15), 358 (12). Anal. Calcd for C19H30N2OSi2 (358.19): C, 63.63; H, 8.43; N, 
7.81. Found: C, 63.48; H, 8.45; N, 7.79. 
4.3.3 - Preparation of Imine 38 
N
N
OMeO
TMS
 
To a solution of (S)-valine methyl ester hydrochloride (1.68 g, 10 mmol) in anhydrous 
CH2Cl2 (30 mL) was added anhydrous MgS04 (5 g) and 2-pyrrolecarboxaldehyde (0.951 g, 10 
mmol). Triethylamine (1.23 g, 12 mmol) was added and the mixture was stirred overnight. The 
solid was filtered off through a pad of Celite and the organic phase was concentrated at 
reduced pressure. 
The crude imine was dissolved in CH2Cl2 (20 mL) and triethylamine (1.23 g, 12 mmol) 
and chlorotrimethylsilane (1.30 g, 12 mmol) were added to the solution cooled at 0 °C. After 
3 h the solvent was removed at reduced pressure. A solution of cyclohexane/diethyl ether 
(1:1, 50 mL) was added and the solid precipitate was filtered off through a pad of Celite. The 
organic solvent was evaporated under reduced pressure to leave the imine 38 which was used 
in the following step avoiding purification. 
(S)-N-(2-Pyrrolmethylidene)valine methylester (38): 2.74 g (98%); yellow oil. [α]D20 +101.4 
(c 0.5, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 0,53 (s, 9 H), 0.95 (d, J = 6.9, 3 H), 1.02 (d, J = 
6.9, 3 H), 2.38 (dsept, J = 8.0, J = 6.9, 1 H), 3.53 (d, J = 8.0, 1 H), 3.76 (s, 3 H), 6.33 (m, 1 H), 
6.76 (dd, J = 1.5, J = 3.4, 1 H), 7.05 (m, 1 H), 8.07 (s, 1 H). 13C NMR (75 MHz, CDCl3): δ = 1.3, 
18.9, 19.5, 28.8, 31.2, 52.4, 81.1, 110.5, 121.5, 130.3, 135.4, 154.2, 172.6, 179.1. GC-MS m/z: 
150 (100), 73 (89), 165 (85), 178 (69), 237 (65), 221 (61), 205 (52), 265 (34), 280 (26). 
 
4.3.4 – General protocol for the preparation of  β-Aminoalcohols 35, 36 
 
Methyllithium (1.6 M in diethyl ther, 2.4 mL, 3.8 mmol) was added to a magnetically 
stirred solution of the imine 32 (0.203 g, 0.95 mmol) in THF (15 mL) cooled at –15 °C. After 
30 min the reaction mixture was slowly warmed up until room temperature was reached, and 
stirring was continued for 24 h. The mixture was quenched by adding a saturated aqueous 
solution of NaHCO3 (10 mL) at 0 °C, then the organic material was extracted with diethyl 
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 ether (3 ×10 mL). The collected ethereal layers were dried over Na2SO4 and concentrated to 
leave the crude product. The diastereomeric ratio was determined by 1H NMR analysis. Flash 
column chromatography (SiO2) eluting with cyclohexane/ethyl acetate 1:1 mixtures gave the 
product 35a. This compound, as well as all the β-aminoalcohols 35 and 36 prepared, 
decomposed on attempted GC-MS and HPLC-MS analyses. 
 
N
H HN
OH
Ph
 
(S)-N-[(S)-1-(2-Pyrrolyl)ethyl]phenylglycinol (35a): 0.210 g, (96%); white solid, mp 86.9-
87.4 °C (Et2O). [α]D20 +34.5 (c 0.8, CHCl3). IR (NuJol): νmax = 3295, 2090, 2955, 2928, 2854, 
1540, 1459,  1261, 1090, 735. 1H NMR (300 MHz, CDCl3): δ 1.39 (d, J = 6.7, 3 H), 2.66 (bs, 2 
H), 3.57 (dd, J = 8.1, J = 10.8, 1 H), 3.74 (dd, J = 4.3, J = 10.8, 1 H), 3.80 (q, J = 6.7, 1 H),  
3.96 (dd, J = 4.3, J = 8.1, 1 H), 5.97 (m, 1 H), 6.13 (m, 1 H), 6.97 (m, 1 H), 7.34 (m, 5H), 8.68 
(bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 20.0, 47.7, 61.1, 66.8, 104.4, 107.9, 116.7, 127.3, 
127.7, 128.7, 135.6, 140.4. Anal. Calcd for C14H18N2O (230.14): C, 73.01; H, 7.88; N, 12.16. 
Found: C, 72.82; H, 7.91; N, 12.15. 
 
N
H HN
OH
Ph
 
(S)-N-[(S)-1-(2-Pyrrolyl)pentyl]phenylglycinol (35b): 0.235 g, (91%); yellow oil. [α]D20 
+48.6 (c 0.7, CHCl3). IR (neat): νmax = 3424, 3023, 2856, 2863, 1495, 1391, 1264, 1093, 1021. 
1H NMR (300 MHz, CDCl3): δ = 0.88 (t, J = 7.3, 3 H), 1.24 (m, 4 H), 1.74 (m, 2 H), 2.51 (bs, 2 
H), 3.59 (dd, J = 7.5, J = 10.8, 1 H), 3.72 (dd, J = 4.3, J = 8.0, 1 H), 3.77 (dd, J = 4.5, J = 10.8, 
1 H), 3.91 (dd, J = 4.4, J = 7.5, 1 H), 5.97 (m, 1 H), 6.13 (q, J = 2.8, 1 H), 6.69 (m, 1 H), 7.23-
7.43 (m, 5 H), 8.54 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 14.0, 22.7, 25.6, 27.9, 53.3, 61.2, 
66.1, 105.4, 107.8, 116.7, 127.1, 127.5, 128.6, 134.0, 140.9. Anal. Calcd for C17H24N2O (272.19): 
C, 74.96; H, 8.88; N, 10.28. Found: C, 74.85; H. 8.89; N, 10.26. 
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 N
H HN
OH
Ph
 
(S)-N-[(S)-2-Methyl-1-(2-pyrrolyl)propyl]phenylglycinol (7c): 0.243 g, (92%); yellowish 
oil. [α]D20 +32.4 (c 1.0, CHCl3). IR (neat): νmax = 3422, 3024, 2853, 2865, 1492, 1261, 1099, 
1021, 742. 1H NMR (300 MHz, CDCl3): δ = 0.93 (d, J = 6.7, 3 H), 0.97 (d, J = 6.7, 3 H), 2.02 
(dsept, J = 5.7, J = 6.7, 1 H), 2.50 (bs, 2 H), 3.61 (dd, J = 5.8, J = 10.2, 1 H), 3.67 (d, J = 5.7, 
1 H), 3.78 (dd, J = 4.5, J = 5.7, 1 H), 3.84 (dd, J = 4.5, J = 10.2, 1 H), 5.98 (m, 1 H), 6.15 (q, J 
= 2.8, 1 H), 6.65 (m, 1 H), 7.25-7.39 (m, 5 H), 8.39 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 
18.0, 19.7, 32.2, 59.5, 61.2, 63.4, 106.3, 107.6, 114.2, 127.1, 127.2, 127.3, 128.5, 132.2, 141.2. 
Anal. Calcd for C16H22N2O (258.17): C, 74.38; H, 8.58; N, 10.84. Found: C, 74.15; H. 8.60; N, 
10.83. 
 
N
H HN
OH
Ph
 
(S)-N-[(S)-2,2-Dimethyl-1-(2-pyrrolyl)propyl]phenylglycinol ((S,S)-35d): 0.081 g, (31%); 
yellowish oil. [α]D20 +40.7 (c 1.0, CHCl3). IR (neat): νmax = 3425, 2953, 2868, 2867, 1478, 
1391, 1362, 1260, 1095. 1H NMR (300 MHz, CDCl3): δ = 0.98 (s, 9 H), 2.15 (bs, 2 H), 3.51 (s, 1 
H), 3.59 (dd, J = 5.9, J = 8.1, 1 H), 3.63 (dd, J = 8.1, J = 12.2, 1 H), 3.83 (dd, J = 5.9, J = 12.2, 
1 H), 5.92 (m, 1 H), 6.08 (q, J = 2.7, 1 H), 6.55 (m, 1 H), 7-21-7.32 (m, 5 H), 8.07 (bs, 1 H). 13C 
NMR (75 MHz, CDCl3): δ = 27.1, 35.4, 61.5, 64.2, 64.3, 107.0, 107.6, 115.8, 127.1, 127.3, 128.4, 
132.0, 142.1. Anal. Calcd for C17H24N2O (272.19): C, 74.96; H, 8.88; N, 10.28. Found: C, 74.98; 
H, 8.91; N, 10.26. 
N
H HN
OH
Ph
 
(S)-N-[(R)-2,2-Dimethyl-1-(2-pyrrolyl)propyl]phenylglycinol ((S,R)-35d): 0.072 g, (28%); 
yellowish oil. [α]D20 +109.6 (c 1.9, CHCl3). IR (neat): νmax = 3425, 3029, 2853, 2868, 1492, 
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 1392, 1363, 1260, 1096, 1028. 1H NMR (300 MHz, CDCl3): δ = 1.39 (s, 9 H), 2.33 (bs, 2 H), 
3.26 (s, 1 H), 3.55 (dd, J = 4.6, J = 8.1, 1 H), 3.61 (dd, J = 8.1, J = 10.0, 1 H), 3.68 (dd, J = 4.6, 
J = 10.0, 1 H), 5.97 (m, 1 H), 6.19 (m, 1 H), 6.77 (m, 1 H), 7.22 (2 H), 7.31-7.40 (m, 3 H), 8.44 
(bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 27.0, 34.8, 61.7, 63.1, 66.7, 107.6, 108.3, 116.5, 127.4, 
127.7, 128.6, 130.4, 140.1. Anal. Calcd for C17H24N2O (272.19): C, 74.96; H, 8.88; N, 10.28. 
Found: C, 74.82; H. 8.89; N, 10.26. 
N
H HN
OH
Ph
 
(S)-N-[(S)-1-(2-Pyrrolyl)-3-buten-1-yl]phenylglycinol (35e): 0.217 g, (89%); yellow oil. 
[α]D20 +16.5 (c 0.4, CHCl3). IR (neat): νmax = 3364, 3102, 3076, 2958, 2930, 2873, 1466, 
1437, 1093, 1044, 2026, 914, 796, 717. 1H NMR (300 MHz, CDCl3): δ = 2.40 (bs, 2 H), 2.79 
(m, 2 H), 3.84 (dd, J = 7.6, J = 10.8, 1 H), 4.01 (dd, J = 4.5, J = 10.8, 1 H), 4.09 (t, J = 5.9, 1 
H),  4.19 (dd, J = 4.5, J = 7.6, 1 H), 5.36 (dd, J = 10.8, J = 17.2, 2 H), 6.01 (m, 1 H), 6.23 (m, 1 
H), 6.38 (d, J = 2.7, 1 H), 6.91 (dd, J = 1.5, J = 2.7, 1 H), 7.52-7.61 (m, 5H), 8.73 (bs, 1 H). 13C 
NMR (75 MHz, CDCl3): δ 38.9, 52.5, 61.3, 66.4, 105.3, 108.0, 116.7, 117.9, 127.3, 127.7, 128.7, 
133.6, 134.7, 140.3. Anal. Calcd for C16H20N2O (256.16): C, 74.97; H, 7.86; N, 10.93. Found: C, 
75.02; H, 7.87; N. 10.89. 
 
N
H HN
OH
Ph
Ph
 
(S)-N-[(S)-2-Phenyl-1-(2-pyrrolyl)ethyl]phenylglycinol (35f): 0.265 g, (91%); white solid, 
mp 115.2-116.2 °C (pentane:Et2O 1:1). [α]D20 +82.5 (c 1.1, CHCl3). IR (NuJol): νmax = 3353, 
3028, 2926, 2856, 1539, 1453, 1261, 1094, 1027, 749. 1H NMR (300 MHz, CDCl3): δ = 1.94 
(bs, 2 H), 3.08 (d, J = 6.6, 2 H), 3.55 (dd, J = 7.4, J = 10.8, 1 H), 3.71 (dd, J = 4.3, J = 10.8, 1 
H), 3.86 (dd, J = 4.3, J = 7.4, 1 H), 3.08 (t, J = 6.6, 1 H), 5.98 (m, 1 H), 6.12 (q, J = 6.7, 1 H), 
6.63 (m, 1 H), 7.09 (m, 2 H), 7.24-7.38 (m, 8H), 8.19 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 
42.3, 54.9, 61.6, 66.1, 105.3, 108.0, 116.6, 126.4, 127.2, 127.6, 128.2, 128.6, 129.3, 133.7, 
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 138.5, 140.8. Anal. Calcd for C20H22N2O (306.17): C, 78.40; H, 7.24; N, 9.14. Found: C, 78.50; 
H, 7.27; N. 9.11. 
N
H HN
OH
Ph
Ph
 
(S)-N-[(S)-1-Phenyl-1-(2-pyrrolyl)methyl]phenylglycinol (35h): this compound was not 
purified; 1H NMR (300 MHz, CDCl3): δ = 3.22 (bs, 2 H), 3.62-6.70 (m, 3 H), 4.73 (s, 1 H), 5.84 
(m, 1 H), 6.13 (q, J = 3.1, 1 H),  6.71 (m, 1 H), 7.26-7.49 (m, 10 H), 8.54 (bs, 1 H). 
 
N
H HN
OH  
(S)-N-[(S)-1-(2-Pyrrolyl)ethyl]valinol (36a): Starting from 1 mmol of 33 0.179 g, (91%); 
yellow oil. [α]D20 −7.7 (c 0.9, CHCl3). IR (neat): νmax = 3394, 2961, 2927, 2874, 1465, 1373, 
1262, 1104, 1029, 793, 747, 720. 1H NMR (300 MHz, CDCl3): δ = 0.89 (d, J = 6.8, 3 H), 0.95 
(d, J = 6.8, 3 H), 1.39 (d, J = 6.5, 3 H), 1.77 (sept, J = 6.8, 1 H), 2.2 (bs, 2 H), 2.45 (dd, J = 
4.1, J = 6.2, 1 H), 3.64 (dd, J = 6.2, J = 10.8, 1 H), 3.39 (dd, J = 4.1, J = 10.8, 1 H), 4.01 (q, J = 
6.5, 1 H),  6.02 (m, 1 H), 6.15 (m, 1 H), 6.72 (m, 1 H), 8.55 (bs, 1 H). 13C NMR (75 MHz, CDCl3): 
δ = 18.4, 19.3, 22.3, 29.2, 48.9, 60.0, 61.1, 104.4, 107.8, 116.7, 135.7. MS (EI) m/z: 197 [M + 
H]+, 94 [M − valinol]+. Anal. Calcd for C11H20N2O (196.16): C, 67.31; H, 10.27; N, 14.27. Found: 
C, 67.02; H, 10.30; N, 14.23. 
 
N
H HN
OH  
((S)-N-[(S)-1-(2-Pyrrolyl)pentyl]valinol (36b): 0.207 g, 0.173 g, (87%); yellow oil. [α]D20 
−4.6 (c 0.5, CHCl3). IR (neat): νmax = 3362, 3301, 3101, 2957, 2929, 2860, 1567, 1464, 1026, 
925, 792, 717. 1H NMR (300 MHz, CDCl3): δ = 0.85 (t, J = 5.2, 3 H), 0.89 (d, J = 6.7, 3 H), 
0.92 (d, J = 6.7, 3 H), 1.25 (m, 4 H), 1.62 (m, 2 H), 1.74 (m, 1H), 1.98 (bs, 2 H), 2.36 (ddd, J = 
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 4.3, J = 5.3, J = 8.0,  1 H), 3.41 (dd, J = 5.6, J = 10.8, 1 H), 3.64 (dd, J = 4.1, J = 10.8, 1 H), 
3.77 (dd, J = 5.9, J = 8.0, 1 H), 5.99 (m, 1 H), 6.13 (q, J = 2.9, 1 H), 6.72 (m, 1 H), 8.42 (bs, 1 
H). 13C NMR (75 MHz, CDCl3): δ = 13.8, 18.5, 19.2, 22.5, 26.4, 29.2, 36.3, 54.2, 60.3, 61.1, 
105.5, 107.4, 116.6, 134.0. MS(EI) m/z: 136.1 [M – n-Bu]+. Anal. Calcd for C14H26N2O (238.20): 
C, 70.54; H, 10.99; N, 11.75. Found: 78.59; H, 10.97; N, 11.71. 
 
N
H HN
OH  
 (S)-N-[(S)-1-(2-Pyrrolyl)-3-buten-1-yl]valinol (36e): 0.173 g, (78%), yellow oil. [α]D20 
−12.4 (c 1.1, CHCl3). IR (Neat): νmax = 3296, 3090, 3062, 2956, 2928, 2858, 1582, 1454, 
1379, 1264, 1093, 1027, 934. 1H NMR (300 MHz, CDCl3): δ = 0.87 (d, J = 6.8, 3 H), 0.93 (d, J 
= 6.8, 3 H), 1.74 (sept, J = 6.8, 1 H), 1.96 (bs, 2 H), 2.37 (dd, J = 4.1, J = 5.3, 1 H), 2.46 (dd, J 
= 6.7, J = 6.9, 2 H), 3.43 (dd, J = 5.3, J = 10.8, 1 H), 3.68 (dd, J = 4.1, J = 10.8, 1 H), 3.90 (t, 
J = 6.7, 1 H), 5.08-5.17 (m, 2 H), 5.76 (m, 1 H), 6.01 (m, 1 H), 6.14 (q, J = 2.7, 1 H), 6.72 (m, 1 
H), 8.52 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 18.7, 19.3, 29.2, 41.3, 53.3, 60.4, 61.2, 105.3, 
107.8, 116.6, 117.4, 133.9, 135.1. MS(EI) m/z: 120 [M - valinol]+. Anal. Calcd for C13H22N2O 
(222.17): C, 70.23; H, 9.97; N, 12.60. Found: C, 69.96; H, 9.99; N, 12.58. 
 
N
H HN
OH
Ph
 
(S)-N-[(S)-2-Phenyl-1-(2-pyrrolyl)ethyl]valinol (36f): 0.245 g, (90%); white solid, mp 
109.5-110.8 °C (pentane:Et2O 1:1). [α]D20 −9.8 (c 0.8, CHCl3). IR (KBr): νmax = 3295, 3021, 
2948, 2818, 1711, 1492, 1457, 1361, 1334, 1095, 1040, 989, 798, 753, 729, 728, 714, 700. 1H 
NMR (300 MHz, CDCl3): δ = 0.84 (d, J = 6.8, 3 H), 0.90 (d, J = 6.8, 3 H), 1.58 (bs, 2 H), 1.69 
(sept, J = 6.8, 1 H), 2.29 (dd, J = 4.1, J = 4.9, 1 H), 2.91 (dd, J = 7.6, J = 13.6, 1 H), 3.00 (dd, 
J = 6.0, J = 13.6, 1 H), 3.34 (dd, J = 4.9, J = 11.2, 1 H), 3.53 (dd, J = 4.1, J = 11.2, 1 H), 2.29 
(dd, J = 6.0, J = 7.6, 1 H), 5.59 (m, 1 H), 6.14 (q, J = 2.7, 1 H), 6.69 (m, 1 H), 7.10-7.16 (m, 2 
H), 7.20-7.32 (m, 3 H), 8.33 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 19.0, 19.5, 29.4, 44.4, 
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 55.4, 60.4, 61.5, 105.3, 108.1, 116.4, 126.5, 128.4, 129.2, 134.1, 138.8. MS(EI) m/z: 170 [M - 
valinol]+. Anal. Calcd for C17H24N2O (272.19): C, 74.96; H, 8.88; N, 10.28. Found: C, 74.62; H, 
8.91; N, 10.25. 
 
N
H HN
OH  
(S)-N-[(S)-1-(2-Pyrrolyl)-2-propen-1-yl]valinol (36g): the crude compound could not be 
purified, owing to decomposition by column chromatography; its structure was confirmed by 
1H NMR (300 MHz, CDCl3): δ = 0.91 (d, J = 6.9, 3 H), 0.97 (d, J = 6.9, 3 H), 1.87 (m, 1 H), 2.58 
(dd, J = 4.1, J = 7.2, 1 H), 3.39 (dd, J = 7.2, J = 10.7, 1 H), 3.66 (dd, J = 4.1, J = 10.7, 1 H), 
4.43 (d, J = 7.6, 1 H),  5.18 (dd, J = 1.4, J = 10.0, 1 H), 5.25 (dd, J = 1.4, J = 17.4, 1 H), 5.90 
(ddd, J = 7.6, J = 10.0, J3 = 17.4, 1 H), 6.07 (m, 1 H), 6.17 (t, J = 3.1, 1 H),  6.75 (dd, J = 1.4, J 
= 2.7, 1 H), 8.78 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ 17.9, 19.3, 28.8, 57.3, 60.6, 61.1, 105.3, 
108.1, 116.0, 117.1, 132.8, 139.5.  The compound was not eluted by GC-MS analysis. 
 
N
H HN
OH
Ph
 
(S)-N-[(S)-1-Phenyl-1-(2-pyrrolyl)methyl]valinol (36h): the crude compound could not be 
purified, owing to decomposition by column chromatography; its structure was confirmed by 
1H NMR analysis 1H NMR (300 MHz, CDCl3): δ = 0.95 (d, J = 6.9, 3 H), 0.98 (d, J = 6.9, 3 H), 
1.95 (m, 1 H), 2.07 (bs, 2 H), 2.45 (dd, J = 4.1, J = 6.8, 1 H), 3.40 (dd, J = 6.8, J = 10.8, 1 H), 
3.58 (dd, J = 4.1, J = 10.8, 1 H), 5.05 (s, 1 H), 6.01 (m, 1 H), 6.14 (q, J = 3.1, 1 H), 6.71 (m, 1 H), 
7.29-7.45 (m, 5 H), 8.32 (bs, 1 H). The compound was not eluted by GC-MS analysis. 
4.3.5 – General protocol for the preparation of  aziridines 35, 36 
 
To a solution of the β-aminoalcohol 35a (0.299 g, 1.3 mmol) in THF (20 mL) was added PPh3 
(0.511 g, 1.95 mmol), then DEAD (0.340 g, 1.95 mmol) was added dropwise. After stirring for 
4 h the mixture was concentrated at reduce pressure and the residue was subJected to 
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 flash-chromatography on a SiO2 column eluting with cyclohexane/ethyl acetate 9:1 mixtures 
to give the compound 41a as yellow oil. 
 
N
H N
Ph 
(S)-2-Phenyl-1-[(S)-1-(2-Pyrrolyl)ethyl]aziridine (41a): 0.240 g, (87%); yellow oil. [α]D20 
+85.4 (c 0.8, CHCl3). IR (neat): νmax = 3214, 3103, 2922, 2856, 1460, 1383, 805, 748, 712. 1H 
NMR (300 MHz, CDCl3): δ = 1.54 (d, J = 6.6, 3 H), 1.89 (d, J = 3.5, 1 H), 2.10 (d, J = 6.7, 1 H), 
2.55 (dd, J = 3.5, J = 6.6, 1 H), 2.93  (q, J = 6.6, 1 H), 6.02 (m, 1 H), 6.16 (q, J = 2.8, 1 H), 6.66 
(m, 1 H), 7.21-7.35 (m, 5 H), 8.44 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 22.0, 36.8, 41.1, 
63.2, 104.4, 107.9, 116.6, 126.3, 127.0, 128.4, 134.4, 139.8. GC-MS m/z  : 118 (100), 93 (91), 
94 (54) 92 (50), 156 (12), 197 (9), 212 (5). Anal. Calcd for C14H16N2 (212.13): C, 79.21; H, 
7.60; N, 13.20. Found: C, 79.02; 7.63; N, 13.18. 
 
N
H N
Ph  
(S)-2-Phenyl-1-[(S)-1-(2-pyrrolyl)pentyl]aziridine (41b): 0.304 g, (92%); white solid, mp 
78.3-79.6 °C; [α]D20 +74.8 (c 0.7, CHCl3). IR (KBr): νmax = 3218, 3100, 3055, 2924, 2852, 
1461, 1388, 1135, 1096, 1029, 807, 744, 718, 699. 1H NMR (300 MHz, CDCl3): δ = 0.94 (t, J = 
6.7, 3 H), 1.36-1.38 (m, 6 H), 1.92 (d, J = 3.4, 1 H), 2.14 (d, J = 6.6, 1 H), 2.55 (dd, J = 3.4, J = 
6.6, 1 H), 2.76 (dd, J = 5.2, J = 7.8, 1 H), 6.01 (m, 1 H), 6.15 (q, J = 2.7, 1 H), 6.67 (dd, J = 1.7, 
J = 2.7, 1 H), 7.16-7.22 (m, 2 H), 7.24-7.34 (m, 3 H), 8.44 (bs, 1 H). 13C NMR (75 MHz, CDCl3): 
δ = 14.0, 22.8, 28.2, 36.4, 37.9, 40,1, 68.3, 105.4, 107.5, 116.6, 126.3, 126.8, 128.3, 133.1, 
140.0. GC-MS m/z: 106 (100), 118 (74), 1636 (62), 80 (51), 91 (34), 197 (16), 254 (10). Anal. 
Calcd for C17H22N2 (254.18): C, 80.27; H, 8.72; N, 11.01. Found: C, 80.35; H. 8.75; N, 11.00. 
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(S)-2-Phenyl-1-[(S)-2-phenyl-1-(2-pyrrolyl)ethyl]aziridine (41f): 0.341 g, (91%); white 
solid, mp 80.9-81.3 °C (pentane). [α]D20 +94.4 (c 0.3, CHCl3). IR (KBr): νmax = 3426, 3175, 
3107, 3059, 3026, 2976, 2917, 2832, 1494, 1454, 1396, 1125, 1100, 1030, 1014, 744, 725 
699. 1H NMR (300 MHz, CDCl3): δ 1.72 (d, J = 6.6, 1 H), 2.05 (d, J = 3.5, 1 H), 2.48 (dd, J = 
3.5, J = 6.6, 1 H), 3.80 (t, J = 6.5, 1 H),  3.14 (dd, J = 6.5, J = 13.1, 1 H), 3.22 (dd, J = 6.5, J = 
13.1, 1 H), 5.89 (m, 1 H), 6.11 (q, J = 2.7, 1 H), 6.62 (dd, J = 1.6, J = 2.7, 1 H), 7.15-7.22 (m, 5 
H), 7.26-7.35 (m, 5 H), 8.28 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 26.9, 38.5, 40.1, 43.9, 
69.9, 105.5, 107.6, 126.2, 126.9, 128.1, 128.3, 129.7, 132.4, 138.6, 139.9. GC-MS m/z: 168 
(100), 169 (94), 197 (66), 118 (60). Anal. Calcd for C20H20N2 (288.16): C, 83.30; H, 6.99; N, 
9.71. Found: C, 83.42; H. 7.01; N, 9.68. 
4.3.6 - Preparation of the amines 43b,c,e through the imines 42b,c,e. 
 
The phenylglycinol derivative 35b (0.136 g, 0.5 mmol) and a 40% solution of MeNH2 in H2O 
(0.6 mL) were dissolved in THF (5 mL). Then a solution of H5IO6 (0.400 g) in H2O (5 mL) was 
added dropwise. After stirring for 1 h at room temperature, most of the solvent was 
evaporated at reduced pressure and the organic materials were extracted with Et2O (3 × 20 
mL). The collected ethereal layers were dried over Na2SO4 and concentrated to leave the 
intermediate imine 42b. This was dissolved in MeOH and NaBH4 (0.75 mmol, 0.028 g) was 
added at 0 °C After 1 h the mixture was quenched with H2O (5 mL), and the mixture was 
concentrated to remove most of the MeOH, then the organic materials were extracted with 
Et2O (3 × 20 mL). The collected ethereal layers were dried over Na2SO4 and concentrated 
to leave a yellow oil which was subjected to flash-chromatography on a SiO2 column eluting 
with a 8:2 cyclohexane/ethyl acetate mixture to give the compound 43b (0.39 mmol,) as 
yellow oil. 
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(S)-N-[1-(2-Pyrrolyl)butyl]benzaldimine (42b): 0.117 g, (93%), >90% pure; brown oil. 1H 
NMR (300 MHz, CDCl3): δ = 0.98 (t, J = 6.4, 3 H), 1.32 (m, 4 H), 1.94 (m, 2 H),  4.44 (t, J = 
6.6, 1 H), 6.09 (m, 1 H), 6.18 (q, J = 2.9, 1 H), 6.74 (m, 1 H),  7.45 (m, 3 H), 7.79 (m, 2 H), 8.32 
(s, 1 H), 8.57 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 160.6, 136.0, 134.0, 130.7, 128.5, 128.2, 
116.6, 108.0, 104.3, 68.7, 32.3, 28.5, 22.5, 14.0. GC-MS m/z: 106 (100), 80 (60), 136 (56), 183 
(56), 93 (16), 240 (7). 
 
N
H N
Ph  
(S)-N-[2-Methyl-1-(2-pyrrolyl)propyl]benzaldimine (42c): 0.096 g, (85%); white solid; mp 
= 135.2-135.8 °C (pentane). [α]D20 −31.2 (c 0.7, CHCl3). IR (neat): νmax = 3457, 3249, 2964, 
2868, 2825, 1634, 1447, 1383, 1096, 1012, 725, 696. 1H NMR (300 MHz, CDCl3): δ = 0.92 (d, 
J = 6.7, 3 H), 0.96 (d, J = 6.7, 3 H), 2.12 (dsept, J = 6.6, J = 6.7, 1 H), 4.14 (d, J = 6.6, 1 H), 
6.06 (m, 1 H), 6.19 (q, J = 2.9, 1 H), 6.74 (q, J = 2.6, 1 H),  7.44 (m, 3 H), 7.79 (m, 2 H), 8.31 
(s, 1 H), 8.60 (bs, 1 H). 13C NMR (75 MHz, CDCl3): δ = 160.6, 136.2, 133.1, 130.6, 128.5, 128.2, 
116.3, 107.8, 104.8, 75.2, 35.2, 19.4, 19.2. GC-MS m/z: 183 (100), 104 (51), 121 (36), 80 (32), 
156 (6), 226 (3). Anal. Calcd for C15H18N2 (226.15): C, 79.61; H, 8.02; N, 12.38. Found: C, 
79.31; H, 8.05; N, 12.35. 
 
N
H N
Ph  
(S)-N-[1-(2-Pyrrolyl)-3-buten-1-yl]benzaldimine (42e): isolated impure as a brown oil in 
86% yield (0.096). Relevant absorptions for structural identification of the main compound 
were drawn from the 1H NMR spectrum (300 MHz, CDCl3): δ = 2.68 (m, 2 H), 4.51 (dd, J = 
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 6.3, J = 7.6, 1 H), 5.11 (m, 2 H), 5.80 (m, 1 H), 6.06 (m, 1 H), 6.17 (q, J = 3.2, 1 H), 6.75 (m, 1 
H), 7.42 (m, 3 H), 7.77 (m, 2 H), 8.30 (s, 1 H), 8.61 (bs, 1 H). 
N
H HN
Ph  
(S)-Benzyl-1-(2-pyrrolyl)pentylamine (43b): 0.094 g (78%); yellow oil. [α]D20 −26.5 (c 0.6, 
CHCl3). IR (neat): νmax = 3432, 3376, 3297, 3062, 3027, 2955, 2928, 2857, 1494, 1453, 
1092, 1026, 792, 717. 1H NMR (300 MHz, CDCl3): δ 0.91 (t, J = 6.8, 3 H), 1.32 (m, 4 H), 1.73 
(m, 2 H), 2.11 (bs, 1 H), 3.65 (d, J = 13.4, 1 H), 3.74 (d, J = 13.4, 1 H), 3.80 (t, J = 7.0, 1 H),  
6.09 (m, 1 H), 6.20 (q, J = 2.7, 1 H), 6.79 (m, 1 H), 7.31-7.39 (m, 5 H), 8.69 (bs, 1 H). 13C NMR 
(75 MHz, CDCl3): δ 14.0, 22.6, 28.3, 36.4, 51.4, 55.9, 106.1, 107.7, 116.6, 126.9, 128.1, 128.4, 
133.7, 140.4. Anal. Calcd for C16H22N2 (242.18): C, 79.29; H, 9.15; N, 11.56. Found: C, 79.06; 
H, 9.16; N, 11.53. 
 
N
H HN
Ph  
(S)-Benzyl-[2-methyl-1-(2-pyrrolyl)propyl]amine (43c): 0.087 g, (76%), yellow oil; [α]D20 
−37.6 (c 0.8, CHCl3). IR (NuJol): νmax = 3430, 3371, 3062, 3024, 2953, 2922, 2853, 1491, 
1022, 794. 1H NMR (300 MHz, CDCl3): δ = 0.83 (d, J = 6.7, 3 H), 0.95 (d, J = 6.7, 3 H), 1.87 
(sept, J = 6.7, 1 H), 3.52 (d, J = 5.8, 1 H), 3.58 (d, J = 13.1, 1 H), 3.71 (d, J = 13.1, 1 H), 6.04 
(m, 1 H), 6.15 (m, 1 H), 6.76 (m, 1 H), 7.25-7.38 (m, 5 H), 8.58 (bs, 1 H). 13C NMR (75 MHz, 
CDCl3): δ = 18.8, 19.7, 33.9, 52.0, 62.1, 106.9, 107.7, 116.2, 126.9, 128.1, 128.4, 131.1, 140.6, 
150.9. Anal. Calcd for C15H20N2 (228.16): C, 78.90; H, 8.83; N, 12.27. Found: C, 79.10; H, 8.85: 
N, 12.26. 
 
N
H HN
Ph  
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 (S)-Benzyl-[1-(2-pyrrolyl)-3-buten-1-yl]amine (43e): yellowish oil, 0.081 g, (72%). [α]D20 -
13.9 (c 1.2, CHCl3). IR (NuJol): νmax 3430, 3373, 3292, 3065, 2957, 2922, 2853, 1499, 
1454, 797. 1H NMR (300 MHz, CDCl3): δ = 2.04 (bs, 1 H), 2.53 (m, 2 H), 3.66 (d, J = 13.2, 1 H),  
3.77 (d, J = 13.2, 1 H),  3.90 (t, J = 5.5, 1 H), 5.16 (m, 2 H), 5.82 (m, 1 H), 6.12 (m, 1 H), 6.22 
(dq, J = 2.7, J = 5.5, 1 H), 6.79 (m, 1 H), 7.30-7.41 (m, 5 H), 8.72 (bs, 1 H). 13C NMR (75 MHz, 
CDCl3): δ = 41.2, 51.1, 54.7, 105.6, 107.9, 116.6, 117.8, 126.9, 128.0, 128.4, 133.5, 135.1, 140.3. 
Anal. Calcd for C15H18N2 (226.15): C, 79.61; H, 8.02; N, 12.38. Found: C, 79.91; H, 8.05: N, 
12.36. 
4.3.7 - Preparation of the α-substituted benzamides 44a,b,e,f. 
The valinol derivative 36b (0.238 g, 1.1 mmol) and a 40% solution of MeNH2 in H2O (1.3 mL, 17 
mmol) were  dissolved in THF (5 mL), then a solution of H5IO6 (0.907 g, 4.0 mmol) in H2O (5 
mL) was added dropwise and the mixture was stirred for 2 h at room temperature. The 
organic materials were extracted with Et2O (3 × 20 mL), then the collected ethereal layers 
were washed with brine, dried over Na2SO4 and concentrated to leave the primary amine as a 
yellow oil. This was dissolved in acetone (5 mL), then H2O (5 mL), K2CO3 (0.304 g, 2.2 mmol) 
and benzoyl chloride (191 μl, 1.7 mmol) were added while magnetically stirring. After 12 h 
most of the solvent was evaporated at reduced pressure, and the organic materials were 
extracted with Et2O (3 × 20 mL). The collected ethereal layers were dried over Na2SO4 and 
concentrated to leave a white solid, which was crystallized from acetone to give pure 44b. 
 
N
H NHCOPh  
(S)-N-[1-(2-Pyrrolyl)ethyl)]benzamide (44a): 0.203 g, (86%); white solid, mp 167.9-168.5 
°C. [α]D20 −74.1 (c 0.8, CHCl3). IR (KBr): νmax = 3396, 3312, 2925, 1853, 1625, 1578, 1524, 
1331, 1083, 1031, 736, 717, 655. 1H NMR (300 MHz, CDCl3): δ = 1.69 (d, J = 7.0, 3 H), 5.34 
(qd, J = 7.0, 1 H), 6.12 (m, 2 H), 6.33 (d, J = 7.0, 1 H), 6.75 (m, 1 H), 7.72-7.78 (m, 5 H), 9.36 
(bs, 1 H). 13C NMR (75 MHz, Cl3): δ 18.3, 43.0, 104.1, 107.3, 117.9, 126.9, 128.6, 131.7, 134.0, 
134.3, 168.0. GC-MS m/z: 105 (100), 77 (74), 93 (55), 214 (46), 121 (24), 199 (18). Anal. Calcd 
for C13H14N2O (214.11): C, 72.87; H, 6.59; N, 13.07. Found: C, 73.03; H, 6.58; N, 13.05. 
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N
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(S)-N-[1-(2-Pyrrolyl)pentyl)]benzamide (42b): 0.247 g (88%); white solid, mp 137.5-138.2 
°C. [α]D20 −90.7 (c 0.8, CHCl3). IR (KBr): νmax = 3336, 2957, 2927, 2856, 1625, 1533, 1337, 
12643, 1091, 1029, 801, 722. 1H NMR (300 MHz, CDCl3): δ = 0.95 (t, J = 5.2, 3 H), 1.47 (m, 4 
H), 1.96 (m, 1 H), 2.15 (m, 1 H), 5.17 (dt, J = 6.1, J = 8.3, 1 H), 6.08 (m, 1 H), 6.12 (q, J = 2.9, 1 
H), 6.26 (d, J = 8.3, 1 H), 6.73 (m, 1 H), 7.39-7.55 (m, 5 H), 9.18 (bs, 1 H). 13C NMR (75 MHz, 
CDCl3): δ = 13.9, 22.4, 28.7, 32.4, 47.5, 104.1, 107.4, 117.6, 126.9, 128.5, 131.6, 133.6, 134.1, 
168.1. GC-MS m/z  : 105 (100), 106 (97), 77 (61), 199 (42), 135 (36), 121 (27), 256 (11). Anal. 
Calcd for C16H20N2O (256.16): C, 74.97; H, 7.86; N, 10.93. Found: 74.76; H, 7.89; N, 10.89. 
 
N
H NHCOPh  
(S)-N-[1-(2-Pyrrolyl)-3-buten-1-yl)]benzamide (44e): 0.217 g, (82%); white solid, m.p. 
122.3-122.8 °C (Et2O). [α]D20 −53.7 (c 2.1, CHCl3). IR (NuJol): νmax = 3320, 3081, 3001, 
2922, 2853, 1626, 1577, 1529, 1489, 1292, 720, 691. 1H NMR (300 MHz, CDCl3): δ = 2.83 (m 
2 H), 5.22 (m, 2 H), 5.25 (m, 1H), 5.95 (m, 1 H), 6.10 (m, 1 H), 6.14 (q, J = 2.9, 1 H), 6.52 (d, J 
= 6.9, 1 H), 6.74 (m, 1 H), 7.37-7.46 (m, 3 H), 7.47-7.54 (m, 2 H), 9.39 (bs, 1 H). 13C NMR (75 
MHz, CDCl3): δ = 36.9, 46.6, 104.5, 107.4, 117.8, 118.4, 126.9, 128.5, 131.6, 132.7, 134.0, 134.4, 
168.1. GC-MS m/z  : 105 (100), 77 (51), 199 (46), 118 (42), 240 (6). Anal. Calcd for C15H16N2O 
(240.13): C, 74.97; H, 6.71; N, 11.66. Found: C, 75.16; H, 6.70; N, 11.68. 
 
N
H NHCOPh
Ph
 
(S)-N-[2-Phenyl-1-(2-pyrrolyl)ethyl)]benzamide (44f): 0.278 g (87%); white solid, mp 
115.5-116.4 °C (cyclohexane:CH2Cl2 9:1). [α]D20 −61.8 (c 0.8, CHCl3). IR (KBr): νmax = 3056, 
2925, 2676, 1690, 1622, 1532, 1423, 1291, 1174, 1042, 1017, 935, 804, 778, 707. 1H NMR 
(300 MHz, CDCl3): δ = 3.26 (dd, J = 9.8, J = 14.2, 1 H), 3.48 (dd, J = 5.7, J = 14.2, 1 H), 3.96 
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(ddd, J = 4.3, J = 8.3, J = 9.8, 1 H), 6.10 (q, J = 2.7, 1 H), 6.14 (m, 1 H), 6.27 (d, J = 8.3, 1 H), 
6.72 (m, 1 H), 7.17-7.38 (m, 3 H), 7.69-7.50 (m 3 H), 7.51-7.64 (m, 4 H), 9.35 (bs, 1 H). 13C 
NMR (75 MHz, Cl3): δ = 38.8, 48.8, 104.6, 107.5, 118.0, 126.8, 128.5, 128.6, 128.7, 129.0, 
130.2, 131.7, 133.7, 168.5. GC-MS m/z: 105 (100), 168 (56), 199 (55), 169 (52), 77 (48), 121 
(15). Anal. Calcd for C19H18N2O (290.14): C, 78.59; H, 6.25; N, 9.65. Found: C, 78.14; H, 6.27; 
N, 9.62. 
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 Chap. 5 – Asymmetric Synthesis of              
8-Aminoindolizidine from Chiral 2-Pyrroleimines 
N
NH2H
n NH
N Aux*
 
5.1 – Introduction 
7-Aminopirrolizidine 1a1,2, and 8-aminoindolizidine 1b (Scheme 1)1 and their ring-
substituted derivatives are relatively unexplored classes of compounds, despite their 
presence in nature and their potential activity as glycosidase inhibitors and Anti-HIV drugs. 
Some examples are the alkaloid (+)-absouline (2),2,3 laburnamine (3),2,4 and the 
compound 4,5 a selective serotonin agonists versus the subunit receptor 5-HT4. Another 
example are the mitomycine antibiotics, among which mitomycine C (5) is clinically used as an 
antitumor agent.6 A derivative of racemic 8-amino-8a-phenylindolizidine (6) was prepared as 
an analogue of the substance P antagonist CP 99,994, but it displayed low biological activity.7 
Finally, some oligonucleotides containing interchain cross-links of bifunctional pyrrole (7) 
were synthesized by Harris and co-workes.8 
 
N
NH2H
N
NH2H
1a,
Aminopirrolizidine
1b,
Aminoindolizidine
 
Scheme 1 
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Also 3-oxo-8-aminoindolizidine (8) has been considered a constrained analogue of 
bioactive peptides and substitutes of β-turns (Scheme 3).9 
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Scheme 3 
Pyrroles have been used as building blocks for the stereoselective synthesis of 
indolizidines, as the heteroaromatic ring can be hydrogenated to pyrrolidine, and the six 
membered ring was constructed by diverse cyclization strategies.10 For example, Smith and 
co-workers prepared racemic pheromone mormorine 11 by hydrogenantion of compound 10.11 
The first step involved the ring opening of γ-valerolactone by the potassium salt of pyrrole, 
then O-alkylation with methyl iodide, gave the product 9. The compound was converted by a 
three step sequence to the bicyclic pyrrole ketone 10, was hydrogenation finally gave 
racemic mormorine 11. 
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Pereira12 reported the synthesis of (-)-indolizidine 167B (14) by cyclization of the 
optically pure amide 12 with boron tribromide. The ketone 13 was then reducted to give the 
alkaloid with good yield (Scheme 5). 
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EtOH, H2O
 
Scheme 5 
Another enantioselective synthesis of (-)-indolizidine 167B (14)13 involved a Rh-
catalyzed intramolecular cyclization of the diazocompound 15 to give the ketone 16, which 
was hydrogenated to give 14.  
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7-Alkyl-8-aminoindolizidines have been synthesized by intramolecular imino-ene 
reactions of (L)-1-(3-alkene-1-yl)prolinal imines, so forming the fused six-membered ring 
(Scheme 7).14 Certainly, this procedure is advantageous because two C-C bonds are formed in 
a single step and the reduction of the pyrrole ring is avoided. However, it should be noticed 
that it allows formation only of the diastereomers with the retained configuration of the 
stereocenter present in the "ex chiral pool" starting material, which is also not readily 
available. 
 
N
N
H
Bn
N
NH
Ph
TiCl4
CH2Cl2
95%  
Scheme 7 
 
On the other hand, an approach which exploit the double reactivity of the chiral 2-
pyrroleimine derived by an optically active amine, acting as a chiral auxiliary available in both 
the enatiomeric form as depicted in Scheme 8, would allow in principle to synthesize all the 
four possible diastereomers of 8-aminopirrolizidine 1a and 7-aminopirrolizidine 1b. 
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Scheme 8 
 
The route we have envisioned takes advantage of the electrophilic reactivity of the 
imine function and nucleophilicity of the pyrrole nitrogen atom, allowing the easy preparation 
of the crucial intermediate 18. Ring closing methatesis (RCM) to construct the bicyclic 
skeleton of fused pyrrole derivatives 17, which can be subsequently hydrogenated to give 
the fully saturated compounds 1.15 The crucial intermediates 18 are in turn obtained by 
addition of an unsaturated organometallic reagent to the 2-pyrroleimine bearing a chiral 
auxiliary at the imine nitrogen and an alkenyl group at pyrrole nitrogen 19. In principle, 
diversely sized rings can be constructed in the RCM step, depending on the nature of the 
either pyrrole N-substituent and the organometallic reagent, i.e. by varying "n" and "m" in 
the intermediate 18. Particularly, a five membered ring is formed when n = m = 0, and a six-
membered ring by choosing n = 1, m = 0, or vice versa. All the routes appeared viable at first 
glance, as we previously described the highly diastereoselective addition of various 
organometallic reagents to chiral 2-pyrrole imines derived from (S)-valinol and (S)-
phenylglycinol, having unprotected or trimethylsilyl-protected OH and NH functions.16  
 
5.2 - Results and discussion 
5.2.1 - Addition of organometallic reagents to chiral pyrrole imines derived from 1(S)-valinol 
and (S)-phenylglycinol 
We started our research by routinely preparing with high yields the 1-allyl-2-
pyrroleimines 21a and 21b from 1-allyl-2-pyrrolealdehyde (20), 16 as desribed in Scheme 9. 
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Scheme 9 
 
The OH-free imines 21a,b were treated with variable amount of allylmagnesium 
chloride in THF at 0 °C (Scheme 10) and the results reported in Table 1 
 
Scheme 10 
N
R
N OH
N
H
R
N OH
N
H
R
N OH
+
22a,b 23a,ba: R = i -Prb: R = Ph
AllylMgCl
THF
21a
21b  
Table 1 
Entry Imine 
AllylMgCl  
(equiv.) 
Time 
(h) 
Ratio 
22/23[c] 
22 + 23  
(Yield %)[b] 
23  
(Yield %)[c] 
1 21a 2.5 48 53:47 98 23a (-[d]) 
2 21a 3 24 24:76 97 23a (66) 
3 21a 4 24 0:100 98 23a (92) 
4 22b 4 24 0:100 98 23b (96) 
[a] Determined by 1H NMR analysis. [b] Yield of crude product. [c] Yield of isolated, pure product. [c] 
The product was not isolated. 
 
Unexpectedly, in the first reaction run on the imine 21a, using only a slight exess of 
Grignard reagent (2.2 equivalents), a 53:47 mixture of two isomeric amines were obtained, as 
evidenced by 1H NMR analysis of the crude product. The major isomer was identified as the 
expected product (22a) on the basis of the 1H NMR spectrum, whereas the minor one (23a) 
was supposed to have an isomerized propenyl substituent on the pyrrole nitrogen. The base-
promoted isomerisation was attributed to the action of the Grignard reagent in excess 
amount (Scheme 11), hence the reaction was carried out with increased amounts of 
 
-158-
 allylmagnesium chloride in order to optimize the yield of compound 23a, because this 
compound has the required 1,7-octadiene moiety for the construction of a six-membered ring 
by the RCM methodology. The results of this investigation are reported in Table 1. 
 
N N
MgCl
NClMg
1'
3'
N
H2O
MgCl
 
Scheme 11 
 
Thus, it was observed that by increasing the amount of the Grignard reagent a 
corresponding increased conversion of 22a to 23a occurred (entries 2 and 3) and the 
complete conversion was achieved using 4 equivalents of allylmagnesium chloride (entry 4). 
The 1H NMR spectrum of the crude product, obtained in 98% yield, showed the presence of 
only one diastereomer, concerning both the newly formed stereocenter and the alkene 
geometry, which was determined as Z on the basis of the coupling constant of the vinylic 
protons. On the other hand, GC-MS analysis could not be used to determine the purity and 
diastereomeric ratio of 23a,b,17 as the products were not eluted or underwent massive 
decomposition. The pure product 23a was then obtained with 92% yield by chromatography 
an a SiO2 column. However, we found that the crude compound could be used without 
purification in the successive step. Similarity in the same conditions, the imine 21b was 
converted to the homoallylic amine 23b with complete selectivity and excellent yield.  
 
5.2.2 – Protection of amino function and RCM reaction 
Before performing the RCM step, it was necessary to protect the amino function. As 
acidic conditions are not suitable in the presence of the pyrrole ring, we chose to convert the 
β-aminoalcohol moiety of 23a,b into an oxazolidinone and prepared the compound 24a,b by 
routine reactions with triphosgene (Scheme 12). 
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Scheme 12 
The reaction performed on the amine 23a using carbonyldiimidazole (CDI) as reagent 
(Scheme 13) gave a mixture of the desired product 24a and the aziridine 25, which were 
isolated with 88% and 5% yields, respectively, by column chromatography. 
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Scheme 13 
Moreover, other derivatives of compounds 23a,b, with protected amino function were 
prepared (Scheme 14). Particularly, we removed the auxiliary group by common oxidative 
procedures and transformed the primary amines 26 into the corresponding benzamide 27 or 
N-Boc derivate 28. 
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Scheme 14 
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 On this compounds the RCM step was investigated, exploring the effectiveness of 
first generation and second generation Grubbs catalysts (ruthenium benzylidene complexes I 
and II, respectively Scheme 15). 
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I
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Scheme 15 
The results obtained, reported in Table 2, showed that both catalysts can be used to 
that purpose, although II was more effective and allowed the reaction to reach completion  
in less time than I: 0.5 h vs 4 h in dichloromethane at the reflux temperature, using 5 mol% 
both catalyst (entries 1 and 2). Moreover, the same high yields of bicycling product 30a 
could be obtained using catalyst II in toluene at 115 °C for 0.5 h with 5 mol% loading (entry 
3) and in dichloromethane at 40 °C for 1.5 h with 2.5 mol% loading (entry 4). By further 
decreasing the catalyst loading to 1 mol%, the reaction time was increased to 4 h achive the 
same high yield (entry 5). The latter conditions were then applied to the diene 30b to obtain 
the same efficient ring closing to give 30b (entry 6). 
 
Scheme 16 
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 Table 2 
Entry Compound 
Grubbs cat. 
(mol%) 
Solvent Temp. (°C) 
Time 
(h) 
Product  
(Yield %)a 
1 29a I (5.0) CH2Cl2 40 4 30a (93) 
3 29a II (5.0) CH2Cl2 40 0.5  30a (94) 
2 29a II (5.0) Toluene 115 0.5 30a (95) 
4 29a II (2.5) CH2Cl2 40 1.5 30a (94) 
5 29a II (1.0) CH2Cl2 40 4 30a (95) 
6 29b II (1.0) CH2Cl2 40 4 30b (96) 
[a] Yield of isolated, pure product. 
 
The compounds 27 and 28 were also submitted to RCM using 1 mol% of Grubbs 
catalyst II in reflux dichloromethane and the corrisponding bicyclic products (32 and 32) 
were obtained with good yields (Scheme 17). 
N
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O
 
Scheme 17 
5.2.3 – Hydrogenation of the pyrrole ring 
Finally, we directed our efforts to the hydrogenation of the unsaturated bicyclic 
compounds 30a,b, 31 and 32. Hydrogenation of only the alkene function of 30a,b to give 
33a,b was easily achieved by stirring a solution of 30a,b in methanol under 1 atm H2 in the 
presence of 10% Pd/C for 2 hours. However we were interested to achieve the fully 
saturated, indolizidine derivatives. 
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Scheme 18 
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 Literature survey showed that substituted pyrroles can be hydrogenated to give 
pyrrolidine derivatives in the presence of palladium, platinum and rhodium heterogeneous 
catalysts.10,18 We have carried out reaction on 30a using 10% Pd/C, 10% Pd(OH)2/C, PtO2, 
most frequently using methanol as the solvent, and the resulta are reported in Table 3. In all 
cases, mixtures of three diastereomers were formed with poor diastereoselectivity, as 
evinced by GC-MS analyses of the crude products (Scheme 19). 
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Scheme 19 
By assuming that hydrogen addition took plan to both the pyrrole faces and the 
stereocenter present in the six-membered ring is uninfluenced in the reaction condition only 
two stereoisomers should be observed. A third stereoisomer should be formed by a 
mechanism involving stepwise reduction of the pyrrole ring to give pirrolines (35) which 
undergo isomerization by migration of the C=C bond to the six-membered ring. The 
intermediate 36 is the obtained, causing loss of the pre-existing stereocenter, than uptake 
of hydrogen can occur on both faces leading two either (R,R)-34 and (S,S)-34 (Scheme 20). 
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Scheme 20 
Fortunately the three diasteroisomers could be separated, cromatographically at lest 
in part and suitable crystals were obtained for two isomers allowing structurely 
identification by X-Ray analysis. So, we could assigned the (S,S), (S,R) configurations of the 
stereocenters in bicylclic skeleton of two diateroisomers, the first and third eluted in GC 
analysis (Figure 1). 
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Figure 1 (R,S)-34 and (S,S)-34 
 
The results are several reports of analogous hydrogenation of, chiral pyrroles having 
stereocenters at the benzylic position. It is noteworthy that (S,R)-34 was the minor one 
when the reaction was performed at 1 atm of H2 in the presence of 10% Pd/C, even in the 
presence of acetic acid (entries 1 and 2). Instead, it was the major diastereomer when 10% 
Pd(OH)2/C was used, although at low conversion of 30a (entry 3). Aiming to improve the yield 
of saturated products, hydrogenation was carried out at higher pressure (8 atm of H2) and in 
the presence of acetic acid, and in these conditions a mixture of the three diastereomers 
was again obtained in quantitative yield (entry 4). The addition of 1M solution of 
hydrochloridric acid in diethyl ether to the MeOH improved the rate of the reaction and a 
complete conversion was observed at 1 atm H2 after 24 hours (entry 5). The Adam catalyst 
(PtO2, 10 mol%) proved to be ineffective, as only 10% conversion was observed after 48 h in 
MeOH (entry 6). 
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 Table 3 
Entry Catalyst (%) Solvent 
t 
(h) 
P H2 
(atm) 
Conversion 
(%)[a] 
(S,S)-34 
(%)[a] 
(R,R)-34 
(%)[a] 
(S,R)-34 
(%)[a] 
1 10% Pd/C (20%) MeOH 48 1 100 43 42 15 
2 10% Pd/C (20%) 
MeOH-
AcOH(20%) 24 1 100 38 47 15 
3 
20% 
Pd(OH)2/C 
(20%) 
MeOH 48 1 30 16 11 73 
4 
20% 
Pd(OH)2/C 
(20%) 
MeOH-
AcOH(20%) 24 8 100 24 28 48 
5 
20% 
Pd(OH)2/C 
(20%) 
MeOH-1 M 
HCl in Et2O 
(20%) 
24 1 100 54 32 14 
6 PtO2 (10%) MeOH 48 1 10 14 14 72 
[a] Determined by GC-MS analysis. 
 
Then we tested rhodium-based catalysts for the hydrogenation of pyrrole ring. 5%-
Rh/Al2O3 gave more satisfactory results (Table 4), as mixture of only (S,S)-34 and (S,R)-34 
was quantitatively formed with a moderate prevalence of the latter compound (entry 1, Table 
4). An increase of their ratio (74:26) was obtained in MeOH at 8 atm hydrogen pressure 
(entry 2), whereas substitution of methanol by ethyl acetate gave a slightly less satisfactory 
conversion and diastereoselectivity (entry 3). The use of DMF as solvent increased markedly 
the diasteroselectivity (d.r. 93:7), but had a negative effect on the rate of the reaction 
(entry 4). When the reaction was carried out using a 1:1 MeOH:DMF mixture we observed an 
increase of rate of the reaction with almost the same disteroselectivity rate (entry 5). No 
reaction occurred when 0.5M of K2CO3 was added to MeOH (entry 6); instead the addition of 
triethyl amine (20 mol%) slightly increase the disteroselectivity but slowly the rate of 
reaction (entry 7). 
We also prepared Rh-graphite from potassium graphite (C8K) and RhCl3. We were 
delighted to observe that this new catalyst was fairly more reactive that Rh/Al2O3 and gave 
the indolizidine 34 after only 11 hours with comparable diasteroselectivity. 
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Table 4 
Entry Catalyst (%) Solvent 
t 
(h) 
P H2 
(atm) 
Conversion 
(%) 
(S,S)-
34 (%) 
(R,R)-
34 (%) 
(S,R)-
34 (%) 
1 5% Rh/Al2O3 (10%) MeOH 24 1 100 31 0 69 
2 5% Rh/Al2O3 (10%) MeOH 24 8 100 26 0 74 
3 5% Rh/Al2O3 (10%) AcOEt 24 8 96 40 0 60 
4 5% Rh/Al2O3 (10%) DMF 72 1 30 7 0 93 
5 5% Rh/Al2O3 (20%) 
DMF:MeOH 
1:1 72 1 70 10 0 90 
6 5% Rh/Al2O3 (10%) 
MeOH-H2O 
(10%)-K2CO3 
72 1 0 - - - 
7 5% Rh/Al2O3 (10%) 
MeOH-
TEA(20%) 72 1 100 22 0 78 
9 26% Rh-Graphite (1,5%) MeOH 11 1 100 39 0 61 
10 26% Rh-Graphite (1,5%) 
MeOH-
TEA(20%) 72 1 100 24 0 76 
[a] Determined by GC-MS analysis. 
 
The same protocol was applied to the phenylglicinol derivate 30b. Using Pd/C and 
Rh/Al2O3 in MeOH we observed a complex a mixture of compounds. Accurate GC-MS analyse, 
demonstrated that hydrogenation of the phenyl ring had partially occurred. Only when the 
reaction was carried out in the presence of acetic acid the fully hydrogenated products (37) 
where only observed being formed with moderate diasteroselectivity. Substitution of 
methanol by acetonitrile gave hydrogenation of the only alkene function. The configuration of 
products was confirmed by X-Ray analysis of (S,R)-37 (Figure 2). 
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 Table 5 
Entry Catalyst (%) Solvent 
t 
(h) 
P H2 
(atm) 
Conversion 
(%)[a] 
(S,S)-
37 (%)[a] 
(R,R)-
37 (%)[a] 
(S,R)-
37 (%)[a] 
1 10% Pd/C (20%) MeOH 48 1 -[b] - - - 
2 5% Rh/Al2O3 (10%) MeOH 48 1 -
[b] - - - 
3 5% Rh/Al2O3 (10%) 
MeOH-
AcOH(20%) 48 1 100 5 31 64 
4 5% Rh/Al2O3 (10%) 
MeOH-
AcOH(20%) 24 8 100 3 28 69 
5 5% Rh/Al2O3 (10%) MeCN 72 1 0
[c] - - - 
6 26% Rh-Graphite (1,5%) 
MeOH-
AcOH(20%) 24 1 100 5 29 66 
[a] Determined by GC-MS analysis. [b] Complex mixure of coumponds. [c] Only the product 33b was recoved with 
97% of yield. 
 
Figure 2 (S,R)-37 
 Hydrogenation of the amide 31 using 5%-Rh/Al2O3 afforted the products with 
saturation of all the aromatic rings (Scheme 22). We obtained two different separable 
diasteroisomers from the GC-MS analysis, but after chiral GC analysis, the compound (S,S)-
38 was present as mixture of enantiomers. The better results was obtained using MeOH as 
solvent under a 1 atm pressure of hydrogen (Table 6). 
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 Scheme 22 
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Table 6 
t (h) P H2 
(atm) 
Conversion 
(%)[a] 
(S,R)-38 
(%)[a] 
(S,S)-38 
(%)[a] 
e.e.(S,S)-38 
(%)[b] 
96 1 100 32 68 84 
24 8 100 38 62 88 
[a] Determined by GC-Ms analysis. [b] Determined by chiral GC analysis. 
 
With the same procedure N-Boc derivate 32 was hydrogenated to give two separable 
diasteroisomer, one of which was present as a mixture of enantiomers (S,S)-39 and (R,R)-39. 
 
N
H
N
O
OH
N
H
N
O
O
(S ,R )-39 (S ,S )-3932
H2 (1 atm)
5%Rh/Al2O3
+N
H
N
O
OH
MeOH
35% 67% (e.e. 91%)  
Scheme 23 
5.3 – Experimental section 
Melting points are uncorrected. Optical rotations were measured on a digital polarimeter in a 
1-dm cell and [α]D-values are given in 10−1 deg cm3 g−1. 1H NMR spectra were recorded on 
Varian Inova and Gemini instruments for samples in CDCl3 which was stored over Mg: 1H 
chemical shifts are reported in ppm relative to CHCl3 (δH 7.27), J-values are given in Hz. and 
in the assignments s = singlet, d = doublet, t = triplet, q = quartet, sept = septet, m = 
multiplet, bs = broad singlet, dd = doublet of doublets and dt = doublet of triplets. Infrared 
spectra were recorded on a Nicolet FT-380 spectrometer and IR assignments are reported 
in wavenumbers (cm−1). MS spectra were taken at an ionising voltage of 70 eV on a Hewlett-
Packard 5975 spectrometer with GLC injection. Analytical gas chromatography (GC) was 
performed on a Hewlett-Packard HP 6890 gas chromatograph  with a flame ionization 
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 detector and split mode capillary injection system, using a Megadex 5 chiral column (25 m, 
flow rate 15mL/min). Molecular weight was determined on an Agilent Technologies MS 1100 
instrument. Chromatographic separations were performed on columns of SiO2 (Merck, 230-
400 mesh) at medium pressure. All the organic, inorganic and organometallic reagents and 
reactants and anhydrous solvents were purchased from Aldrich. 
5.3.1 – Preparation of Aldehyde 20 
O
N
 
To a solution of 2-pyrrolecarbaldehyde (2.420 g, 25.4 mmol) in dioxane (40 mL) 
allylbromide was added (6.6 mL, 9.22 g, 76.2 mmol) and K2CO3 (12.30 g, 89.0 mmol) and the 
mixture was refluxed for 8 hours. Then the mixture was cooled at room temperature and 
cyclohexane (40 mL). The solid was filtered off through a pad of Celite and the organic 
phase was concentrated at reduced pressure. Flash column chromatography (SiO2) eluting 
with cyclohexane/ethyl acetate 9:1 mixtures gave the product 20 (89 %, 3.05 g, 22.6 mmol). 
1-allyl-2-pyrrolealdehyde (20): Red oil; IR (neat): ν = 3109, 3085, 2929, 2807, 2768, 2724, 
1662, 1479, 1405, 1369, 1317, 1218, 1075, 1030, 993, 924, 749, 609; 1H NMR (300 MHz, 
CDCl3): δ = 9.55 (d, J = 0.9 Hz, 1 H), 6.95 (m, 2 H), 6.26 (dd, J = 2.6 Hz, J = 3.9 Hz, 1 H), 5.99 
(m, 1 H), 5.18 (dd, J = 1.3 Hz, J = 2.7 Hz, 1 H), 5.15 (dd, J = 1.3 Hz, J = 2.7 Hz, 1 H), 5.08 (dd, 
J = 1.5 Hz, J = 3.2 Hz, 1 H), 4.98 (t, J = 1.7 Hz, 2 H), 4.96 (d, J = 1.5 Hz, 2 H); 13C NMR (75 
MHz, CDCl3): δ = 50.7, 109.7, 116.9, 124.4, 130.9, 131.2, 133.9, 179.1; MS (EI): m/z = 118 (100), 
134 (67), 106 (62), 135 (61), 79 (46). 
 
5.3.2 – General protocol for the preparation of imines 21a and 21b 
To a solution of (S)-phenylglycinol (1.50 g, 11.1 mmol) or (S)-valinol (1.14 g, 11.1 mmol) in 
anhydrous CH2Cl2 (40 mL) was added anhydrous MgS04 (5 g) and 5 (1.5 g, 11.1 mmol) and the 
mixture was stirred overnight. The solid was filtered off through a pad of Celite and the 
organic phase was concentrated at reduced pressure to gave the desire imine. 
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 N
N OH
 
(S)-N-(1-Allyl-2-pyrrolmethylidene)valinol (21a): Red oil; 2.39 g (98%); [α]D20 -101.5 (c 1.3, 
CHCl3); IR (neat): v = 3060, 3023, 2831, 1642, 1530, 1367, 1025, 920, 733; 1H NMR (300 
MHz, CDCl3): δ = 8.11 (s, 1 H), 6.77 (t, J = 2.1 Hz, 1 H), 6.53 (ddd, J = 0.6 Hz, J = 1.7 Hz, J = 
3.7 Hz,  1 H), 6.19 (dd, J = 2.7 Hz, J = 3.6 Hz, 1 H), 5.99 (ddd, J = 5.0 Hz, J = 5.2 Hz, J = 10.1 
Hz, 1 H), 5.14 (t, J = 1.4 Hz, 1 H), 5.10 (t, J = 1.7 Hz, 1 H), 5.03 (m, 2 H), 3.73 (d, J = 6.0 Hz, 2 
H), 2.80 (q, J = 6.0 Hz, 1 H), 2.08 (bs, 1 H), 1.87 (sept, J = 6.8 Hz, 1 H), 0.93 (d, J = 6.8 Hz, 3 
H), 0.86 (d, J = 6.8 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 19.5, 20.2, 30.7, 51.3, 65.2, 79.6, 
109.0, 116.2, 117.4, 128.5, 129.6, 135.9, 153.4; GC-MS (EI): m/z = 118 (100), 189 (34), 134 (26), 
117 (18), 205 (7), 220 (4). 
 
N
Ph
N OH
 
(S)-N-(1-Allyl-2-pyrrolmethylidene)phenylglycinol (21b): Red oil; 2.73 g (97%); [α]D20 -
126.3 (c 1.8, CHCl3); IR (neat): v = 3387, 3083, 3062, 3027, 2825, 2863, 1638, 1534, 1425, 
1371, 1310, 1031, 921, 733; 1H NMR (300 MHz, CDCl3): δ = 8.26 (s, 1 H), 7.29-7.44 (m, 5 H), 
6.82 (t, J = 2.1 Hz, 1 H), 6.58 (dd, J = 1.8 Hz, J = 3.8 Hz, 1 H), 6.33 (dd, J = 2.7 Hz, J = 3.8 
Hz, 1 H), 6.07 (ddd, J = 5.1 Hz, J = 10.3 Hz, J = 17.1 Hz, 1 H), 5.22 (ddt, J = 1.7 Hz, J = 5.2 
Hz, J = 16.0 Hz, 1 H), 5.17 (dq, J = 1.7 Hz, J = 10.3 Hz, 1 H), 5.03 (ddt, J = 1.7 Hz, J = 4.7 Hz, 
J = 16.0 Hz, 1 H), 4.93 (dq, J = 1.7 Hz, J = 17.1 Hz, 1 H), 4.36 (t, J = 6.4 Hz, 3 H), 3.86 (d, J = 
6.4 Hz, 2 H); 13C NMR (75 MHz, CDCl3): δ = 50.9, 68.0, 76.6, 108.5, 115.8,  117.7, 126.4, 127.1, 
127.3, 128.3, 128.8, 135.3, 141.1, 153.6; GC-MS (EI): m/z = 118 (100), 223 (92), 106 (41), 91 
(34), 79 (30), 239 (21), 254 (11). 
5.3.3 – General protocol for the preparation of β-Aminoalcohols 23a,b 
Allylmagnesium chloride (1.0 M in THF, 23.6 mL, 23.6 mmol) was added to a magnetically 
stirred solution of the imine 23b (1.50 g, 5.9 mmol) in THF (25 mL) cooled at 0 °C. After 30 
min the reaction mixture was slowly warmed up until room temperature was reached, and 
stirring was continued for 24 h. The mixture was quenched by adding a saturated aqueous 
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 solution of NaHCO3 (30 mL) at 0 °C, then the organic material was extracted with diethyl 
ether (3 ×20 mL). The collected ethereal layers were dried over Na2SO4 and concentrated to 
leave the crude product. Flash column chromatography (SiO2) eluting with cyclohexane/ethyl 
acetate 9:1 mixtures gave the product 24b. This compound decomposed on attempted GC-MS 
and HPLC-MS analyses. 
 
N
HN OH
 
(23a): Yellow oil; [α]D20 -27.3 (c 1.6, CHCl3); IR (neat): v =3326, 3062, 2918, 2864, 1662, 
1474, 1363, 1067, 915; 1H NMR (300 MHz, CDCl3): δ = 6.66 (dq, J = 1.8 Hz, J = 8.3 Hz, 1 H), 
6.62 (dd, J = 1.7 Hz, J = 2.8 Hz, 1 H), 6.16 (dd, J = 2.8 Hz, J = 3.6 Hz, 1 H), 6.16 (dd, J = 1.7 
Hz, J = 3.6 Hz, 1 H), 5.73 (m, 1 H), 6.16 (ddd, J = 7.0 Hz, J = 8.3 Hz, J = 14.1 Hz, 1 H), 5.06 
(m, 2 H), 3.85 (dd, J = 4.1 Hz, J = 4.7 Hz, 1 H), 3.56 (dd, J = 4.1 Hz, J = 10.7 Hz, 1 H), 3.37 
(dd, J = 4.7 Hz, J = 10.7 Hz, 1 H), 2.45 (tt, J = 1.2 Hz, J = 7.0 Hz, 2 H), 2.37 (m, 1 H), 2.16 
(bs, 2 H), 1.74 (dd, J = 1.8 Hz, J = 7.0 Hz, 3 H), 0.92 (d, J = 6.9 Hz, 3 H), 0.87 (d, J = 6.9 Hz, 
3 H); 13C NMR (75 MHz, CDCl3): δ = 12.5, 18.7, 19.6, 29.5, 41.2, 52.2, 59.9, 61.2, 106.2, 107.5, 
117.2, 121.2, 121.4, 126.1, 135.0, 135.3; MS (ES): m/z = 285.4 [M + Na]+, 160.2 [M - valinol]+. 
 
N
H
Ph
N OH
 
(23b): Yellow oil; [α]D20 -31.9 (c 1.5, CHCl3); IR (neat): v = 3407, 3077, 2957, 2872, 1662, 
1640, 1470, 1311, 1068, 917, 713; 1H NMR (300 MHz, CDCl3): δ = 7.22-7.44 (m, 5 H), 6.63 (dd, 
J = 1.7 Hz, J = 2.8 Hz, 1 H), 6.43 (dq, J = 1.6 Hz, J = 8.4 Hz, 1 H), 6.16 (t, J = 3.4 Hz, 1 H), 
5.63-5.83 (m, 1 H), 5.37 (ddd, J = 7.0 Hz, J = 8.4 Hz, J = 14.2 Hz, 1 H), 4.98-5.06 (m, 2 H), 
3.85 (dd, J = 4.5 Hz, J = 7.6 Hz, 1 H), 3.78 (t, J = 6.6 Hz, 1 H), 3.68 (dd, J = 4.5 Hz, J = 10.7 
Hz, 1 H), 3.50 (dd, J = 7.6 Hz, J = 10.7 Hz, 1 H), 2.49 (dd, J = 6.4 Hz, J = 7.0 Hz, 2 H), 2.26 
(bs, 2 H), 1.68 (dd, J = 1.8 Hz, J = 7.0 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 12.4, 39.1, 51.7, 
60.9, 65.7, 106.6, 107.4, 117.2, 120.7, 121.3, 125.8, 127.2, 127.5, 128.5, 134.1, 135.0, 141.0; MS 
(ES): m/z = 319.4 [M + Na]+, 160.1 [M - valinol]+. 
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 5.3.4 – General protocol for the preparation of Oxazolidinones 24a,b 
To a solution of β-aminoalcohol 23b (1.3 g, 4.4 mmol) in CH2Cl2 (20 mL) was added a 
saturated aqueous solution of NaHCO3 (10 mL), triphosgene (0.652 g, 2.2 mmol) at 0 °C, and 
the mixture was stirred overnight. The mixture was extracted with dichlorometane (3 ×20 
mL). The collected organic layers were dried over Na2SO4 and concentrated to leave the 
crude product. Flash column chromatography (SiO2) eluting with cyclohexane/ethyl acetate 
8:2 mixtures gave the product 24b (91 %, 1.290 g, 4 mmol). 
 
N
N
O
O
 
(24a): White solid; 93 % (0.785 g, 2.73 mmol) from 3.0 mmol (0.787 g) of 8a; mp = (77.3-
77.5)°C; [α]D20 -76.8 (c 1.0, CHCl3); IR (KBr): v = 3129, 3104, 2932, 2873, 1732, 1665, 1482, 
1412, 1230, 1070, 1049, 925, 745, 725, 626; 1H NMR (300 MHz, CDCl3): δ = 6.77 (dd, J = 1.6 
Hz, J = 2.8 Hz, 1 H), 6.48 (ddd, J = 1.7 Hz, J = 3.5 Hz, J = 8.2 Hz, 1 H), 6.2 (m, 2 H), 5.90 (m, 
1 H), 5.55 (ddd, J = 6.1 Hz, J = 8.4 Hz, J = 13.9 Hz, 1 H), 5.04-5.21 (m, 2 H), 4.00 (dd, J = 4.8 
Hz, J = 9.0 Hz, 1 H), 3.92 (dd, J = 8.2 Hz, J = 9.0 Hz, 1 H), 4.01 (ddd, J = 3.2 Hz, J = 4.9 Hz, 
J = 9.0 Hz, 1 H), 2.74-2.89 (m, 2 H), 1.98 (dsept, J = 3.3 Hz J = 6.9 Hz, 1 H), 1.76 (dd, J = 1.9 
Hz, J = 7.2 Hz, 1 H), 0.92 (d, J = 6.9 Hz, 3 H), 0.70 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, 
CDCl3): δ = 12.2, 13.6, 29.7, 37.6, 50.6, 58.3, 62.2, 107.3, 108.9, 117.5, 120.7, 122.5, 124.9, 
128.1, 134.5, 158.2; GC-MS (EI): m/z = 247 (100), 118 (67), 159 (38), 86 (25), 207 (16), 281 
(5). 
 
N
N
O
Ph O
 
(24b): Yellow oil; [α]D20 -83.9 (c 1.6, CHCl3); IR (neat): v = 3076, 3034, 2977, 2918, 2858, 
1746, 1663, 1476, 1403, 1218, 1070, 1045, 918, 702; 1H NMR (300 MHz, CDCl3): δ = 7.38 (m, 3 
H), 7.23 (m, 2 H), 6.84 (dd, J = 1.6 Hz, J = 2.8 Hz, 1 H), 6.58 (dq, J = 1.7 Hz, J = 8.4 Hz, 1 H), 
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 6.20 (t, J = 3.3 Hz, 1 H), 5.96 (ddd, J = 0.8 Hz, J = 1.5 Hz, J = 3.6 Hz, 1 H), 5.74 (dddd, J = 
6.1 Hz, J = 7.3 Hz, J = 10.2 Hz, J = 13.7 Hz, 1 H), 5.61 (ddd, J = 7.1 Hz, J = 8.4 Hz, J = 14.2 
Hz, 1 H), 5.14 (dd, J = 6.9 Hz, J = 7.0 Hz, 1 H), 5.01 (dq, J = 1.3 Hz, J = 10.2 Hz, 1 H), 4.89 
(dq, J = 1.5 Hz, J = 17.0 Hz, 1 H), 4.40 (t, J = 7.9 Hz, 1 H), 4.14 (dd, J = 7.9 Hz, J = 13.9 Hz, 1 
H), 4.09 (dd, J = 7.9 Hz, J = 13.6 Hz, 1 H), 2.18-2.28 (m, 1 H), 2.03-2.13 (m, 1 H), 1.84 (dd, J = 
1.8 Hz, J = 8.1 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 12.3, 36.5, 50.9, 57.7, 70.2, 107.2, 
109.6, 117.4, 120.7, 122.6, 125.2, 127.6, 128.5, 128.8, 134.3, 139.8, 158.0; GC-MS (EI): m/z = 
281 (100), 118 (66), 159 (25), 91 (24), 322 (2). 
 
5.3.5 – Preparation of benzamide 27 
The valinol derivative 23a (0.445 g, 1.7 mmol) and a 40% solution of MeNH2 in H2O 
(4.0 mL, 5.2 mmol) were  dissolved in MeOH (5 mL), then a solution of H5IO6 (1.40 g, 6.0 
mmol) in H2O (5 mL) was added dropwise and the mixture was stirred for 2 h at room 
temperature. The organic materials were extracted with Et2O (3 × 20 mL), then the 
collected ethereal layers were washed with brine, dried over Na2SO4 and concentrated to 
leave the primary amine 26 as a yellow oil. This was dissolved in acetone (5 mL), then H2O (5 
mL), K2CO3 (0.470 g, 3.4 mmol) and benzoyl chloride (296 μl, 2.6 mmol) were added while 
magnetically stirring. After 12 h most of the solvent was evaporated at reduced pressure, 
and the organic materials were extracted with Et2O (3 × 20 mL). The collected ethereal 
layers were dried over Na2SO4 and concentrated to leave a white solid, which was 
crystallized from acetone to give pure 27 (88%, 420 mg, 1.7 mmol). 
 
N
HN
O
 
(27):White crystals (from pentane:Et2O, 9:1); m.p. = (88.3-88.9) °C; [α]D20 -23.2 (c 0.9, 
CHCl3); IR (KBr): v =3287, 3076, 3040, 2939, 1662, 1631, 1578, 1528, 1477, 1306, 1076, 719, 
697; 1H NMR (300 MHz, CDCl3): δ = 7.72-7.78 (m, 2 H), 7.41-7.54 (m, 3 H), 6.67 (dd, J = 1.7 
Hz, J = 2.6 Hz, 1 H), 6.67 (dq, J = 1.8 Hz, J = 8.5 Hz, 1 H), 6.22 (ddd, J = 0.6 Hz, J = 1.7 Hz, 
J = 3.7 Hz,  1 H), 6.18 (dd, J = 2.7 Hz, J = 3.6 Hz, 1 H), 6.13 (d, J = 8.0 Hz, 1 H), 5.81-5.94 (m, 
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 1 H), 5.52 (dd, J = 7.1 Hz, J = 8.5 Hz, J = 14.1 Hz, 1 H), 5.41 (q, J = 7.0 Hz, 1 H), 5.15 (dq, J = 
1.5 Hz, J = 17.1 Hz, 1 H), 5.12 (ddd, J = 1.0 Hz, J = 2.0 Hz, J = 10.1 Hz, 1 H), 2.76 (m, 2 H), 
1.74 (dd, J = 1.8 Hz, J = 7.1 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 12.3, 39.0, 45.3, 106.6, 
107.5, 118.0, 121.1, 122.2, 125.5, 126.8, 128.5, 131.4, 132.3, 134.2, 134.4, 166.2; GC-MS (EI): 
m/z = 105 (100), 239 (77), 77 (44), 118 (14), 159 (12), 136 (9), 280 (2). 
 
5.3.6 – Preparation of NBoc derivate 28 
The phenylglycinol derivative 23b (0.500 g, 1.7 mmol) and a 40% solution of MeNH2 in 
H2O (2.2 mL, 5.8 mmol) were  dissolved in MeOH (5 mL), then a solution of H5IO6 (1.35 g, 
5.7 mmol) in H2O (5 mL) was added dropwise and the mixture was stirred for 2 h at room 
temperature. The organic materials were extracted with Et2O (3 × 20 mL), then the 
collected ethereal layers were washed with brine, dried over Na2SO4 and concentrated to 
leave the primary amine 26 as a yellow oil. This was dissolved in THF (5 mL), then a saturated 
solution of NaHCO3 (5 mL), and Boc2O (744 mg, 3.4 mmol) were added while magnetically 
stirring. After 2 h Et2O (10 mL) was added, and the organic materials were extracted with 
Et2O (3 × 20 mL). The collected ethereal layers were dried over Na2SO4 and concentrated 
to leave a white solid, which was crystallized from acetone to give pure 414 mg of 28 (1.5 
mmol, 91%). 
 
N
HN
O
O
 
(28):White crystals (from pentane); m.p. = (46.8-47.5) °C; [α]D20 -11.5 (c 0.7, CHCl3); IR 
(KBr): v = 3361, 2979, 2922, 2848, 1681, 1528, 1474, 1385, 1261, 1175, 1045, 1023, 712; ; 1H 
NMR (300 MHz, CDCl3): δ = 6.67 (s, 1 H), 6.61 (d, J = 8.1 Hz, 1 H), 6.12 (t, J = 3.0 Hz, 1 H), 
6.09 (s, 1 H), 5.77 (m, 1 H), 5.53 (q, J = 7.1 Hz, 1 H), 5.12 (d, J = 16.9 Hz, 1 H), 5.06 (d, J = 
10.7 Hz, 1 H), 4.78 (bs, 1 H), 4.63 (bs, 1 H), 2.57 (m, 2 H), 1.73 (d, J = 7.0 Hz, 3 H), 1.43 (s, 9 
H); 13C NMR (75 MHz, CDCl3): δ = 12.4, 28.3, 39.4, 46.4, 79.1, 106.0, 107.3, 117.5, 120.9, 121.7, 
125.6, 132.9, 134.3, 154.8; GC-MS (EI): m/z = 179 (100), 235 (28), 135 (26), 118 (25), 57 
(24), 158 (21), 276 (2). 
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 5.3.7 - General protocol for the ring-closing metathesis reactions 
The oxazolidinone 29b (1.29 g, 4.4 mmol) was dissolved in anhydrous CH2Cl2 (20 mL). 
The solution was de-aerated by bubbling a stream of Ar through it, the Grubbs catalyst II 
(0.044 g, 0.01 mmol) was added, the solution was again de-aerated and heated to reflux. The 
progress of the reaction was monitored by TLC analysis and the disappearance of the 
starting material was observed within 4 h. The solvent was removed at reduced pressure to 
leave the crude product. Flash column chromatography (SiO2) eluting with cyclohexane/ethyl 
acetate 9:1 mixtures gave the product 30b (96 %, 1.182 g, 4.2 mmol). 
 
N
N
O
O
 
(30a): White solid (from pentane:Et2O, 7:3); 95 % (0.795 g, 3.23 mmol) from 3.4 mmol 
(0.979 g) of 8a; m.p. = (65.4-66.9) °C;  [α]D20 +68.3 (c 1.0, CHCl3); IR (KBr): v = 3448, 2966, 
2874, 1732, 1658, 1482, 1298, 1229, 1079, 1047, 732; 1H NMR (300 MHz, CDCl3): δ = 6.78 (m, 
1 H), 6.66 (dd, J = 1.5 Hz, J = 2.8 Hz, 1 H), 6.18 (t, J = 3.4 Hz, 1 H), 6.14 (m, 1 H), 5.40 (dd, J 
= 4.7 Hz, J = 7.6 Hz, 1 H), 5.32 (ddd, J = 3.6 Hz, J = 5.0 Hz, J = 8.7 Hz, 1 H), 4.01 (d, J = 6.9 
Hz, 2 H), 3.44 (dt, J = 3.3 Hz, J = 6.9 Hz, 1 H), 2.73 (dddd, J = 2.5 Hz, J = 6.0 Hz, J = 7.7 
Hz, J = 18.0 Hz, 1 H), 2.58 (ddt, J = 1.4 Hz, J = 4.7 Hz, J = 18.0 Hz, 1 H), 1.87 (dsept, J = 3.3 
Hz J = 6.8 Hz, 1 H), 0.88 (d, J = 6.9 Hz, 3 H), 0.72 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, 
CDCl3): δ = 14.0, 18.1, 27.3, 29.3, 46.7, 58.1, 62.9, 108.0, 108.5, 108.9, 118.7, 123.8, 125.1, 
158.7; GC-MS (EI): m/z = 117 (100), 86 (16), 132 (12), 158 (6), 245 (2). 
 
N
N
O
Ph O
 
(30b):White crystals (from pentane:Et2O, 9:1); m.p. = (97.9-98.5) °C; [α]D20 +165.1 (c 1.3, 
CHCl3); IR (KBr): v = 3097, 2949, 2909, 1736, 1655, 1492, 1416, 1358, 1216, 1076, 1039, 888, 
772, 722, 701; 1H NMR (300 MHz, CDCl3): δ = 7.29-7.36 (m, 3 H), 8.07-7.11 (m, 2 H), 6.52 (t, 
J = 2.2 Hz, 1 H), 6.21 (m, 3 H), 5.41 (dd, J = 4.4 Hz, J = 7.3 Hz, 1 H), 4.72 (ddd, J = 3.3 Hz, J 
= 5.2 Hz, J = 8.1 Hz,  1 H), 4.52 (dd, J = 6.8 Hz, J = 9.1 Hz, 1 H), 4.50 (dd, J = 4.6 Hz, J = 9.1 
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 Hz, 1 H), 4.08 (dd, J = 4.6 Hz, J = 6.8 Hz, 1 H), 2.44 (dddd, J = 2.7 Hz, J = 6.1 Hz, J = 7.1 Hz, 
J = 17.9 Hz, 1 H), 2.30 (dddd, J = 1.2 Hz, J = 4.5 Hz, J = 5.2 Hz, J = 17.9 Hz, 1 H); 13C NMR 
(75 MHz, CDCl3): δ = 27.0, 46.8, 58.2, 70.6, 107.6, 108.4, 108.5, 118.5, 123.3, 124.1, 127.1, 
128.3, 128.4, 139.8, 158.5; GC-MS (EI): m/z = 117 (100), 118 (26), 104 (21), 132 (16), 176 (7), 
280 (2). 
N
NH
O
Ph
 
(31): White crystals (from pentane:Et2O, 9:1); m.p. = (145.8-146.9) °C; [α]D20 +53.4 (c 0.8, 
CHCl3); IR (KBr): v = 3283, 3066, 2923, 1632, 1538, 1478, 1306, 1285, 1079, 728, 869; 1H 
NMR (300 MHz, CDCl3): δ = 7.73-7.79 (m, 2 H), 7.40-7.53 (m, 3 H), 6.83 (dt, J = 1.7 Hz, J = 
7.6 Hz, 1 H), 6.71 (dd, J = 1.8 Hz, J = 2.5 Hz, 1 H), 6.42 (d, J = 7.6 Hz, 1 H), 6.18 (m, 2 H), 
5.51 (q, J = 6.2 Hz, 1 H), 5.35 (m, 1 H), 2.74 (dddd, J = 2.6 Hz, J = 4.0 Hz, J = 6.2 Hz, J = 17.1 
Hz, 1 H), 2.50 (dddd, J = 1.4 Hz, J = 4.9 Hz, J = 6.2 Hz, J = 17.1 Hz, 1 H); 13C NMR (75 MHz, 
CDCl3): δ = 28.3, 42.9, 106.8, 107.9, 108.6, 118.8, 125.6, 126.9, 127.1, 128.5, 131.5, 134.3, 
166.4; GC-MS (EI): m/z = 117 (100), 77 (32), 105 (29), 90 (13), 237 (4), 238 (2). 
 
N
NH
O
O
 
(32): White crystals (from pentane); m.p. = (91.7-92.3) °C; [α]D20 -15.8 (c 0.6, CHCl3); IR 
(KBr): v = 332, 2977, 2621, 1680, 1531, 1481, 1365, 1253, 1156, 1049, 716; 1H NMR (300 
MHz, CDCl3): δ = 6.75 (dt, J = 1.6 Hz, J = 7.7 Hz, 1 H), 6.64 (t, J = 2.1 Hz, 1 H), 6.14 (m, 2 H), 
5.29 (dd, J = 4.3 Hz, J = 7.7 Hz, 1 H), 4.98 (m, 1 H), 4.86 (bs, 1 H), 2.60 (dt, J = 4.2 Hz, J = 
16.8 Hz, 1 H), 2.32 (dt, J = 4.9 Hz, J = 16.8 Hz, 1 H) 1.46 (s, 9 H); 13C NMR (75 MHz, CDCl3): 
δ = 28.3, 28.6, 43.7, 79.4, 106.3, 107.7, 108.4, 118.5, 125.5, 127.9, 154.9; GC-MS (EI): m/z = 
117 (100), 177 (16), 133 (15), 57 (12), 90 (10), 159 (69), 234 (4); MS (ES): m/z = 257.1 [M + 
Na]+. 
 
 
-176-
 5.3.8 – General protocol for hydrogenation reactions 
To a solution of 30a (0.500 g, 2.0 mmol) in anhydrous (20 mL) was added 5% rhodium 
on alumina (10%, 0.050 g) and the mixture was strirres under hydrogen atmosphere. The 
progress of the reaction was monitored by GC-MS analysis and the disappearance of the 
starting material was observed within 24 h. The solid was filtered off through a pad of 
Celite and the organic phase was concentrated at reduced pressure. Flash column 
chromatography (SiO2) eluting with ethyl acetate/methanol/30% NH4OH 9:1:0.1 mixtures 
gave the product 33. 
 
N
N
O
O
 
(33a):White Oil; 96 % (0.094 g, 0.38 mmol) from 0.40 mmol (0.100 g) of 30°; IR (Neat): v = 
2960, 2875, 1741, 1414, 1225, 1052, 716; 1H NMR (300 MHz, CDCl3): δ = 6.57 (ddd, J = 0.6 
Hz, J = 1.7 Hz, J = 2.4 Hz, 1 H), 6.13 (dd, J = 2.7 Hz, J = 3.6 Hz, 1 H), 5.89 (dt, J = 1.4 Hz, J 
= 3.5 Hz, 1 H), 5.13 (dd, J = 5.9 Hz, J = 10.6 Hz, 1 H), 4.15 (dd, J = 8.9 Hz, J = 17.5 Hz, 1 H), 
4.12 (dd, J = 4.3 Hz, J = 8.9 Hz, 1 H), 3.81-3.99 (m, 3 H), 2.26 (m, 1 H), 2.07 (m, 1H), 1.76-
1.98 (m, 4 H), 0.92 (d, J = 6.9 Hz, 3 H), 0.77 (d, J = 6.9 Hz, 3 H); 13C NMR (75 MHz, CDCl3): 
δ = 13.8, 18.1, 22.6, 27.7, 29.4, 44.9, 50.1, 57.5, 62.7, 105.3, 107.8, 119.9, 126.1, 158.7; GC-MS 
(EI): m/z = 120 (100), 177 (98), 178 (79), 118 (68), 248 (54), 133 (22); MS (ES): m/z = 249.2 
[M + H]+, 519.2 [M + Na]+. 
 
N
N
O
Ph O
 
(33b): White solid (from Et2O:Pentane, 1:1); 97 % (0.098 g, 0.35 mmol) from 0.36 mmol 
(0.100 g) of 30b; [α]D20 +34.1 (c 2.0, CHCl3); IR (KBr): v = 3093, 2965, 2921, 1746, 1407, 
1364, 1229, 1069, 1048, 768, 715; 1H NMR (300 MHz, CDCl3): δ = 7.33-7.39 (m, 3 H), 7.07-
7.11 (m, 2 H), 6.57 (dd, J = 1.7 Hz, J = 2.5 Hz, 1 H), 6.25 (dd, J = 2.8 Hz, J = 3.6 Hz, 1 H), 
6.07 (dt, J = 1.5 Hz, J = 3.5 Hz, 1 H), 5.26 (dd, J = 6.1 Hz, J = 9.6 Hz, 1 H), 4.91 (dd, J = 5.6 
Hz, J = 9.1 Hz, 1 H), 4.66 (t, J = 8.8 Hz, 1 H), 4.29 (dd, J = 5.6 Hz, J = 8.7 Hz, 1 H), 3.79 (dt, 
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 J = 4.5 Hz, J = 11.8 Hz, 1 H), 3.38 (ddd, J = 4.7 Hz, J = 9.9 Hz, J = 11.9 Hz, 1 H), 1.84-1.93 
(m, 1 H), 1.53-1.76 (m, 2 H), 1.15-1.29 (m, 1H); 13C NMR (75 MHz, CDCl3): δ = 21.7, 27.1, 44.6, 
49.7, 57.1, 70.1, 106.1, 108.0, 119.8, 125.6, 127.3, 128.7, 128.8, 140.2, 158.5; GC-MS (EI): m/z 
= 178 (100), 118 (35), 282 (34), 104 (33), 120 (33), 91 (18), 163 (11), 207 (10). 
 
N
N
O
O
H
 
(S,S-34): White crystals (from Et2O:CH2Cl2, 10:1); m.p. = (114.5-115.3) °C; IR (Neat): v = 
2928, 2782, 1741, 1415, 1220, 1100, 1040; ; 1H NMR (300 MHz, CDCl3): δ = 4.32 (dt, J = 2.7 
Hz, J = 7.5 Hz, 1 H), 4.21 (m, 1 H), 4.16 (dd, J = 2.7 Hz, 1 H), 4.12 (dd, J = 7.5 Hz, 1 H), 3.07 
(dt, J = 3.7 Hz, J = 11.1 Hz, 1 H), 2.98 (ddd, J = 4.7 Hz, J = 5.7 Hz, J = 9.5 Hz, 1 H), 1.94-2.14 
8m, 5 H), 1.63-1.82 (m, 6 H), 1.39 (m, 1 H), 0.92 (d, J = 6.9 Hz, 3 H), 0.89 (d, J = 6.9 Hz, 3 H); 
13C NMR (75 MHz, CDCl3): δ = 13.8, 18.4, 20.6, 22.5, 25.7, 26.9, 30.5, 49.9, 52.8, 5438, 59.8, 
63.1, 67.6, 159.8; GC-MS (EI): m/z = 123 (100), 96 (20), 83 (16), 69 (10), 55 (8), 251 (1); MS 
(ES): m/z = 253.1 [M + H]+. 
N
N
O
O
H
 
(R,R-34): White crystals (from Et2O:CH2Cl2, 10:1); [α]D20 +35.4 (c 1.1, CHCl3); IR (KBr): v = 
2947, 2784, 1732, 1416, 1218, 1038, 973, 778; 13C NMR (75 MHz, CDCl3): δ = 13.8, 18.7, 20.7, 
23.1, 24.8, 29.7, 28.4, 51.8, 51.9, 54.7, 59.1, 59.8, 63.1, 65.9, 159.5; GC-MS (EI): m/z = 123 
(100), 96 (25), 122 (20), 97 (20), 83 (15), 69 (11), 55 (9); MS (ES): m/z = 253.1 [M + H]+. 
 
N
N
O
O
H
 
(S,R-34): White crystals (from Et2O:CH2Cl2, 10:1); m.p. = (89.6-90.9) °C; [α]D20 +9.4 (c 1.9, 
CHCl3); IR (KBr): v = 3440, 2936, 2785, 1728, 1428, 1253, 1117, 1064, 771, 714; 1H NMR (300 
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 MHz, CDCl3): δ = 4.15 (t, J = 9.0 Hz, 1 H), 4.08 (dd, J = 5.2 Hz, J = 8.9 Hz, 1 H), 3.71 (ddd, J = 
3.2 Hz, J = 5.2 Hz, J = 9.0 Hz, 1 H), 3.02-3.19 (m, 3 H), 2.56 (q, J = 9.7 Hz, 1 H), 2.24 (q, J = 
9.0 Hz, 1 H), 1.93-2.12 (m, 5 H), 1.48-1.83 (m, 5 H), 0.92 (d, J = 6.8 Hz, 3 H), 0.89 (d, J = 6.8 
Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ = 13.8, 18.2, 20.4, 24.7, 27.9, 28.6, 28.7, 29.7, 51.8, 
54.1, 59.9, 62.6, 64.8, 157.9; GC-MS (EI): m/z = 123 (100), 122 (70), 96 (44), 97 (35), 83 
(26), 69 (24), 55 (18); MS (ES): m/z = 253.1 [M + H]+. 
 
N
N
O
O
H
 
(R,R-39): White solid (from Et2O:CH2Cl2, 8:2); IR (KBr): v = 3452, 2923, 2854, 2783, 1735, 
1415, 1209, 1102, 1033, 803; GC-MS (EI): m/z = 123 (100), 96 (16), 124 (15), 55 (12), 83 (11), 
209 (3), 291 (2). 
N
N
O
O
H
 
(S,S-37): White solid; IR (KBr): v = 3449, 2932, 2853, 2785, 1732, 1420, 1248, 1035, 766, 
710; GC-MS (EI): m/z = 123 (100), 96 (17), 97 (14), 55 (13), 83 (12), 209 (4),291 (2). 
 
N
N
O
O
H
 
(S,R-37): White crystals (from Et2O:CH2Cl2, 8:2); m.p. = (117.8-118.5) °C; [α]D20 +77.6 (c 0.6, 
CHCl3); IR (KBr): v =2929, 2852, 2789, 1730, 1425, 1250, 1058, 768, 710; 1H NMR (300 MHz, 
CDCl3): δ = 4.14 (d, J = 3.5 Hz, 1 H), 4.12 (d, J = 1.2 Hz, 1 H), 3.65 (ddd, J = 2.9 Hz, J = 5.7 
Hz, J = 8.6 Hz, 1 H), 3.00-3.18 (m, 3 H), 2.56 (dt, J = 6.1 Hz, J = 10.2 Hz, 1 H), 2.36 (q, J = 
9.1 Hz, 1 H), 1.90-2.07 (m, 6 H), 1.57-1.86 (m, 7 H), 1.42-1.52 (m, 3 H), 1.09-1.32 (m, 2 H), 
0.85-1.04 (m, 2 H); 13C NMR (75 MHz, CDCl3): δ = 20.5, 24.3, 25.1, 25.5, 26.3, 28.2, 28.8, 
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 28.9, 39.3, 51.9, 54.3, 57.5, 59.7, 63.4, 64.6, 157.9; GC-MS (EI): m/z = 123 (100), 96 (13), 55 
(10), 83 (9)209 (2), 291 (2). 
 
The e.e. of 38 was determined by chiral GC (Megadex Chiral column (25 m, flow rate: 
15mL/min, isotherm 150 °C for 2 min. then 2°C/min. to 220°C, FID detection); retention 
times: S,R-38 21.2 min, S,S-38 28.2 min (major enantiomer), 28.6 min (minor enantiomer). 
 
N
H
N O
H
 
(S,R-38): White crystals (from Et2O:CH2Cl2, 9:1); m.p. = (126.7-127.8) °C; [α]D20 +20.9 (c 1.9, 
CHCl3); IR (KBr): v = 3464, 3297, 2927, 2852, 2785, 2745, 1638, 1528, 1449, 1340, 1262, 
1123, 1099; 1H NMR (300 MHz, CDCl3): δ = 6.09 (d, J = 6.9 Hz, 1 H), 4.16 (ddd, J = 2.7 Hz, J = 
5.7 Hz, J = 8.7 Hz, 1 H), 3.02 (m, 1 H), 2.96 (m, 1 H), 1.92-2.12 (m, 4 H), 1.76-1.86 (m, 5 H), 
1.61-1.70 (m, 5 H), 1.38-1.53 (m, 3 H), 1.17-1.31 (m, 5 H), 1.18-1.32 (m, 2 H); 13C NMR (75 MHz, 
CDCl3): δ = 20.6, 20.9, 25.6, 25.7, 29.5, 29.8, 29.9, 44.7, 45.7, 53.1, 24.5, 65.8, 175.8; GC-MS 
(EI): m/z = 123 (100), 55 (16), 70 (14), 83 (9), 108 (8), 249 (4). 
 
N
H
N OH
 
(S,S-38): White crystals (from Et2O:CH2Cl2, 9:1); m.p. = (197.9-198.7) °C; [α]D20 +22.1 (c 2.0, 
CHCl3); IR (KBr): v = 3460, 3077, 2828, 2853, 2790, 2722, 1638, 1550, 1445, 1331, 1260, 
1113, 1095, 1022, 802, 702; 1H NMR (300 MHz, CDCl3): δ = 5.30 (d, J = 8.6 Hz, 1 H), 3.76 
(ddd, J = 4.2 Hz, J = 8.9 Hz, J = 11.6 Hz, 1 H), 3.07 (td, J = 1.6 Hz, J = 9.2 Hz, 1 H), 3.02 (dt, 
J = 2.7 Hz, J = 10.6 Hz, 1 H), 2.13 (q, J = 8.9 Hz, 1 H), 1.88-2.02 (m, 4 H), 1.75-1.83 (m, 5 H), 
1.59-1.71 (m, 4 H), 1.37-1.48 (m, 2 H), 1.17-1.31 (m, 5 H), 0.97-1.10 (m, 1 H); 13C NMR (75 MHz, 
CDCl3): δ =20.3, 24.5, 25.6, 25.7, 25.8, 28.3, 29.5, 29.9, 31.8, 45.7, 50.9, 51.8, 54.3, 69.2, 
175.4; GC-MS (EI): m/z =123 (100), 55 (11), 70 (10), 96 (9), 249 (2). 
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The e.e. of 39 was determined by chiral GC (Megadex Chiral column (25 m, flow rate: 
15mL/min, isotherm 100 °C for 2 min. then 5°C/min. to 220°C, FID detection); retention 
times: S,R-39 15.8 min, S,S-39 17.6 min (major enantiomer), 18.3 min (minor enantiomer). 
 
N
H
N
O
OH
 
(S,R-39): White crystals (from Et2O:CH2Cl2, 9:1); [α]D20 -14.3 (c 0.4, CHCl3); 1H NMR (300 
MHz, CDCl3): δ = 5.19 (d, J = 8.6 Hz, 1 H), 3.86 (dq, J = 3.1 Hz, J = 9.6 Hz, 1 H), 2.95-3.01 (m, 
2 H), 1.97-2.03 (m, 1 H), 1.86-1.95 (m, 2 H), 1.62-1.69 (m, 4 H), 1.50-1.57 (m, 2 H), 1.44 (s, 9 
H), 1.33-1.39 (m, 1 H); 13C NMR (75 MHz, CDCl3): δ = 20.6, 20.8, 25.6, 28.4, 29.9, 46.5, 53.2, 
54.5, 66.1, 78.7, 155.9; GC-MS (EI): m/z =123 (100), 83 (31), 96 (21), 111 (17), 70 (14), 59 
(12), 167 (11), 183 (6). 
 
N
H
N
O
OH
 
 (S,S-39): White crystals (from Et2O:CH2Cl2, 9:1); m.p. = (105.4-106.1) °C; [α]D20 -5.4 (c 0.4, 
CHCl3); IR (KBr): v = 3359, 2972, 2905, 2785, 2723, 1684, 1529, 1447, 1309, 1245, 1172, 
1053, 994, 636; 1H NMR (300 MHz, CDCl3): δ = 4.35 (bs , 1 H), 3.38 (bs, 1 H), 3.08 (t, J = 7.8 
Hz, 1 H), 3.02 (dt, J = 3.0 Hz, J = 10.7 Hz, 1 H), 2.14 (q, J = 8.9 Hz, 1 H), 2.01-2.07 (m, 1 H), 
1.87-1.96 (m, 2 H), 1.76-1.82 (m, 1 H), 1.58-1.73 (m, 5 H), 1.44 (s, 9 H), 0.95-1.08 (m, 1 H); 13C 
NMR (75 MHz, CDCl3): δ = 20.4, 24.7, 28.4, 28.5, 32.2, 51.9, 52.7, 54.3, 69.5, 79.0, 155.3; GC-
MS (EI): m/z =123 (100), 83 (34), 97 (21), 96 (18), 70 (16), 69 (13), 57 (11), 167 (8), 183 (6). 
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